[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, a synonym for Acrokeratosis paraneoplastica is Bazex syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Bazex syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Bazex syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Weaver syndrome is similar to Sotos syndrome in that they are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes. However, they are distinct syndromes caused by different genetic mechanisms.\nWeaver syndrome is caused by pathogenic variants in the PTCH1 gene, which encodes a protein involved in the Hedgehog signaling pathway. Sotos syndrome, on the other hand, is caused by pathogenic variants in the NSD1 gene, which also plays a role in the Hedgehog signaling pathway.\nThe Tatton-Brown-Rahman syndrome, also known as DNMT3A-related overgrowth syndrome, is another autosomal dominant OGID syndrome caused by pathogenic variants in the DNMT3A gene, which is involved in DNA methylation.\nWhile these syndromes share some similarities in their genetic mechanisms, they have distinct clinical features and outcomes. It is important to note that each individual with one of these syndromes may have a unique combination of symptoms and characteristics, and the severity of the syndrome can vary greatly between individuals.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct syndromes caused by different genetic mechanisms, and each has its own unique set of clinical features and outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes.\n2. Weaver syndrome is caused by pathogenic variants in the PTCH1 gene.\n3. Sotos syndrome is caused by pathogenic variants in the NSD1 gene.\n4. The Tatton-Brown-Rahman syndrome is caused by pathogenic variants in the DNMT3A gene.\n5. The PTCH1, NSD1, and DNMT3A genes are all involved in genetic mechanisms related to overgrowth and intellectual disability syndromes.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes.",
      "Weaver syndrome is caused by pathogenic variants in the PTCH1 gene.",
      "Sotos syndrome is caused by pathogenic variants in the NSD1 gene.",
      "The Tatton-Brown-Rahman syndrome is caused by pathogenic variants in the DNMT3A gene.",
      "The PTCH1, NSD1, and DNMT3A genes are all involved in genetic mechanisms related to overgrowth and intellectual disability syndromes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by pathogenic variants in the EZH2 gene, not the PTCH1 gene.\n3. TRUE\n4. TRUE\n5. TRUE (with the correction that PTCH1 is not associated with Weaver syndrome as stated in statement 2, but it is involved in Gorlin syndrome, another genetic disorder. However, since the statement does not explicitly link PTCH1 to Weaver syndrome, it is generally true that these genes are involved in genetic mechanisms related to overgrowth and intellectual disability syndromes.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the releases of the JASPAR database are:\n1. JASPAR v6.0 (2016-04-11)\n2. JASPAR v6.1 (2016-09-23)\n3. JASPAR v6.2 (2018-06-07)\n4. JASPAR v6.3 (2020-11-07)\n5. JASPAR v7.0 (2022-04-22)\nPlease note that these releases are listed in the order they were curated by the JASPAR team, and the dates may not necessarily reflect the exact release dates of the database.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR v6.0 was released on 2016-04-11.\n2. JASPAR v6.1 was released on 2016-09-23.\n3. JASPAR v6.2 was released on 2018-06-07.\n4. JASPAR v6.3 was released on 2020-11-07.\n5. JASPAR v7.0 was released on 2022-04-22.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR v6.0 was released on 2016-04-11.",
      "JASPAR v6.1 was released on 2016-09-23.",
      "JASPAR v6.2 was released on 2018-06-07.",
      "JASPAR v6.3 was released on 2020-11-07.",
      "JASPAR v7.0 was released on 2022-04-22."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JASPAR v6.0 was released on 2018-01-08.\n2. FALSE [correction]: JASPAR v6.1 has not been released; the versioning went from v6.0 directly to v7.0.\n3. FALSE [correction]: JASPAR v6.2 has not been released; the versioning went from v6.0 directly to v7.0.\n4. FALSE [correction]: JASPAR v6.3 has not been released; the versioning went from v6.0 directly to v7.0.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the function of the viral KP4 protein is to:\n1. Kill sensitive Ustilago strains: The KP4 protein is secreted by the maize smut fungus Ustilago maydis and is toxic to sensitive Ustilago strains.\n2. Inhibit Fusarium and plant root growth: The KP4 protein inhibits calcium uptake, which inhibits the growth of Fusarium and plant roots.\nTherefore, the function of the KP4 protein is to regulate the interactions between the fungus and its host plant, and to protect the fungus from competition.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is secreted by the maize smut fungus Ustilago maydis.\n2. The KP4 protein is toxic to sensitive Ustilago strains.\n3. The KP4 protein inhibits calcium uptake.\n4. Inhibition of calcium uptake by the KP4 protein affects the growth of Fusarium and plant roots.\n5. The KP4 protein plays a role in regulating interactions between the fungus and its host plant.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is secreted by the maize smut fungus Ustilago maydis.",
      "The KP4 protein is toxic to sensitive Ustilago strains.",
      "The KP4 protein inhibits calcium uptake.",
      "Inhibition of calcium uptake by the KP4 protein affects the growth of Fusarium and plant roots.",
      "The KP4 protein plays a role in regulating interactions between the fungus and its host plant."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known functions of the KP4 protein from Ustilago maydis. KP4 is a viral protein that the fungus can express, and it has been shown to have toxic effects on sensitive strains of the same species. It inhibits calcium uptake, which can affect the growth of other fungi and plant roots. Additionally, KP4 is involved in the interaction between the fungus and its host plant, playing a role in the regulation of this complex relationship.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA is a thyroid hormone analog that has been utilized in both experimental and clinical studies. According to the information provided in Document 0, DITPA has shown beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure. Thyroid hormone analogs, such as DITPA, are synthetic versions of thyroid hormones that mimic the action of these hormones in the body. They have been investigated as potential treatments for various conditions, including heart failure, due to their ability to improve cardiac function and reduce symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog.\n2. DITPA has been used in experimental studies.\n3. DITPA has been used in clinical studies.\n4. DITPA has shown beneficial hemodynamic effects in animal studies.\n5. DITPA was involved in a pilot trial with patients suffering from congestive heart failure.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog.",
      "DITPA has been used in experimental studies.",
      "DITPA has been used in clinical studies.",
      "DITPA has shown beneficial hemodynamic effects in animal studies.",
      "DITPA was involved in a pilot trial with patients suffering from congestive heart failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nDITPA, or 3,5-diiodothyropropionic acid, is indeed a thyroid hormone analog. It has been used in both experimental and clinical studies. In animal studies, DITPA has shown beneficial hemodynamic effects. Additionally, DITPA was involved in a pilot trial with patients suffering from congestive heart failure, indicating its exploration in a clinical context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the COUGER tool is a software tool that supports system definition and specification tasks. Specifically, it describes early tools such as decision table processors and techniques that were used in the analysis and design of systems.",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is a software tool.\n2. The COUGER tool supports system definition and specification tasks.\n3. The COUGER tool involves early tools such as decision table processors.\n4. The COUGER tool is used in the analysis and design of systems.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is a software tool.",
      "The COUGER tool supports system definition and specification tasks.",
      "The COUGER tool involves early tools such as decision table processors.",
      "The COUGER tool is used in the analysis and design of systems."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\n[Note: The statements provided are not enough to determine the veracity of the claims about the COUGER tool. Without additional context or information about what COUGER stands for or its functions, it is not possible to accurately assess these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat Tick-borne Encephalitis (TBE). While there is no specific medication to treat the TBE virus itself, there are antiviral drugs that can help manage the symptoms of the infection. These drugs include:\n1. Ribavirin: This drug is commonly used to treat viral infections, including TBE. It works by reducing the replication of the virus in the body.\n2. Aztreonam: This antibiotic is used to treat bacterial infections that can occur as a complication of TBE.\n3. Acetaminophen: This over-the-counter pain medication can help relieve headaches, muscle aches, and other symptoms associated with TBE.\n4. Ibuprofen: This nonsteroidal anti-inflammatory drug (NSAID) can help reduce fever and relieve pain.\nIt's important to note that these drugs may not be effective in all cases of TBE, and their effectiveness may vary depending on the severity of the infection. In addition, these drugs may have side effects, so it's important to discuss the potential benefits and risks with a healthcare provider before taking them.\nIn addition to these medications, rest and hydration are also important for managing the symptoms of TBE. Getting plenty of rest and staying hydrated can help the body recover from the infection more quickly.\nIt's also important to note that the TBE vaccine is available for prevention of the infection, and it is recommended for certain individuals, such as travelers to areas where TBE is common, and for people who work outdoors or in forests.\nIn summary, while there are no specific medications to treat TBE, antiviral drugs, antibiotics, and over-the-counter pain medications can help manage the symptoms of the infection. Rest and hydration are also important for recovery. The TBE vaccine is available for prevention of the infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is used to treat viral infections, including Tick-borne Encephalitis, by reducing the replication of the virus in the body.\n2. Aztreonam is an antibiotic used to treat bacterial infections that can occur as a complication of Tick-borne Encephalitis.\n3. Acetaminophen is an over-the-counter medication that can help relieve headaches, muscle aches, and other symptoms associated with Tick-borne Encephalitis.\n4. Ibuprofen is a nonsteroidal anti-inflammatory drug that can help reduce fever and relieve pain in cases of Tick-borne Encephalitis.\n5. A vaccine is available for the prevention of Tick-borne Encephalitis and is recommended for certain individuals, such as travelers to areas where the disease is common.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is used to treat viral infections, including Tick-borne Encephalitis, by reducing the replication of the virus in the body.",
      "Aztreonam is an antibiotic used to treat bacterial infections that can occur as a complication of Tick-borne Encephalitis.",
      "Acetaminophen is an over-the-counter medication that can help relieve headaches, muscle aches, and other symptoms associated with Tick-borne Encephalitis.",
      "Ibuprofen is a nonsteroidal anti-inflammatory drug that can help reduce fever and relieve pain in cases of Tick-borne Encephalitis.",
      "A vaccine is available for the prevention of Tick-borne Encephalitis and is recommended for certain individuals, such as travelers to areas where the disease is common."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations that is available is GBshape.",
    "llama-2-7b-chat-hf_fact_raw": "1. GBshape is a genome browser database for DNA shape annotations.",
    "llama-2-7b-chat-hf_fact": [
      "GBshape is a genome browser database for DNA shape annotations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the EZH2 gene has been associated with the following syndromes:\n1. Weaver Syndrome: The p.Glu745Lys mutation (detected in 2 patients) was previously associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\nWeaver Syndrome is a rare genetic disorder caused by mutations in the EZH2 gene. It is characterized by a combination of developmental delays, intellectual disability, and a higher risk of developing cancer, particularly acute lymphoblastic leukemia and lymphoma.\nIt is important to note that the association between the EZH2 gene and Weaver Syndrome is not limited to the p.Glu745Lys mutation, and other mutations in the EZH2 gene have also been linked to this syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The EZH2 gene has been associated with Weaver Syndrome.\n2. The p.Glu745Lys mutation in the EZH2 gene was detected in 2 patients with Weaver Syndrome.\n3. Weaver Syndrome is characterized by developmental delays, intellectual disability, and a higher risk of developing cancer.\n4. Acute lymphoblastic leukemia and lymphoma are types of cancer associated with Weaver Syndrome.\n5. Mutations in the EZH2 gene, not limited to the p.Glu745Lys mutation, have been linked to Weaver Syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "The EZH2 gene has been associated with Weaver Syndrome.",
      "The p.Glu745Lys mutation in the EZH2 gene was detected in 2 patients with Weaver Syndrome.",
      "Weaver Syndrome is characterized by developmental delays, intellectual disability, and a higher risk of developing cancer.",
      "Acute lymphoblastic leukemia and lymphoma are types of cancer associated with Weaver Syndrome.",
      "Mutations in the EZH2 gene, not limited to the p.Glu745Lys mutation, have been linked to Weaver Syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Inositol-Requiring enzyme 1α (IRE1): IRE1 is a transmembrane protein that plays a crucial role in the unfolded protein response (UPR) pathway. It can exist as a dimer or a tetramer, and the transition between these two states is thought to be involved in the regulation of its activity.\n2. Protein kinase R (PKR)-like ER kinase (PERK): PERK is another transmembrane protein that is involved in the UPR pathway. Like IRE1, it can exist as a dimer or a tetramer, and the transition between these states may play a role in regulating its activity.\n3. Activating transcription factor 6 (ATF6): ATF6 is a transcription factor that is activated in response to ER stress and plays a role in the UPR pathway. It can exist as a dimer or a tetramer, and the transition between these states may be involved in the regulation of its activity.\nIt is worth noting that the dimer-to-tetramer transition is a complex process that is not yet fully understood, and there may be other human proteins that undergo this transition as well. Additionally, the transition may not always be a simple binary process, but can involve a range of intermediate states and conformations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inositol-Requiring enzyme 1α (IRE1) is a human protein that can undergo a dimer-to-tetramer transition.\n2. Protein kinase R (PKR)-like ER kinase (PERK) is a human protein that can exist as both a dimer and a tetramer.\n3. Activating transcription factor 6 (ATF6) is a human protein that can transition between dimer and tetramer states.\n4. IRE1, PERK, and ATF6 are involved in the unfolded protein response (UPR) pathway.\n5. The dimer-to-tetramer transition of these proteins is thought to be involved in the regulation of their activity.",
    "llama-2-7b-chat-hf_fact": [
      "Inositol-Requiring enzyme 1α (IRE1) is a human protein that can undergo a dimer-to-tetramer transition.",
      "Protein kinase R (PKR)-like ER kinase (PERK) is a human protein that can exist as both a dimer and a tetramer.",
      "Activating transcription factor 6 (ATF6) is a human protein that can transition between dimer and tetramer states.",
      "IRE1, PERK, and ATF6 are involved in the unfolded protein response (UPR) pathway.",
      "The dimer-to-tetramer transition of these proteins is thought to be involved in the regulation of their activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Activating transcription factor 6 (ATF6) does not transition between dimer and tetramer states. ATF6 is a transmembrane protein that, upon activation, is transported to the Golgi apparatus where it is cleaved, releasing a cytosolic fragment that acts as a transcription factor.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2.\nThe abstract mentions that PLN plays a role in cardiomyocyte calcium handling as a primary inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). Bcl-2 is an anti-apoptotic protein that has been shown to interact with PLN and play a role in regulating cardiomyocyte survival and apoptosis.\nIn particular, the abstract mentions the p. (Arg14del) pathogenic variant in PLN, which has been associated with cardiomyopathy and heart failure. Bcl-2 has been shown to protect against apoptosis in response to oxidative stress and other forms of cellular stress, and may play a role in protecting against the adverse effects of the p. (Arg14del) variant in PLN.\nTherefore, based on the information provided in Document 0, the answer to the user's question is Bcl-2.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 is a protein that interacts with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.\n3. Phospholamban (PLN) is involved in cardiomyocyte calcium handling as a primary inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA).\n4. The p. (Arg14del) pathogenic variant in PLN has been associated with cardiomyopathy and heart failure.\n5. Bcl-2 has been shown to protect against apoptosis in response to oxidative stress and other forms of cellular stress.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 is a protein that interacts with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein.",
      "Phospholamban (PLN) is involved in cardiomyocyte calcium handling as a primary inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA).",
      "The p. (Arg14del) pathogenic variant in PLN has been associated with cardiomyopathy and heart failure.",
      "Bcl-2 has been shown to protect against apoptosis in response to oxidative stress and other forms of cellular stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is specific and requires knowledge of the interactions between proteins. Without specific information or a reliable source, it is not possible to confirm or deny the interaction between Bcl-2 and phospholamban (PLN).\n2. TRUE: Bcl-2 is indeed known as an anti-apoptotic protein that helps to prevent programmed cell death.\n3. TRUE: Phospholamban (PLN) is a regulatory protein that inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), which is involved in cardiomyocyte calcium handling.\n4. TRUE: The p. (Arg14del) pathogenic variant in PLN has been associated with dilated cardiomyopathy and heart failure in multiple studies.\n5. TRUE: Bcl-2 is known to protect against apoptosis in response to various forms of cellular stress, including oxidative stress.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there is evidence to suggest that vitamin D may reduce the incidence of falls in older people in clinical trials. The document provides a 15-year literature overview and highlights the potential mechanisms by which vitamin D may influence fall risk, including its effects on muscles and the central nervous system.\nThe document notes that falls are a major public health concern in older adults, particularly those with mobility or balance difficulties, and that the underlying mechanisms involve a complex interplay of factors, including muscle weakness, sensory impairment, and cognitive decline. Vitamin D, which is important for maintaining muscle and bone health, has been shown to have a positive effect on these factors, potentially reducing the risk of falls.\nWhile the document acknowledges that there are some controversies and differences in the results of previous studies, it concludes that the available evidence suggests that vitamin D supplementation may be effective in reducing the incidence of falls in older people. Specifically, the document highlights several clinical trials that have found a significant reduction in fall rates among older adults who received vitamin D supplements compared to those who did not.\nOverall, based on the information provided in Document 0, there is evidence to suggest that vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. However, it is important to note that the evidence is not uniform across all studies, and further research is needed to fully understand the effects of vitamin D on fall risk in older adults.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitamin D may reduce the incidence of falls in older people according to clinical trials.\n2. Falls are a major public health concern in older adults, especially those with mobility or balance difficulties.\n3. Vitamin D is important for maintaining muscle and bone health.\n4. Clinical trials have found a significant reduction in fall rates among older adults who received vitamin D supplements compared to those who did not.\n5. The evidence regarding the effect of vitamin D on reducing falls in older people is not uniform across all studies.",
    "llama-2-7b-chat-hf_fact": [
      "Vitamin D may reduce the incidence of falls in older people according to clinical trials.",
      "Falls are a major public health concern in older adults, especially those with mobility or balance difficulties.",
      "Vitamin D is important for maintaining muscle and bone health.",
      "Clinical trials have found a significant reduction in fall rates among older adults who received vitamin D supplements compared to those who did not.",
      "The evidence regarding the effect of vitamin D on reducing falls in older people is not uniform across all studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells. According to Document 0, Jarid2 recruits the polycomb repressive complex 2 (PRC2) which cooperates with the polycomb repressive complex 1 (PRC1) to regulate the transcriptional regulation of cytokine genes in Th17 cells. miR-155 is known to play a role in post-transcriptional regulation of cytokine genes in Th17 cells, and Jarid2's association with PRC2 suggests that it may also play a role in regulating the expression of miR-155 in these cells. Therefore, it is likely that Jarid2 and miR-155 are associated in the regulation of Th17 cell function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is associated with miR-155 in Th17 cells.\n2. Jarid2 recruits the polycomb repressive complex 2 (PRC2) to regulate transcription of cytokine genes in Th17 cells.\n3. The polycomb repressive complex 1 (PRC1) cooperates with PRC2 in the transcriptional regulation of cytokine genes in Th17 cells.\n4. miR-155 is involved in the post-transcriptional regulation of cytokine genes in Th17 cells.\n5. Jarid2's association with PRC2 may influence the regulation of the expression of miR-155 in Th17 cells.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is associated with miR-155 in Th17 cells.",
      "Jarid2 recruits the polycomb repressive complex 2 (PRC2) to regulate transcription of cytokine genes in Th17 cells.",
      "The polycomb repressive complex 1 (PRC1) cooperates with PRC2 in the transcriptional regulation of cytokine genes in Th17 cells.",
      "miR-155 is involved in the post-transcriptional regulation of cytokine genes in Th17 cells.",
      "Jarid2's association with PRC2 may influence the regulation of the expression of miR-155 in Th17 cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE - Jarid2 is known to recruit the polycomb repressive complex 2 (PRC2) to target genes, which can include cytokine genes in various cell types, including Th17 cells.\n3. TRUE - The polycomb repressive complexes 1 (PRC1) and 2 (PRC2) are known to cooperate in the transcriptional regulation of genes, though the specific interaction in Th17 cells would require more specific context to confirm.\n4. TRUE - miR-155 is known to be involved in the post-transcriptional regulation of various genes, including cytokine genes, which can affect the function of Th17 cells.\n5. UNKNOWN - While Jarid2 is associated with PRC2, and PRC2 can influence gene expression, the specific regulatory relationship between Jarid2's association with PRC2 and the expression of miR-155 in Th17 cells is not provided in the statements and would require specific scientific evidence to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0 from 2009, the human Hoxd cluster contains 9 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human Hoxd cluster contains 9 genes according to a document from 2009.",
    "llama-2-7b-chat-hf_fact": [
      "The human Hoxd cluster contains 9 genes according to a document from 2009."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human Hoxd cluster contains 9-11 genes, with the most commonly accepted number being 10.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the phosphorylation consensus motifs for Casein Kinase 1 (CK1) are:\n1. Acidic motifs N-terminal to phosphorylation sites: CK1s typically recognize substrates with acidic motifs located N-terminal to the phosphorylation sites.\n2. Consecutive phosphoserines: CK1s tend to generate clusters of consecutive phosphoserines on their substrates.\nTherefore, the consensus motifs for CK1 are:\nX-X-S-S-S-P\nWhere X represents any amino acid, S represents serine, and P represents phosphate.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) typically recognizes substrates with acidic motifs located N-terminal to the phosphorylation sites.\n2. Casein Kinase 1 (CK1) tends to generate clusters of consecutive phosphoserines on their substrates.\n3. The consensus motif for CK1 can be represented as X-X-S-S-S-P, where X is any amino acid, S is serine, and P is phosphate.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) typically recognizes substrates with acidic motifs located N-terminal to the phosphorylation sites.",
      "Casein Kinase 1 (CK1) tends to generate clusters of consecutive phosphoserines on their substrates.",
      "The consensus motif for CK1 can be represented as X-X-S-S-S-P, where X is any amino acid, S is serine, and P is phosphate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The consensus motif for CK1 does not typically include consecutive serines followed by a phosphate. Instead, it is often represented as S/TxxS/T (where \"S\" is serine, \"T\" is threonine, \"x\" is any amino acid, and the serine or threonine at the +1 or +3 position relative to the first serine or threonine is the phosphorylation site).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the different proteins/isoforms encoded by the ASPH (aspartate beta-hydroxylase) gene in humans are:\n1. Aspartyl/Asparaginyl beta-hydroxylase domain: This is the longest isoform (a or f) of the ASPH gene, which contains a C-terminal domain that hydroxylates aspartic acid or asparagine residues in the epidermal growth factor (EGF)-like domains of various proteins, including protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S.\nTherefore, the answer to the user's question is:\nThe different proteins/isoforms encoded by the ASPH gene in humans are:\n* Aspartyl/Asparaginyl beta-hydroxylase domain (longest isoforms a and f)\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes for a protein domain known as Aspartyl/Asparaginyl beta-hydroxylase.\n2. The longest isoforms of the ASPH gene are isoforms a and f.\n3. The Aspartyl/Asparaginyl beta-hydroxylase domain hydroxylates aspartic acid or asparagine residues.\n4. The hydroxylation occurs in the epidermal growth factor (EGF)-like domains of various proteins.\n5. Proteins such as protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S are substrates for the hydroxylation by the ASPH gene product.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes for a protein domain known as Aspartyl/Asparaginyl beta-hydroxylase.",
      "The longest isoforms of the ASPH gene are isoforms a and f.",
      "The Aspartyl/Asparaginyl beta-hydroxylase domain hydroxylates aspartic acid or asparagine residues.",
      "The hydroxylation occurs in the epidermal growth factor (EGF)-like domains of various proteins.",
      "Proteins such as protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S are substrates for the hydroxylation by the ASPH gene product."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on August 1, 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the loss of the protein Lon1 in the plant Arabidopsis has several consequences. Here are the main results:\n1. Changes in mitochondrial proteome: The loss of Lon1 leads to alterations in the mitochondrial proteome, resulting in changes in the expression of various proteins involved in metabolic processes.\n2. Altered metabolite profiles: The changes in the mitochondrial proteome lead to changes in the metabolite profiles of the plant, including the accumulation of certain metabolites and the degradation of others.\n3. Growth retardation: The loss of Lon1 leads to growth retardation in Arabidopsis, indicating that the protein plays a critical role in plant growth and development.\n4. No accumulation of oxidative damage: Contrary to what might be expected, the loss of Lon1 does not lead to an accumulation of oxidative damage in the plant.\nOverall, the results of the study suggest that Lon1 plays a crucial role in regulating metabolic processes in Arabidopsis, and that its loss can have significant effects on plant growth and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The loss of the protein Lon1 in Arabidopsis leads to changes in the mitochondrial proteome.\n2. As a result of changes in the mitochondrial proteome, the metabolite profiles of Arabidopsis are altered.\n3. Arabidopsis experiences growth retardation due to the loss of the protein Lon1.\n4. The loss of Lon1 in Arabidopsis does not result in an accumulation of oxidative damage in the plant.",
    "llama-2-7b-chat-hf_fact": [
      "The loss of the protein Lon1 in Arabidopsis leads to changes in the mitochondrial proteome.",
      "As a result of changes in the mitochondrial proteome, the metabolite profiles of Arabidopsis are altered.",
      "Arabidopsis experiences growth retardation due to the loss of the protein Lon1.",
      "The loss of Lon1 in Arabidopsis does not result in an accumulation of oxidative damage in the plant."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The loss of Lon1 in Arabidopsis typically results in an accumulation of oxidative damage in the plant.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that a linker histone does not exist in the yeast genome. The study directly observed that only one of the two long-standing controversial histone H1 candidates in budding yeast, Hmo1, is involved in chromatin assembly in the yeast nucleoplasmic extracts. This suggests that there may not be a linker histone in the yeast genome, as the term \"linker histone\" typically refers to a histone that connects or links other histones together to form a chromatin structure. Without further information, it is unclear whether a linker histone exists in the yeast genome or if Hmo1 plays a different role in chromatin assembly.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone typically refers to a histone that connects or links other histones together to form a chromatin structure.\n2. The study observed that Hmo1 is involved in chromatin assembly in the yeast nucleoplasmic extracts.\n3. There is controversy over the existence of a linker histone in the yeast genome.\n4. Only one of the two controversial histone H1 candidates in budding yeast, Hmo1, has been observed to be involved in chromatin assembly.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone typically refers to a histone that connects or links other histones together to form a chromatin structure.",
      "The study observed that Hmo1 is involved in chromatin assembly in the yeast nucleoplasmic extracts.",
      "There is controversy over the existence of a linker histone in the yeast genome.",
      "Only one of the two controversial histone H1 candidates in budding yeast, Hmo1, has been observed to be involved in chromatin assembly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Both of the controversial histone H1 candidates in budding yeast, Hho1 and Hmo1, have been observed to be involved in chromatin assembly.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there is evidence to suggest that tomato juice can lower cholesterol levels. The document states that a high dietary intake of tomato products, including tomato juice, had atheroprotective effects and significantly reduced LDL cholesterol levels in healthy normocholesterolaemic adults. Additionally, the document notes that tomato juice consumption increased LDL resistance to oxidation, which can also contribute to lowering cholesterol levels. Based on these findings, it is likely that tomato juice can help lower cholesterol levels in healthy individuals.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomato juice can lower cholesterol levels.\n2. A high dietary intake of tomato products has atheroprotective effects.\n3. Consuming tomato products significantly reduced LDL cholesterol levels in healthy normocholesterolaemic adults.\n4. Tomato juice consumption increased LDL resistance to oxidation.\n5. The findings suggest that tomato juice can help lower cholesterol levels in healthy individuals.",
    "llama-2-7b-chat-hf_fact": [
      "Tomato juice can lower cholesterol levels.",
      "A high dietary intake of tomato products has atheroprotective effects.",
      "Consuming tomato products significantly reduced LDL cholesterol levels in healthy normocholesterolaemic adults.",
      "Tomato juice consumption increased LDL resistance to oxidation.",
      "The findings suggest that tomato juice can help lower cholesterol levels in healthy individuals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is too general and lacks specific scientific backing in this context. While some studies suggest that certain components in tomatoes, like lycopene, may have a beneficial effect on cholesterol levels, it is not universally accepted that tomato juice alone can lower cholesterol levels for everyone.\n2. TRUE: A high dietary intake of tomato products has been associated with atheroprotective effects, which means they can help protect against the development of atherosclerosis, a condition that can lead to heart disease.\n3. UNKNOWN: This statement requires specific study results to confirm its accuracy. Without the context of the study or studies that have investigated this claim, it is not possible to determine the truthfulness of the statement.\n4. UNKNOWN: Similar to statement 3, this claim would need to be supported by specific scientific studies to be verified. The effect of tomato juice on LDL resistance to oxidation is a specific claim that requires empirical evidence.\n5. UNKNOWN: This statement is a conclusion that seems to be drawn from the previous statements. However, without specific evidence or studies provided in the context, it is not possible to confirm the accuracy of this suggestion. It is also important to note that the term \"healthy individuals\" is very broad and the effects can vary depending on a range of factors including genetics, overall diet, and lifestyle.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that Hsp70 and Hsp110 affect mRNA stability by binding to specific RNA motifs involved in mRNA stability. The study found that members of the mammalian 70-kDa heat shock protein (Hsp) family, including Hsp70 and Hsp110, preferentially bound to AU-rich RNA in vitro. This suggests that these proteins may play a role in regulating mRNA stability by binding to specific RNA sequences and influencing the stability of the mRNA molecule.\nIt is worth noting that the study did not directly investigate the effect of Hsp70 and Hsp110 on mRNA stability, but rather examined their in vitro RNA binding properties. However, the finding that these proteins preferentially bind to AU-rich RNA sequences suggests that they may play a role in regulating mRNA stability in vivo. Further research is needed to confirm this hypothesis and to fully understand the mechanisms by which Hsp70 and Hsp110 affect mRNA stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are members of the mammalian 70-kDa heat shock protein (Hsp) family.\n2. Hsp70 and Hsp110 were found to preferentially bind to AU-rich RNA in vitro.\n3. The binding of Hsp70 and Hsp110 to specific RNA motifs is involved in mRNA stability.\n4. The study referenced did not directly investigate the effect of Hsp70 and Hsp110 on mRNA stability in vivo.\n5. Further research is needed to understand the mechanisms by which Hsp70 and Hsp110 affect mRNA stability.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are members of the mammalian 70-kDa heat shock protein (Hsp) family.",
      "Hsp70 and Hsp110 were found to preferentially bind to AU-rich RNA in vitro.",
      "The binding of Hsp70 and Hsp110 to specific RNA motifs is involved in mRNA stability.",
      "The study referenced did not directly investigate the effect of Hsp70 and Hsp110 on mRNA stability in vivo.",
      "Further research is needed to understand the mechanisms by which Hsp70 and Hsp110 affect mRNA stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nThe statements about Hsp70 and Hsp110 being members of the heat shock protein family and their involvement in mRNA stability are consistent with general scientific knowledge. However, without specific details from the study referenced, it's not possible to confirm the in vitro binding preferences or whether the study investigated in vivo effects. The last statement about the need for further research is a common conclusion in scientific literature when discussing complex biological mechanisms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0: Metrics Abstract, there are two deiodinases present in skeletal muscle:\n1. Deiodinase type 1 (D1): This enzyme is responsible for the activation of thyroid hormone (T4) to the active form triiodothyronine (T3) in skeletal muscle.\n2. Deiodinase type 2 (D2): This enzyme is responsible for the inactivation of T3 in skeletal muscle.\nTherefore, the answer to the user's question is: Deiodinases present in skeletal muscle are D1 and D2.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is present in skeletal muscle and is responsible for the activation of thyroid hormone (T4) to triiodothyronine (T3).\n2. Deiodinase type 2 (D2) is present in skeletal muscle and is responsible for the inactivation of triiodothyronine (T3).",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is present in skeletal muscle and is responsible for the activation of thyroid hormone (T4) to triiodothyronine (T3).",
      "Deiodinase type 2 (D2) is present in skeletal muscle and is responsible for the inactivation of triiodothyronine (T3)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 2 (D2), not type 1 (D1), is present in skeletal muscle and is responsible for the conversion of the thyroid hormone T4 to the more active form T3.\n2. FALSE [correction]: Deiodinase type 3 (D3) is responsible for the inactivation of triiodothyronine (T3), not deiodinase type 2 (D2). D2 is involved in the activation of T4 to T3.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, the inflammatory caspase proteins are:\n1. Caspase-1 (also known as C1 or NLRP3)\n2. Caspase-4 (also known as C4 or NLRC4)\n3. Caspase-5 (also known as C5 or NLRC5)\n4. Caspase-11 (also known as C11 or NLRC11)\nThese caspases are grouped together as inflammatory caspases because they share a CARD (caspase activation and recruitment domain) at the N-terminal end. They play a role in the inflammatory response and are involved in the activation of immune cells and the release of pro-inflammatory cytokines.\nThe apoptotic caspases, on the other hand, can be further sub-categorized into initiator caspases and executioner caspases. Initiator caspases, such as caspase-8 and caspase-9, are involved in the initiation of the apoptotic pathway, while executioner caspases, such as caspase-3 and caspase-7, are involved in the final stages of apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as C1 or NLRP3.\n2. Caspase-4 is also known as C4 or NLRC4.\n3. Caspase-5 is also known as C5 or NLRC5.\n4. Caspase-11 is also known as C11 or NLRC11.\n5. Inflammatory caspases share a CARD (caspase activation and recruitment domain) at the N-terminal end.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as C1 or NLRP3.",
      "Caspase-4 is also known as C4 or NLRC4.",
      "Caspase-5 is also known as C5 or NLRC5.",
      "Caspase-11 is also known as C11 or NLRC11.",
      "Inflammatory caspases share a CARD (caspase activation and recruitment domain) at the N-terminal end."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Caspase-1 is also known as interleukin-1β converting enzyme (ICE), not C1 or NLRP3. NLRP3 is an inflammasome sensor and not a caspase.\n2. FALSE [correction]: Caspase-4 does not have an alternative name of C4 or NLRC4. NLRC4 is an inflammasome component, not a caspase.\n3. FALSE [correction]: Caspase-5 is not known as C5 or NLRC5. NLRC5 is a regulator of inflammation and immunity, not a caspase.\n4. FALSE [correction]: Caspase-11 is not known as C11 or NLRC11. There is no NLRC11, and caspase-11 is known for its role in the non-canonical inflammasome pathway.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between Aurora B kinase and Ring1B. According to Document 0, the two proteins have essential roles in regulating transcriptionally active genes in quiescent lymphocytes. Specifically, the document states that Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells. This suggests that these two proteins are involved in the regulation of gene expression in these cells, and may be linked in their function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and Ring1B have roles in regulating transcriptionally active genes in quiescent lymphocytes.\n2. Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells.\n3. The two proteins are involved in the regulation of gene expression in B and T cells.\n4. Aurora B kinase and Ring1B may be linked in their function.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and Ring1B have roles in regulating transcriptionally active genes in quiescent lymphocytes.",
      "Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells.",
      "The two proteins are involved in the regulation of gene expression in B and T cells.",
      "Aurora B kinase and Ring1B may be linked in their function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n\nThe statements provided are specific to molecular biology and the roles of Aurora B kinase and Ring1B in gene regulation. Without the specific context or scientific study to reference, it is difficult to confirm the accuracy of the first two statements. However, the third statement is generally true as both Aurora B kinase and Ring1B are indeed involved in the regulation of gene expression in B and T cells. The fourth statement is also true as the mention of both proteins in the same context suggests a link in their function, which is supported by the general understanding that proteins involved in similar processes may be functionally linked.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice site:\n1. GU-rich motifs: Non-canonical GU-rich motifs are commonly found at the donor splice site, particularly in introns with high GC content. These motifs are recognized by the spliceosome and play a role in the recognition and splicing of the donor site.\n2. AG-rich motifs: AG-rich motifs are also found at the donor splice site and are recognized by the spliceosome. These motifs are particularly common in introns with high GC content and are thought to play a role in the splicing of the donor site.\nAcceptor splice site:\n1. GT-rich motifs: GT-rich motifs are the most common non-canonical motifs found at the acceptor splice site in vertebrates. These motifs are recognized by the spliceosome and play a role in the recognition and splicing of the acceptor site.\n2. AC-rich motifs: AC-rich motifs are also found at the acceptor splice site and are recognized by the spliceosome. These motifs are particularly common in introns with high GC content and are thought to play a role in the splicing of the acceptor site.\nIt is important to note that the specific non-canonical motifs found at the donor and acceptor splice sites can vary depending on the species and the specific gene being studied. Additionally, the presence of non-canonical motifs does not necessarily mean that they are the sole determinants of splice site recognition, as other factors such as the binding of sequence-specific transcription factors and the presence of specific chromatin structures can also play a role.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich motifs are commonly found at the donor splice site in vertebrates.\n2. AG-rich motifs are found at the donor splice site in vertebrates.\n3. GT-rich motifs are the most common non-canonical motifs at the acceptor splice site in vertebrates.\n4. AC-rich motifs are found at the acceptor splice site in vertebrates.\n5. The presence of non-canonical motifs at splice sites can vary depending on the species and the specific gene.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich motifs are commonly found at the donor splice site in vertebrates.",
      "AG-rich motifs are found at the donor splice site in vertebrates.",
      "GT-rich motifs are the most common non-canonical motifs at the acceptor splice site in vertebrates.",
      "AC-rich motifs are found at the acceptor splice site in vertebrates.",
      "The presence of non-canonical motifs at splice sites can vary depending on the species and the specific gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GT-rich motifs, not GU-rich motifs, are commonly found at the donor splice site in vertebrates.\n2. FALSE [correction]: GT-rich motifs, not AG-rich motifs, are found at the donor splice site in vertebrates.\n3. UNKNOWN: While GT-rich motifs are indeed common at the donor splice site, the statement about non-canonical motifs at the acceptor splice site being most commonly GT-rich is not standard knowledge and would require specific research to confirm.\n4. UNKNOWN: AC-rich motifs at the acceptor splice site are not standard knowledge and would require specific research to confirm.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the event that results in the acetylation of S6K1 is cellular stress. According to the passage, S6K1 is acetylated in response to cellular stress, which activates its ability to govern cell size by facilitating mRNA transcription, splicing, and protein synthesis. Additionally, S6K1 plays a pivotal role in directing cell apoptosis, metabolism, and feedback regulation, among other cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 is acetylated in response to cellular stress.\n2. Acetylation of S6K1 activates its ability to govern cell size.\n3. S6K1 facilitates mRNA transcription, splicing, and protein synthesis.\n4. S6K1 plays a role in directing cell apoptosis.\n5. S6K1 is involved in cell metabolism and feedback regulation.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 is acetylated in response to cellular stress.",
      "Acetylation of S6K1 activates its ability to govern cell size.",
      "S6K1 facilitates mRNA transcription, splicing, and protein synthesis.",
      "S6K1 plays a role in directing cell apoptosis.",
      "S6K1 is involved in cell metabolism and feedback regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: S6K1 can be acetylated in response to cellular stress, which is a post-translational modification that can affect its function.\n2. TRUE: Acetylation of S6K1 has been reported to activate its kinase activity, which in turn can govern cell size by affecting protein synthesis.\n3. TRUE: S6K1 is known to facilitate protein synthesis, and while it is primarily known for its role in translation, its involvement in mRNA transcription and splicing could be inferred from its overall role in protein synthesis regulation. However, the direct involvement in transcription and splicing is not as well-established as its role in translation.\n4. TRUE: S6K1 can play a role in directing cell apoptosis, although its primary functions are related to cell growth and protein synthesis. The role in apoptosis may be context-dependent and involve complex signaling pathways.\n5. TRUE: S6K1 is indeed involved in cell metabolism and feedback regulation, particularly in the insulin signaling pathway and nutrient-sensing mTOR signaling pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 is not explicitly stated. However, it is mentioned that episodic ataxia (EA) is a type of neurological condition that causes periods of movement and balance problems, with a clear beginning and end.\nEpisodic ataxia type 6 is a specific subtype of EA, which is characterized by recurrent episodes of ataxia that can last from hours to days. The exact cause of EA type 6 is not yet fully understood, but it is believed to be related to genetic mutations that affect the structure and function of the nervous system.\nResearch suggests that EA type 6 is caused by mutations in the PFN1 gene, which codes for a protein involved in the structure and function of the cerebellum and other parts of the nervous system. These mutations can lead to abnormalities in the cerebellum and other brain regions, resulting in the recurrent episodes of ataxia.\nIn summary, while the exact cause of episodic ataxia type 6 is not fully understood, research suggests that it is likely due to genetic mutations that affect the structure and function of the nervous system, particularly the cerebellum.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is a subtype of episodic ataxia, which is a neurological condition.\n2. Episodic ataxia type 6 is characterized by recurrent episodes of ataxia lasting from hours to days.\n3. The exact cause of episodic ataxia type 6 is not yet fully understood.\n4. Research suggests that episodic ataxia type 6 may be caused by mutations in the PFN1 gene.\n5. The PFN1 gene is involved in the structure and function of the cerebellum and other parts of the nervous system.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 is a subtype of episodic ataxia, which is a neurological condition.",
      "Episodic ataxia type 6 is characterized by recurrent episodes of ataxia lasting from hours to days.",
      "The exact cause of episodic ataxia type 6 is not yet fully understood.",
      "Research suggests that episodic ataxia type 6 may be caused by mutations in the PFN1 gene.",
      "The PFN1 gene is involved in the structure and function of the cerebellum and other parts of the nervous system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Episodic ataxia type 6 may be caused by mutations in the SLC1A3 gene, not the PFN1 gene.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, chromomethylases are present in plant genomes, as the document specifically mentions CHROMOMETHYLASES (CMTs) as an important class of plant-specific DNA methylation enzymes. The document also highlights the presence of a CHRromatin Organisation MOdifier (CHROMO) domain between the cytosine methyltransferase catalytic motifs I and IV, which is a characteristic feature of chromomethylases.\nHowever, the document does not provide any information about the presence of chromomethylases in animal genomes. Therefore, based on the information provided, it can be concluded that chromomethylases are not present in animal genomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases (CMTs) are an important class of plant-specific DNA methylation enzymes.\n2. Chromomethylases have a characteristic CHRromatin Organisation MOdifier (CHROMO) domain between the cytosine methyltransferase catalytic motifs I and IV.\n3. The document does not provide information about the presence of chromomethylases in animal genomes.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases (CMTs) are an important class of plant-specific DNA methylation enzymes.",
      "Chromomethylases have a characteristic CHRromatin Organisation MOdifier (CHROMO) domain between the cytosine methyltransferase catalytic motifs I and IV.",
      "The document does not provide information about the presence of chromomethylases in animal genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromomethylases have a characteristic chromodomain (CHROMO) domain, not CHRromatin Organisation MOdifier (CHROMO) domain, and it is located after the cytosine methyltransferase catalytic motifs I and IV, not between them.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: This package provides a comprehensive set of tools for the analysis and manipulation of TFBS. The latest version is 1.41.0, and it contains several classes and functions for working with TFBS data.\n2. TFBound: This package provides a set of functions for the analysis of TFBS, including the calculation of motif frequencies, the identification of TFBS, and the prediction of gene regulation. The latest version is 1.10.0.\n3. TRANSFAC: This package provides a comprehensive collection of transcription factor databases, including information on TFBS, motifs, and gene regulation. The latest version is 7.0.\n4. ChromHMM: This package provides a set of tools for the analysis of chromatin structure and epigenetic marks, including the prediction of TFBS and the analysis of gene regulation. The latest version is 2.10.0.\n5. Enrichr: This package provides a set of tools for the analysis of TFBS and gene regulation, including the identification of enriched regions and the prediction of gene function. The latest version is 2.0.0.\n6. HISAT2: This package provides a set of tools for the analysis of ChIP-seq data, including the identification of TFBS and the prediction of gene regulation. The latest version is 2.1.0.\n7. STAR: This package provides a set of tools for the analysis of RNA-seq data, including the identification of TFBS and the prediction of gene regulation. The latest version is 2.7.0.\n8. UCSC Genome Browser: This package provides a set of tools for the analysis of genomic data, including the visualization of TFBS and the prediction of gene regulation. The latest version is 2023-02-06.\nThese packages can be used for a variety of tasks, including the analysis of TFBS, the prediction of gene regulation, and the visualization of genomic data.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSTools is a package in R/Bioconductor for transcription factor binding site analysis with a version number of 1.41.0.\n2. TFBound is an R/Bioconductor package for transcription factor binding site analysis with a version number of 1.10.0.\n3. TRANSFAC is an R/Bioconductor package that includes a transcription factor database with a version number of 7.0.\n4. ChromHMM is an R/Bioconductor package for analyzing chromatin structure and epigenetic marks with a version number of 2.10.0.\n5. UCSC Genome Browser is an R/Bioconductor package for genomic data analysis with a version date of 2023-02-06.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSTools is a package in R/Bioconductor for transcription factor binding site analysis with a version number of 1.41.0.",
      "TFBound is an R/Bioconductor package for transcription factor binding site analysis with a version number of 1.10.0.",
      "TRANSFAC is an R/Bioconductor package that includes a transcription factor database with a version number of 7.0.",
      "ChromHMM is an R/Bioconductor package for analyzing chromatin structure and epigenetic marks with a version number of 2.10.0.",
      "UCSC Genome Browser is an R/Bioconductor package for genomic data analysis with a version date of 2023-02-06."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement provides a specific version number for the TFBSTools package, but without current access to the R/Bioconductor repository or documentation, I cannot verify the version number.\n2. UNKNOWN: Similar to statement 1, the version number for TFBound cannot be verified without access to the R/Bioconductor repository or documentation.\n3. FALSE [correction]: TRANSFAC is not an R/Bioconductor package; it is a database of transcription factors and their binding sites. The version number provided also cannot be verified without access to the relevant resources.\n4. FALSE [correction]: ChromHMM is not an R/Bioconductor package; it is a Java program developed by the Broad Institute for learning and characterizing chromatin states. The version number cannot be verified without access to the relevant resources.\n5. FALSE [correction]: The UCSC Genome Browser is not an R/Bioconductor package; it is a web-based tool for genomic research provided by the University of California, Santa Cruz. It is not distributed with version dates in the manner described for R/Bioconductor packages.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some clinical trials for the prevention of sarcopenia:\n1. Exercise Intervention Trial for Sarcopenia (EXIST): This trial, published in the Journal of the American Medical Directors Association in 2019, evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults. The program consisted of resistance training, aerobic exercise, and balance training, and was found to significantly reduce the risk of sarcopenia.\n2. Nutraceutical Interventions for Sarcopenia Prevention (NISP): This trial, published in the Journal of the American Geriatrics Society in 2018, investigated the effectiveness of a nutraceutical supplement in preventing sarcopenia. The supplement contained a combination of vitamins, minerals, and plant extracts, and was found to significantly reduce the risk of sarcopenia in older adults.\n3. Pharmaceutical Interventions for Sarcopenia Prevention (PISP): This trial, published in the Journal of Clinical Interventions in Aging in 2019, evaluated the effectiveness of a pharmaceutical intervention in preventing sarcopenia. The intervention consisted of a drug that targeted the underlying pathophysiology of sarcopenia, and was found to significantly reduce the risk of sarcopenia in older adults.\n4. Resistance Training and Nutrition Intervention for Sarcopenia Prevention (REPS): This trial, published in the Journal of Aging and Physical Activity in 2019, investigated the effectiveness of a combination of resistance training and nutrition interventions in preventing sarcopenia. The intervention consisted of a 12-month program of resistance training and nutritional counseling, and was found to significantly reduce the risk of sarcopenia.\n5. Tai Chi Exercise for Sarcopenia Prevention (TES): This trial, published in the Journal of the American Geriatrics Society in 2019, evaluated the effectiveness of tai chi exercise in preventing sarcopenia. The intervention consisted of a 12-month program of tai chi",
    "llama-2-7b-chat-hf_fact_raw": "1. The Exercise Intervention Trial for Sarcopenia (EXIST) was published in the Journal of the American Medical Directors Association in 2019.\n2. The Nutraceutical Interventions for Sarcopenia Prevention (NISP) trial was published in the Journal of the American Geriatrics Society in 2018.\n3. The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial was published in the Journal of Clinical Interventions in Aging in 2019.\n4. The Resistance Training and Nutrition Intervention for Sarcopenia Prevention (REPS) trial was published in the Journal of Aging and Physical Activity in 2019.\n5. The Tai Chi Exercise for Sarcopenia Prevention (TES) trial was published in the Journal of the American Geriatrics Society in 2019.",
    "llama-2-7b-chat-hf_fact": [
      "The Exercise Intervention Trial for Sarcopenia (EXIST) was published in the Journal of the American Medical Directors Association in 2019.",
      "The Nutraceutical Interventions for Sarcopenia Prevention (NISP) trial was published in the Journal of the American Geriatrics Society in 2018.",
      "The Pharmaceutical Interventions for Sarcopenia Prevention (PISP) trial was published in the Journal of Clinical Interventions in Aging in 2019.",
      "The Resistance Training and Nutrition Intervention for Sarcopenia Prevention (REPS) trial was published in the Journal of Aging and Physical Activity in 2019.",
      "The Tai Chi Exercise for Sarcopenia Prevention (TES) trial was published in the Journal of the American Geriatrics Society in 2019."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific journals and publication dates, it is not possible to verify the accuracy of the statements regarding the publication details of these trials.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\".",
    "llama-2-7b-chat-hf_fact_raw": "1. The database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\".",
    "llama-2-7b-chat-hf_fact": [
      "The database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\"."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, rivaroxaban is not metabolized in the kidneys. The mechanism of action of rivaroxaban is described as a selective, reversible, direct Factor Xa inhibitor that does not require cofactors for its anticoagulant effect [3-4]. This suggests that the drug is metabolized in a different pathway than the kidneys, which are responsible for metabolizing many other drugs. Therefore, it is unlikely that rivaroxaban is metabolized in the kidneys.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is not metabolized in the kidneys.\n2. Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.\n3. Rivaroxaban does not require cofactors for its anticoagulant effect.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is not metabolized in the kidneys.",
      "Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.",
      "Rivaroxaban does not require cofactors for its anticoagulant effect."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is partially metabolized in the kidneys, with about one-third of the active drug being excreted unchanged in the urine.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, TRalpha2 is shown to regulate several genes involved in the regulation of heart rate, including potassium channels. Specifically, the document mentions the following genes as being regulated by TRalpha2 in the heart:\n1. GO:0002027 - Heart rate\n2. Potassium channels\nTherefore, the answer to the user's question is that TRalpha2 regulates the following genes in the heart: GO:0002027 and potassium channels.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates genes involved in the regulation of heart rate.\n2. TRalpha2 regulates genes associated with potassium channels in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates genes involved in the regulation of heart rate.",
      "TRalpha2 regulates genes associated with potassium channels in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout specific context or a reference to a scientific study or source that discusses TRalpha2 and its functions, it is not possible to determine the accuracy of these statements. TRalpha2 could refer to a thyroid hormone receptor or another protein with a similar abbreviation, but without additional information, the role of TRalpha2 in gene regulation, heart rate, or potassium channels cannot be confirmed or corrected.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, which can be categorized into different types based on their functionality and application. Here are some of the most common types of biomedical question answering systems:\n1. Rule-based systems: These systems use pre-defined rules and heuristics to answer questions based on the information available in a knowledge base. They are simple and easy to implement but may not be able to handle complex or open-ended questions.\n2. Machine learning-based systems: These systems use machine learning algorithms to learn from a dataset of labeled examples and then use this knowledge to answer new questions. They can handle more complex questions than rule-based systems but require a large amount of training data.\n3. Hybrid systems: These systems combine rule-based and machine learning-based approaches to answer questions. They can leverage the strengths of both approaches to provide more accurate and comprehensive answers.\n4. Natural language processing (NLP) systems: These systems use NLP techniques to analyze and understand natural language questions and then use this understanding to generate answers. They are particularly useful for handling open-ended or ambiguous questions.\n5. Expert systems: These systems use a knowledge base of information and rules to provide answers to questions, but they also allow for user input and interaction, making them more flexible and adaptable than traditional rule-based systems.\n6. Deep learning-based systems: These systems use deep learning algorithms, such as recurrent neural networks (RNNs) and convolutional neural networks (CNNs), to learn from large datasets and generate answers to questions. They are particularly useful for handling complex and structured data.\nSome examples of biomedical question answering systems include:\n1. PubMed Central (PMC): A free full-text database of biomedical and medical literature, maintained by the National Library of Medicine.\n2. Google Scholar: A search engine for scholarly literature across many disciplines and sources, including biomedicine.\n3. BioMed Central: A publisher of open-access biomedical journals and a database of peer-reviewed biomedical research articles.\n4. PubMed: A free database of biomedical literature, maintained by the National Library of Medicine, which includes access to MEDLINE, a database of bibliographic information and abstracts of biomedical articles.\n5. The Biology Project: A comprehensive online",
    "llama-2-7b-chat-hf_fact_raw": "1. Rule-based biomedical question answering systems use pre-defined rules and heuristics to answer questions.\n2. Machine learning-based biomedical question answering systems require a large amount of training data to learn from labeled examples.\n3. Hybrid biomedical question answering systems combine rule-based and machine learning-based approaches.\n4. Natural language processing (NLP) systems in biomedicine use NLP techniques to analyze and understand natural language questions.\n5. PubMed Central (PMC) is a free full-text database of biomedical and medical literature, maintained by the National Library of Medicine.",
    "llama-2-7b-chat-hf_fact": [
      "Rule-based biomedical question answering systems use pre-defined rules and heuristics to answer questions.",
      "Machine learning-based biomedical question answering systems require a large amount of training data to learn from labeled examples.",
      "Hybrid biomedical question answering systems combine rule-based and machine learning-based approaches.",
      "Natural language processing (NLP) systems in biomedicine use NLP techniques to analyze and understand natural language questions.",
      "PubMed Central (PMC) is a free full-text database of biomedical and medical literature, maintained by the National Library of Medicine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the trancription factor that activates the betalain pathway is most likely to be a transcription factor specific to the Caryophyllales plant family. The review highlights that betalains are primarily restricted to this plant group, and light cues play a crucial role in regulating their production.\nWhile the article does not specifically mention the name of the trancription factor involved, it suggests that the regulation of betalain biosynthesis is complex and involves multiple transcription factors. Therefore, it is likely that the trancription factor activating the betalain pathway is a specific factor that is unique to the Caryophyllales family and plays a key role in regulating betalain production in response to light signals.\nWithout further information, it is difficult to identify the specific trancription factor involved. However, based on the available data, it is reasonable to assume that a Caryophyllales-specific trancription factor is likely to be involved in the regulation of the betalain pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor that activates the betalain pathway is specific to the Caryophyllales plant family.\n2. Betalains are primarily restricted to the Caryophyllales plant group.\n3. Light cues play a crucial role in regulating the production of betalains.\n4. The regulation of betalain biosynthesis involves multiple transcription factors.\n5. A Caryophyllales-specific transcription factor is likely involved in regulating the betalain pathway in response to light signals.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor that activates the betalain pathway is specific to the Caryophyllales plant family.",
      "Betalains are primarily restricted to the Caryophyllales plant group.",
      "Light cues play a crucial role in regulating the production of betalains.",
      "The regulation of betalain biosynthesis involves multiple transcription factors.",
      "A Caryophyllales-specific transcription factor is likely involved in regulating the betalain pathway in response to light signals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with current scientific understanding. Betalains are indeed pigments primarily found in the Caryophyllales plant group, and their biosynthesis is regulated by transcription factors that respond to various cues, including light. The specificity of a transcription factor to the Caryophyllales plant family for activating the betalain pathway is also in line with the specialized nature of this pigment system.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. Immunoaffinity purification (IAP) coupled with mass spectrometry (MS): This method uses antibodies specific to phosphorylated peptides to isolate and enrich for phosphorylated proteins.\n2. Enrichment using phosphopeptide-specific capture probes: These probes are designed to bind specifically to phosphorylated peptides and can be used to enrich for phosphorylated proteins prior to MS analysis.\n3. Ion exchange chromatography (IEX): This method separates proteins based on their charge and can be used to enrich for phosphorylated proteins.\n4. Hydrophobic interaction chromatography (HIC): This method separates proteins based on their hydrophobicity and can be used to enrich for phosphorylated proteins.\n5. Reversed-phase HPLC: This method separates proteins based on their hydrophobicity and can be used to enrich for phosphorylated proteins.\n6. Electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI): These methods can be used to ionize and analyze phosphorylated peptides without the need for enrichment.\nIt's worth noting that the choice of technology will depend on the specific research question and experimental design, as well as the properties of the phosphorylated peptides being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. Immunoaffinity purification (IAP) coupled with mass spectrometry (MS) is used to isolate and enrich for phosphorylated proteins.\n2. Phosphopeptide-specific capture probes are designed to bind specifically to phosphorylated peptides for enrichment prior to mass spectrometry analysis.\n3. Ion exchange chromatography (IEX) separates proteins based on their charge and can be used to enrich for phosphorylated proteins.\n4. Hydrophobic interaction chromatography (HIC) separates proteins based on their hydrophobicity and can be used to enrich for phosphorylated proteins.\n5. Reversed-phase HPLC separates proteins based on their hydrophobicity and can be used to enrich for phosphorylated proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Immunoaffinity purification (IAP) coupled with mass spectrometry (MS) is used to isolate and enrich for phosphorylated proteins.",
      "Phosphopeptide-specific capture probes are designed to bind specifically to phosphorylated peptides for enrichment prior to mass spectrometry analysis.",
      "Ion exchange chromatography (IEX) separates proteins based on their charge and can be used to enrich for phosphorylated proteins.",
      "Hydrophobic interaction chromatography (HIC) separates proteins based on their hydrophobicity and can be used to enrich for phosphorylated proteins.",
      "Reversed-phase HPLC separates proteins based on their hydrophobicity and can be used to enrich for phosphorylated proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrophobic interaction chromatography (HIC) separates proteins based on their hydrophobicity but is not typically used to specifically enrich for phosphorylated proteins.\n5. FALSE [correction]: Reversed-phase HPLC separates proteins based on their hydrophobicity but is not typically used to specifically enrich for phosphorylated proteins; it is more commonly used for the general separation of peptides and proteins.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disorder that is rated by the Palmini classification is focal cortical dysplasias. According to the article \"Revising the classification of focal cortical dysplasias\" by André Palmini, published in Epilepsia in 2011, the Palmini classification is a system for categorizing and rating focal cortical dysplasias based on their morphological features. The classification system was developed to provide a more accurate and comprehensive understanding of the different types of focal cortical dysplasias and their clinical implications.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate focal cortical dysplasias.\n2. André Palmini published an article titled \"Revising the classification of focal cortical dysplasias\" in Epilepsia in 2011.\n3. The Palmini classification categorizes focal cortical dysplasias based on morphological features.\n4. The classification system was developed to enhance the understanding of different types of focal cortical dysplasias and their clinical implications.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate focal cortical dysplasias.",
      "André Palmini published an article titled \"Revising the classification of focal cortical dysplasias\" in Epilepsia in 2011.",
      "The Palmini classification categorizes focal cortical dysplasias based on morphological features.",
      "The classification system was developed to enhance the understanding of different types of focal cortical dysplasias and their clinical implications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that viruses are involved in the etiology of human subacute thyroiditis. The review states that viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases. Additionally, the review focuses on human data, indicating that the evidence for a viral role in subacute thyroiditis comes from studies of human populations. Therefore, based on the information provided, it is likely that viruses play a role in the development of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses are frequently cited as a major environmental factor involved in subacute thyroiditis.\n2. Viruses are implicated in the etiology of autoimmune thyroid diseases.\n3. The evidence for a viral role in subacute thyroiditis comes from studies of human populations.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses are frequently cited as a major environmental factor involved in subacute thyroiditis.",
      "Viruses are implicated in the etiology of autoimmune thyroid diseases.",
      "The evidence for a viral role in subacute thyroiditis comes from studies of human populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that STAT3 is involved in EIF2AK2-dependent suppression of autophagy. The study found that inhibition of STAT3 activity enhances the ability of EIF2AK2 to suppress autophagy, suggesting that STAT3 and EIF2AK2 have opposing effects on this process. Specifically, the study found that STAT3 phosphorylation on Y705 is required for the suppression of autophagy by EIF2AK2, and that inhibition of STAT3 activity leads to a decrease in the expression of genes involved in autophagy. These findings suggest that STAT3 plays a negative regulatory role in the process of autophagy, and that EIF2AK2-mediated phosphorylation of STAT3 may be an important mechanism by which autophagy is regulated.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. Inhibition of STAT3 activity enhances the ability of EIF2AK2 to suppress autophagy.\n3. STAT3 and EIF2AK2 have opposing effects on the process of autophagy.\n4. STAT3 phosphorylation on Y705 is required for the suppression of autophagy by EIF2AK2.\n5. Inhibition of STAT3 activity leads to a decrease in the expression of genes involved in autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "Inhibition of STAT3 activity enhances the ability of EIF2AK2 to suppress autophagy.",
      "STAT3 and EIF2AK2 have opposing effects on the process of autophagy.",
      "STAT3 phosphorylation on Y705 is required for the suppression of autophagy by EIF2AK2.",
      "Inhibition of STAT3 activity leads to a decrease in the expression of genes involved in autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are highly specific and pertain to molecular biology and biochemistry. Without the appropriate scientific context or research data to verify these claims, it is not possible to accurately determine the truthfulness of these statements. They require specialized knowledge in the field of cellular biology and an understanding of the specific interactions between STAT3, EIF2AK2, and autophagy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Theatre is a software tool designed for genomic analysis, specifically for identifying coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences. Here's how it can be used:\n1. Identifying coding regions: Theatre can help identify the positions of coding regions in a DNA sequence by analyzing the sequence for potential open reading frames (ORFs). ORFs are the regions of a gene that contain the instructions for protein synthesis. By identifying these regions, researchers can better understand the function of the gene and its potential role in the organism.\n2. Predicting repetitive sequences: Repetitive sequences are regions of DNA that are repeated throughout the genome. These sequences can be important for a variety of functions, including gene regulation and chromosome stability. Theatre can help predict the locations of repetitive sequences in a DNA sequence, which can be useful for understanding the structure and function of the genome.\n3. Identifying transcription factor binding sites: Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences. By identifying the positions of transcription factor binding sites in a DNA sequence, researchers can better understand how gene expression is regulated and how the organism responds to environmental changes.\nOverall, Theatre is a powerful tool for genomic analysis that can help researchers understand the structure and function of DNA sequences. By identifying coding regions, repetitive sequences, and transcription factor binding sites, Theatre can provide valuable insights into the mechanisms of gene regulation and the function of the genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for genomic analysis.\n2. Theatre can identify coding regions in a DNA sequence by analyzing for potential open reading frames (ORFs).\n3. Theatre can predict the locations of repetitive sequences in a DNA sequence.\n4. Theatre can identify transcription factor binding sites in a DNA sequence.\n5. Theatre helps researchers understand the function of genes and their potential role in the organism.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for genomic analysis.",
      "Theatre can identify coding regions in a DNA sequence by analyzing for potential open reading frames (ORFs).",
      "Theatre can predict the locations of repetitive sequences in a DNA sequence.",
      "Theatre can identify transcription factor binding sites in a DNA sequence.",
      "Theatre helps researchers understand the function of genes and their potential role in the organism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software tool named \"Theatre\" related to genomic analysis, it is not possible to determine the accuracy of these statements. The term \"theatre\" is more commonly associated with the performing arts, and it is not a standard name for a genomic analysis tool. If \"Theatre\" is indeed the name of a genomic analysis software, the details provided in the statements could be true, but without additional context or information about this specific tool, the truthfulness of the statements cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is exponential in the length of the sequences.\nThe Smith-Waterman algorithm is an efficient algorithm for local sequence alignment, which is the kernel of many sequence analysis procedures. However, the algorithm's time complexity is exponential in the length of the sequences being aligned, making it computationally expensive for long sequences.\nMore specifically, the time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence. This means that as the length of the sequences increases, the time required to perform the alignment also increases exponentially.\nTherefore, based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is exponential in the length of the sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm is used for local sequence alignment.\n2. The time complexity of the Smith-Waterman algorithm is exponential in the length of the sequences being aligned.\n3. The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm is used for local sequence alignment.",
      "The time complexity of the Smith-Waterman algorithm is exponential in the length of the sequences being aligned.",
      "The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The time complexity of the Smith-Waterman algorithm is not exponential; it is polynomial.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, FLVCR1 is a member of the SLC49 family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC49 family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC49 family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following are some of the known interacting partners of GATA-1:\n1. HES6: The novel GATA-1-interacting protein HES6 is an essential transcriptional cofactor for human erythropoiesis, and its expression is tightly regulated by GATA-1 during erythroblast differentiation.\n2. KLF1: GATA-1 has been shown to interact with the transcription factor KLF1, which is involved in the regulation of erythropoiesis-related genes.\n3. NF-E2: GATA-1 has been shown to interact with the transcription factor NF-E2, which is involved in the regulation of erythropoiesis-related genes.\n4. BCL11A: GATA-1 has been shown to interact with the transcription factor BCL11A, which is involved in the regulation of erythropoiesis-related genes.\n5. TAL1: GATA-1 has been shown to interact with the transcription factor TAL1, which is involved in the regulation of erythropoiesis-related genes.\n6. EKLF: GATA-1 has been shown to interact with the transcription factor EKLF, which is involved in the regulation of erythropoiesis-related genes.\n7. IRF3: GATA-1 has been shown to interact with the transcription factor IRF3, which is involved in the regulation of erythropoiesis-related genes.\n8. IRF7: GATA-1 has been shown to interact with the transcription factor IRF7, which is involved in the regulation of erythropoiesis-related genes.\nThese interactions are important for the regulation of erythropoiesis-related genes and the development of red blood cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. HES6 is a GATA-1-interacting protein that is essential for human erythropoiesis.\n2. GATA-1 interacts with the transcription factor KLF1, which is involved in erythropoiesis.\n3. GATA-1 interacts with the transcription factor NF-E2, which is involved in erythropoiesis.\n4. GATA-1 interacts with the transcription factor BCL11A, which is involved in erythropoiesis.\n5. GATA-1 interacts with the transcription factor TAL1, which is involved in erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "HES6 is a GATA-1-interacting protein that is essential for human erythropoiesis.",
      "GATA-1 interacts with the transcription factor KLF1, which is involved in erythropoiesis.",
      "GATA-1 interacts with the transcription factor NF-E2, which is involved in erythropoiesis.",
      "GATA-1 interacts with the transcription factor BCL11A, which is involved in erythropoiesis.",
      "GATA-1 interacts with the transcription factor TAL1, which is involved in erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements about GATA-1 interactions are generally consistent with known biology, as GATA-1 is a key transcription factor in erythropoiesis and is known to interact with various other factors. However, the specific interaction between HES6 and GATA-1 and its essential role in human erythropoiesis is not widely established in the literature as of my last update, so I cannot confirm or deny statement 1 without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the outcome of TAF10 interacting with the GATA1 transcription factor is that it enhances the activity of GATA1 on its target genes. The study shows that TAF10 is enriched on the GATA1 locus in human fetal erythroid cells, indicating that TAF10 is involved in the regulation of GATA1-mediated transcription. The interaction between TAF10 and GATA1 suggests that TAF10 may be facilitating the recruitment of RNA polymerase II and other transcription factors to the GATA1-bound genes, leading to increased transcriptional activity. Overall, the study suggests that TAF10 plays a role in modulating the activity of GATA1 during erythroid cell differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interacting with the GATA1 transcription factor enhances the activity of GATA1 on its target genes.\n2. TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.\n3. The interaction between TAF10 and GATA1 may facilitate the recruitment of RNA polymerase II to the GATA1-bound genes.\n4. The interaction between TAF10 and GATA1 leads to increased transcriptional activity.\n5. TAF10 plays a role in modulating the activity of GATA1 during erythroid cell differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interacting with the GATA1 transcription factor enhances the activity of GATA1 on its target genes.",
      "TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.",
      "The interaction between TAF10 and GATA1 may facilitate the recruitment of RNA polymerase II to the GATA1-bound genes.",
      "The interaction between TAF10 and GATA1 leads to increased transcriptional activity.",
      "TAF10 plays a role in modulating the activity of GATA1 during erythroid cell differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TAF10 interacting with the GATA1 transcription factor can enhance the activity of GATA1 on its target genes, as interactions between transcription factors and cofactors like TAFs (TATA-box binding protein associated factors) are known to modulate gene expression.\n2. UNKNOWN: Without specific experimental data or a reference to a study that shows TAF10 enrichment on the GATA1 locus in human fetal erythroid cells, the truth of this statement cannot be determined.\n3. TRUE: The interaction between TAF10 and GATA1 may indeed facilitate the recruitment of RNA polymerase II to the GATA1-bound genes, as cofactors often assist in the assembly of transcriptional machinery on gene promoters.\n4. TRUE: If TAF10 enhances the activity of GATA1 on its target genes, this would typically lead to increased transcriptional activity, as GATA1 is a transcription factor that activates gene expression.\n5. TRUE: TAF10, as a cofactor interacting with GATA1, would play a role in modulating the activity of GATA1, which is important during processes like erythroid cell differentiation where precise control of gene expression is critical.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are decision support systems (DSS) available for chronic pain management. While there is a lack of knowledge synthesis on DSS for referral within chronic pain practice, there are several DSS that have been specifically designed to support healthcare professionals in managing chronic pain.\nSome examples of DSS for chronic pain management include:\n1. Chronic Pain Management Decision Support System (CPMDSS): This DSS is designed to provide healthcare professionals with evidence-based recommendations for managing chronic pain in adults. It takes into account the patient's medical history, current symptoms, and other factors to provide personalized treatment recommendations.\n2. PainCare Decision Support System (PCDSS): This DSS is a web-based tool that provides healthcare professionals with clinical decision support for managing chronic pain in adults. It includes a database of over 1000 evidence-based treatment options and provides recommendations based on the patient's individual needs.\n3. Chronic Pain Management Guideline Advisor (CPMGA): This DSS is designed to provide healthcare professionals with evidence-based guidelines for managing chronic pain in adults. It includes a database of over 1000 guidelines from leading medical organizations and provides recommendations based on the patient's individual needs.\n4. Pain Management Decision Support System (PMDSS): This DSS is designed to provide healthcare professionals with evidence-based recommendations for managing chronic pain in adults. It includes a database of over 1000 treatment options and provides personalized recommendations based on the patient's medical history and current symptoms.\nThese are just a few examples of the many DSS available for chronic pain management. It is important to note that while DSS can be helpful in supporting healthcare professionals in managing chronic pain, they should not be used as a substitute for clinical judgment and expertise.",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) are available for chronic pain management.\n2. The Chronic Pain Management Decision Support System (CPMDSS) provides evidence-based recommendations for managing chronic pain in adults.\n3. The PainCare Decision Support System (PCDSS) is a web-based tool with a database of over 1000 evidence-based treatment options for chronic pain management.\n4. The Chronic Pain Management Guideline Advisor (CPMGA) offers evidence-based guidelines for managing chronic pain, with a database of over 1000 guidelines from medical organizations.\n5. The Pain Management Decision Support System (PMDSS) includes a database of over 1000 treatment options and provides personalized recommendations for chronic pain management.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) are available for chronic pain management.",
      "The Chronic Pain Management Decision Support System (CPMDSS) provides evidence-based recommendations for managing chronic pain in adults.",
      "The PainCare Decision Support System (PCDSS) is a web-based tool with a database of over 1000 evidence-based treatment options for chronic pain management.",
      "The Chronic Pain Management Guideline Advisor (CPMGA) offers evidence-based guidelines for managing chronic pain, with a database of over 1000 guidelines from medical organizations.",
      "The Pain Management Decision Support System (PMDSS) includes a database of over 1000 treatment options and provides personalized recommendations for chronic pain management."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about specific decision support systems (DSS) such as CPMDSS, PCDSS, and PMDSS, including their features and databases, cannot be verified as true or false without additional context or information about these specific systems. If these systems are hypothetical or proprietary with limited public information, their details would not be verifiable.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, angiogenin (ANG) is localized to the cytoplasm.\nAccording to the passage, angiogenin is a member of the vertebrate-specific secreted ribonucleases, which means it is secreted from cells and present in the extracellular space. The passage also states that angiogenin plays important roles in various physiological and pathological processes, including regulating cell proliferation, survival, migration, invasion, and angiogenesis (the formation of new blood vessels).\nGiven these functions, it is likely that angiogenin is localized to the cytoplasm, where it can interact with other proteins and molecules involved in these processes. The cytoplasm is the region of the cell where many metabolic processes take place, including protein synthesis, folding, and degradation, and it is also the site of many cellular signaling pathways.\nTherefore, based on the information provided in Document 0, the subcellular localization of angiogenin is the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin (ANG) is localized to the cytoplasm.\n2. Angiogenin is a member of the vertebrate-specific secreted ribonucleases.\n3. Angiogenin is secreted from cells and present in the extracellular space.\n4. Angiogenin is involved in regulating cell proliferation, survival, migration, invasion, and angiogenesis.\n5. The cytoplasm is the region of the cell where many metabolic processes take place, including protein synthesis, folding, and degradation.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin (ANG) is localized to the cytoplasm.",
      "Angiogenin is a member of the vertebrate-specific secreted ribonucleases.",
      "Angiogenin is secreted from cells and present in the extracellular space.",
      "Angiogenin is involved in regulating cell proliferation, survival, migration, invasion, and angiogenesis.",
      "The cytoplasm is the region of the cell where many metabolic processes take place, including protein synthesis, folding, and degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAngiogenin (ANG) is indeed known to be localized to the cytoplasm and is a member of the vertebrate-specific secreted ribonucleases. It is secreted from cells and can be found in the extracellular space. Angiogenin plays a role in various cellular processes, including cell proliferation, survival, migration, invasion, and angiogenesis. The cytoplasm is the region of the cell where numerous metabolic processes occur, such as protein synthesis, folding, and degradation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ranolazine appears to affect kinase signaling activation in the heart by reducing the late phase of the inward sodium current in ventricular myocardial cells. This reduction in sodium current leads to a decrease in intracellular calcium overload and associated diastolic contractile dysfunction.\nKinase signaling is a crucial pathway involved in regulating various cellular processes, including cell proliferation, differentiation, and survival. In the heart, kinase signaling plays a critical role in regulating cardiac contractility and relaxation. Activation of kinase signaling can lead to the phosphorylation and activation of various downstream targets, including protein kinases, which can modulate cardiac contractility and relaxation.\nRanolazine's inhibition of the late phase of the inward sodium current in ventricular myocardial cells can reduce the amount of intracellular calcium overload, which can lead to decreased kinase signaling activation. This can result in improved diastolic function and reduced cardiac workload, which can be beneficial in conditions such as heart failure.\nHowever, it is important to note that the effect of ranolazine on kinase signaling activation in the heart is still a novel finding and requires further evaluation. Further studies are needed to fully understand the mechanisms by which ranolazine affects kinase signaling in the heart and to determine its potential therapeutic applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine reduces the late phase of the inward sodium current in ventricular myocardial cells.\n2. The reduction in sodium current by ranolazine leads to a decrease in intracellular calcium overload.\n3. Decreased intracellular calcium overload can lead to improved diastolic function in the heart.\n4. Kinase signaling in the heart is involved in regulating cardiac contractility and relaxation.\n5. The effect of ranolazine on kinase signaling activation in the heart requires further evaluation and is considered a novel finding.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine reduces the late phase of the inward sodium current in ventricular myocardial cells.",
      "The reduction in sodium current by ranolazine leads to a decrease in intracellular calcium overload.",
      "Decreased intracellular calcium overload can lead to improved diastolic function in the heart.",
      "Kinase signaling in the heart is involved in regulating cardiac contractility and relaxation.",
      "The effect of ranolazine on kinase signaling activation in the heart requires further evaluation and is considered a novel finding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the regulation of Vsr endonuclease appears to be growth phase dependent. The study found that Vsr endonuclease levels are higher during the log phase of bacterial growth, while the levels of Dcm cytosine methylase are maintained at a constant level throughout the growth phase. This suggests that the regulation of Vsr endonuclease is separate from the regulation of Dcm cytosine methylase and is dependent on the growth phase of the bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is growth phase dependent.\n2. Vsr endonuclease levels are higher during the log phase of bacterial growth.\n3. The levels of Dcm cytosine methylase are maintained at a constant level throughout the growth phase of bacteria.\n4. The regulation of Vsr endonuclease is separate from the regulation of Dcm cytosine methylase.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is growth phase dependent.",
      "Vsr endonuclease levels are higher during the log phase of bacterial growth.",
      "The levels of Dcm cytosine methylase are maintained at a constant level throughout the growth phase of bacteria.",
      "The regulation of Vsr endonuclease is separate from the regulation of Dcm cytosine methylase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements provided seem to be specific claims about the regulation of certain enzymes in bacteria. Without the specific context or scientific study to reference, it's difficult to confirm the accuracy of statements 3 and 4. Statements 1 and 2 are consistent with what might be expected in a typical enzyme regulation scenario, where certain enzymes are regulated according to the growth phase of bacteria, but without specific data or sources, it's not possible to verify the details about Dcm cytosine methylase levels or the relationship between the regulation of Vsr endonuclease and Dcm cytosine methylase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Great, thank you for providing the question and information! Based on the information provided, the computational tools for the prediction of beta-barrel transmembrane proteins are:\n1. Hidden Markov Model (HMM) based method: This is the method mentioned in the question, which predicts the exposure status of residues predicted to be in the membrane.\n2. Other methods from the literature: The question mentions that the TMBHMM method has been compared with 2 other methods from the literature, but no further details are provided.\n3. Web server: The TMBHMM method has been implemented as a web server, which allows users to submit protein sequences for prediction and receive the predicted results.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hidden Markov Model (HMM) based methods are used for the prediction of beta-barrel transmembrane proteins.\n2. The TMBHMM method has been compared with two other methods from the literature.\n3. The TMBHMM method is implemented as a web server for predicting beta-barrel transmembrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Hidden Markov Model (HMM) based methods are used for the prediction of beta-barrel transmembrane proteins.",
      "The TMBHMM method has been compared with two other methods from the literature.",
      "The TMBHMM method is implemented as a web server for predicting beta-barrel transmembrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Hidden Markov Model (HMM) based methods are indeed used for the prediction of beta-barrel transmembrane proteins, as they are suitable for modeling the statistical properties of amino acid sequences in proteins.\n2. UNKNOWN: Without specific information on which methods TMBHMM has been compared to, it is not possible to verify the accuracy of this statement.\n3. UNKNOWN: Without additional context or a source confirming the implementation of TMBHMM as a web server, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Galassi classification is used to classify middle cranial fossa arachnoid cysts.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is used to classify middle cranial fossa arachnoid cysts.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is used to classify middle cranial fossa arachnoid cysts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some common features of Shapiro syndrome:\n1. Spontaneous periodic hypothermia: This is the most distinctive feature of Shapiro syndrome, and it occurs regardless of age or sex. Patients experience recurrent episodes of hypothermia, which can last for several hours or even days.\n2. Limited number of cases: As of the current knowledge, there have been fewer than 60 cases of Shapiro syndrome reported worldwide, indicating that it is a rare condition.\n3. Lack of understanding of pathogenesis and etiology: Despite being recognized as a distinct medical condition, the underlying cause of Shapiro syndrome is still not well understood. The pathogenesis and etiology of the disease are considered controversial, and more research is needed to shed light on these aspects.\n4. Clinical features: The clinical features of Shapiro syndrome are primarily related to the recurrent episodes of hypothermia. These can include fever, confusion, lethargy, and changes in behavior and cognitive function.\nIt is important to note that these features are based on the information provided in the document, and there may be additional features or variations of Shapiro syndrome that have not been reported or documented.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by spontaneous periodic hypothermia.\n2. There have been fewer than 60 cases of Shapiro syndrome reported worldwide.\n3. The underlying cause and pathogenesis of Shapiro syndrome are not well understood.\n4. Clinical features of Shapiro syndrome can include fever, confusion, lethargy, and changes in behavior and cognitive function.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by spontaneous periodic hypothermia.",
      "There have been fewer than 60 cases of Shapiro syndrome reported worldwide.",
      "The underlying cause and pathogenesis of Shapiro syndrome are not well understood.",
      "Clinical features of Shapiro syndrome can include fever, confusion, lethargy, and changes in behavior and cognitive function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Clinical features of Shapiro syndrome can include hypothermia, confusion, lethargy, and changes in behavior and cognitive function, but not fever, as fever is the opposite of hypothermia.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the disease that is linked to mutations within the BRAG1 gene is nonsyndromic X-chromosome-linked intellectual disability (XLID).",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Note: The statement refers to a specific gene, BRAG1, and its association with nonsyndromic X-linked intellectual disability (XLID). Without access to current and specific genetic research data or literature, it is not possible to verify the accuracy of this statement. The correct gene associated with XLID might be ARX or another gene entirely, but without the proper context or reference, the truthfulness of the statement cannot be determined.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the main inhibitor of protein phosphatase 1 (PP1) is Inhibitor-3. The paper describes Inhibitor-3 as a dynamic protein-protein interaction that binds to PP1 and inhibits its activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inhibitor-3 is the main inhibitor of protein phosphatase 1 (PP1).\n2. Inhibitor-3 binds to PP1 to inhibit its activity.",
    "llama-2-7b-chat-hf_fact": [
      "Inhibitor-3 is the main inhibitor of protein phosphatase 1 (PP1).",
      "Inhibitor-3 binds to PP1 to inhibit its activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Inhibitor-1 (I-1) and Inhibitor-2 (I-2) are better known as the main inhibitors of protein phosphatase 1 (PP1), not Inhibitor-3.\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. DNA damage: The stationary phase of growth can lead to increased DNA damage, which can result in mutations (Hall, 1998; Martinez and Baquero, 2000).\n2. Reactive oxygen species (ROS): ROS, such as hydrogen peroxide, can damage DNA and lead to mutations during the stationary phase (Hall, 1998).\n3. Methylation-dependent mutagenesis: Methylation of DNA can result in mutations during the stationary phase (Giraud et al., 2001).\n4. Phase variation: Phase variation, which is the switching between different genetic phases, can occur during the stationary phase and result in mutations (Rosenberg, 2001).\nThese mechanisms may play a role in the development of antibiotic resistance mutations, colonization of new bacterial hosts, and mutational escape of growth control.",
    "llama-2-7b-chat-hf_fact_raw": "1. The stationary phase of growth in Bacillus subtilis can lead to increased DNA damage, which can result in mutations.\n2. Reactive oxygen species (ROS), such as hydrogen peroxide, can damage DNA and lead to mutations during the stationary phase in Bacillus subtilis.\n3. Methylation of DNA can result in mutations during the stationary phase in Bacillus subtilis.\n4. Phase variation, which is the switching between different genetic phases, can occur during the stationary phase in Bacillus subtilis and result in mutations.\n5. These mechanisms may contribute to the development of antibiotic resistance mutations in Bacillus subtilis.",
    "llama-2-7b-chat-hf_fact": [
      "The stationary phase of growth in Bacillus subtilis can lead to increased DNA damage, which can result in mutations.",
      "Reactive oxygen species (ROS), such as hydrogen peroxide, can damage DNA and lead to mutations during the stationary phase in Bacillus subtilis.",
      "Methylation of DNA can result in mutations during the stationary phase in Bacillus subtilis.",
      "Phase variation, which is the switching between different genetic phases, can occur during the stationary phase in Bacillus subtilis and result in mutations.",
      "These mechanisms may contribute to the development of antibiotic resistance mutations in Bacillus subtilis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The stationary phase of growth in bacteria, including Bacillus subtilis, is associated with increased stress and can lead to DNA damage, potentially resulting in mutations.\n2. TRUE: Reactive oxygen species (ROS), such as hydrogen peroxide, are known to cause oxidative damage to DNA, which can lead to mutations. This can occur during the stationary phase when the bacteria's metabolism changes and may result in increased ROS.\n3. FALSE [correction]: Methylation of DNA is a normal cellular process involved in gene regulation and is not inherently mutagenic. However, errors in methylation or improper methylation patterns can potentially lead to mutations, but this statement is too vague to directly link methylation to mutations during the stationary phase without additional context.\n4. TRUE: Phase variation is a mechanism in bacteria, including Bacillus subtilis, where they switch between different genetic states. This can lead to phenotypic changes and, in some cases, may result in genetic mutations.\n5. TRUE: The mechanisms mentioned, such as DNA damage due to increased stress or ROS, can contribute to genetic changes. These changes may include mutations that confer antibiotic resistance, which is a significant concern in the context of bacterial evolution and the treatment of bacterial infections.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, erucism is caused by the toxins released by the moth larvae's bristles when they penetrate the skin. The toxins contain thermolabile proteins, proteolytic enzymes, and histamine, which can cause inflammation and tissue damage in the affected area. The bristles are hollow and when they enter the skin and break, these toxins are released, leading to the development of erucism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by toxins released by moth larvae's bristles.\n2. The bristles of moth larvae penetrate the skin to cause erucism.\n3. The toxins that cause erucism contain thermolabile proteins.\n4. The toxins that cause erucism contain proteolytic enzymes.\n5. The toxins that cause erucism contain histamine.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by toxins released by moth larvae's bristles.",
      "The bristles of moth larvae penetrate the skin to cause erucism.",
      "The toxins that cause erucism contain thermolabile proteins.",
      "The toxins that cause erucism contain proteolytic enzymes.",
      "The toxins that cause erucism contain histamine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide are:\n1. High blood pressure (hypertension)\n2. Fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders\n3. Edema caused by taking steroids or estrogen.\nIt is important to note that hydrochlorothiazide should not be used in individuals who are unable to urinate.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is indicated for the treatment of high blood pressure (hypertension).\n2. Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure.\n3. Hydrochlorothiazide is used to treat fluid retention (edema) in people with cirrhosis of the liver.\n4. Hydrochlorothiazide is used to treat fluid retention (edema) in people with kidney disorders.\n5. Hydrochlorothiazide is indicated for treating edema caused by taking steroids or estrogen.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is indicated for the treatment of high blood pressure (hypertension).",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure.",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with cirrhosis of the liver.",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with kidney disorders.",
      "Hydrochlorothiazide is indicated for treating edema caused by taking steroids or estrogen."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nHydrochlorothiazide is a diuretic medication often used to treat high blood pressure and edema, including the conditions mentioned in statements 2 through 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence, specifically in the form of bulking agents injected periurethrally or transurethrally. The information provided in Document 0 supports the use of silicon-based bulking agents as a minimally invasive surgical procedure for the treatment of stress urinary incontinence (SUI) in adult women.\nSilicon-based bulking agents, such as polydimethylsiloxane (PDMS), are injected into the urethral mucosa to increase the volume of the urethral wall and improve the function of the urethral sphincter. This can help to prevent the involuntary leakage of urine that occurs with SUI.\nStudies have shown that periurethral or transurethral injection of bulking agents can lead to significant improvements in urinary incontinence in women, with cure rates ranging from 50% to 80%. The effects of the treatment can last for several years, with some studies reporting long-term success rates of up to 10 years or more.\nIt is important to note that while silicon-based bulking agents have been shown to be effective in the treatment of SUI, they may not be suitable for all patients. Factors such as the severity of the incontinence, the presence of other medical conditions, and the patient's overall health should be taken into consideration when determining the most appropriate treatment.\nIn summary, silicon has been used in the treatment of urinary incontinence in the form of bulking agents injected periurethrally or transurethrally. These treatments have been shown to be effective in improving the function of the urethral sphincter and reducing the incidence of urinary incontinence in women.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence as bulking agents injected periurethrally or transurethrally.\n2. Silicon-based bulking agents, such as polydimethylsiloxane (PDMS), are used to increase the volume of the urethral wall and improve the function of the urethral sphincter.\n3. The use of silicon-based bulking agents can lead to significant improvements in urinary incontinence in women, with cure rates ranging from 50% to 80%.\n4. The effects of silicon-based bulking agent treatments for urinary incontinence can last for several years, with some studies reporting long-term success rates of up to 10 years or more.\n5. The appropriateness of silicon-based bulking agents for treating urinary incontinence may depend on factors such as the severity of incontinence, other medical conditions, and the patient's overall health.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence as bulking agents injected periurethrally or transurethrally.",
      "Silicon-based bulking agents, such as polydimethylsiloxane (PDMS), are used to increase the volume of the urethral wall and improve the function of the urethral sphincter.",
      "The use of silicon-based bulking agents can lead to significant improvements in urinary incontinence in women, with cure rates ranging from 50% to 80%.",
      "The effects of silicon-based bulking agent treatments for urinary incontinence can last for several years, with some studies reporting long-term success rates of up to 10 years or more.",
      "The appropriateness of silicon-based bulking agents for treating urinary incontinence may depend on factors such as the severity of incontinence, other medical conditions, and the patient's overall health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The effectiveness of silicon-based bulking agents can vary, and while they may lead to improvements in urinary incontinence, the cure rates can differ widely based on individual cases and the specific product used. Therefore, stating a specific range of cure rates without context is misleading.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document 0, there is no established association between the moon cycle and the risk of intracranial aneurysm rupture. The document encourages further studies to investigate this topic using more sensitive approaches.\nIntracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain that can potentially rupture and cause bleeding in the brain. While some studies have suggested that certain environmental factors, such as changes in altitude or temperature, may influence the risk of aneurysm rupture, the relationship between the moon cycle and aneurysm rupture remains unclear.\nSome studies have suggested that the lunar cycle may have an impact on the incidence of certain medical conditions, including cardiovascular disease and stroke. However, these findings are not consistent across all studies and the evidence is limited.\nIn summary, while there is some evidence to suggest that certain environmental factors may influence the risk of aneurysm rupture, there is currently no established association between the moon cycle and the risk of intracranial aneurysm rupture. Further research is needed to fully understand the relationship between these factors and aneurysm rupture.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no established association between the moon cycle and the risk of intracranial aneurysm rupture according to Document 0.\n2. Intracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain.\n3. Some studies have suggested that changes in altitude or temperature may influence the risk of aneurysm rupture.\n4. The lunar cycle may have an impact on the incidence of certain medical conditions, including cardiovascular disease and stroke, according to some studies.\n5. The evidence regarding the lunar cycle's impact on medical conditions is not consistent across all studies.",
    "llama-2-7b-chat-hf_fact": [
      "There is no established association between the moon cycle and the risk of intracranial aneurysm rupture according to Document 0.",
      "Intracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain.",
      "Some studies have suggested that changes in altitude or temperature may influence the risk of aneurysm rupture.",
      "The lunar cycle may have an impact on the incidence of certain medical conditions, including cardiovascular disease and stroke, according to some studies.",
      "The evidence regarding the lunar cycle's impact on medical conditions is not consistent across all studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein has been shown to regulate the splicing process. According to Document 0, HuR regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle. This suggests that HuR plays a role in the splicing of mRNAs involved in the cell cycle, which is a critical process that regulates the progression of cells through the cell cycle.\nHuR is a protein that is involved in the regulation of mRNA splicing and stability. It is known to bind to specific sequences in the pre-mRNA and regulate the splicing of certain exons, leading to the production of different isoforms of proteins. The splicing process is critical for the proper functioning of cells, as it allows for the removal of introns and the joining of exons to form mature mRNAs.\nIn addition to its role in splicing, HuR has been shown to regulate the abundance of mRNAs required for entry into and transition through the S phase of the cell cycle. This suggests that HuR may play a role in regulating the expression of genes involved in the cell cycle, which is a complex process that involves the coordinated regulation of multiple genes and signaling pathways.\nOverall, the information provided in Document 0 suggests that HuR protein plays a critical role in regulating the splicing process and the expression of genes involved in the cell cycle.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.\n2. HuR is involved in the regulation of mRNA splicing and stability.\n3. HuR binds to specific sequences in the pre-mRNA and regulates the splicing of certain exons.\n4. The splicing process, which HuR is involved in, is essential for the removal of introns and the joining of exons to form mature mRNAs.\n5. HuR may play a role in regulating the expression of genes involved in the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.",
      "HuR is involved in the regulation of mRNA splicing and stability.",
      "HuR binds to specific sequences in the pre-mRNA and regulates the splicing of certain exons.",
      "The splicing process, which HuR is involved in, is essential for the removal of introns and the joining of exons to form mature mRNAs.",
      "HuR may play a role in regulating the expression of genes involved in the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known functions of the HuR protein, which is involved in the regulation of mRNA splicing, stability, and abundance, affecting various aspects of the cell cycle and gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Kelch-binding: Prothymosin alpha (ProTα) and its c-terminal peptide have been shown to bind to the Kelch domain of the Keap1 protein, which is involved in regulating the activity of the Nrf2 transcription factor.\n2. Neh2 binding: ProTα and its c-terminal peptide have also been shown to bind to the Neh2 protein, which is involved in the regulation of the Keap1-Nrf2 pathway.\n3. Regulation of Nrf2 activity: ProTα has been shown to regulate the activity of the Nrf2 transcription factor by modulating its stability and localization in the cell.\n4. Antioxidant activity: ProTα has been shown to have antioxidant activity, which may contribute to its protective effects against oxidative stress.\nOverall, the c-terminal peptide of prothymosin alpha appears to play a role in regulating the Keap1-Nrf2 pathway and modulating the activity of the Nrf2 transcription factor, which is involved in the response to oxidative stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha (ProTα) and its c-terminal peptide bind to the Kelch domain of the Keap1 protein.\n2. Prothymosin alpha and its c-terminal peptide bind to the Neh2 protein.\n3. Prothymosin alpha regulates the activity of the Nrf2 transcription factor by modulating its stability and localization in the cell.\n4. Prothymosin alpha has antioxidant activity.\n5. The c-terminal peptide of prothymosin alpha plays a role in regulating the Keap1-Nrf2 pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha (ProTα) and its c-terminal peptide bind to the Kelch domain of the Keap1 protein.",
      "Prothymosin alpha and its c-terminal peptide bind to the Neh2 protein.",
      "Prothymosin alpha regulates the activity of the Nrf2 transcription factor by modulating its stability and localization in the cell.",
      "Prothymosin alpha has antioxidant activity.",
      "The c-terminal peptide of prothymosin alpha plays a role in regulating the Keap1-Nrf2 pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Prothymosin alpha and its c-terminal peptide do not bind to the Neh2 protein. Instead, the Neh2 domain is a region within the Nrf2 protein that interacts with Keap1.\n3. TRUE\n4. TRUE: Prothymosin alpha has been reported to have antioxidant activity, as it is involved in the regulation of the Nrf2 pathway, which is known for controlling the expression of antioxidant proteins.\n5. TRUE: The c-terminal peptide of prothymosin alpha does play a role in regulating the Keap1-Nrf2 pathway, as it can bind to the Kelch domain of Keap1, thereby modulating the activity of Nrf2.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the peptide that plays a pivotal role in human cystatin C fibrillization is LQVVR.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide LQVVR plays a pivotal role in human cystatin C fibrillization.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide LQVVR plays a pivotal role in human cystatin C fibrillization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout additional context or specific scientific references, it is not possible to confirm the accuracy of the statement regarding the role of the peptide LQVVR in human cystatin C fibrillization. This would require specialized knowledge in biochemistry or a related field, and access to the relevant scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that the concentration of protein HIF-1α does increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\nThe document states that HIF-1α protein levels transiently increase during the G1 phase of the cell cycle (designated as G1-HIF) in an AMP-activated protein kinase (AMPK)-dependent manner. This suggests that the administration of amifostine (ethyol) leads to an increase in HIF-1α protein levels, which is consistent with the user's question.\nTherefore, based on the information provided, the answer to the user's question is yes, the concentration of protein HIF-1α does increase after the administration of amifostine (ethyol).",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. HIF-1α protein levels transiently increase during the G1 phase of the cell cycle.\n3. The increase in HIF-1α protein levels is dependent on AMP-activated protein kinase (AMPK).",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "HIF-1α protein levels transiently increase during the G1 phase of the cell cycle.",
      "The increase in HIF-1α protein levels is dependent on AMP-activated protein kinase (AMPK)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The concentration of the protein HIF-1α (hypoxia-inducible factor 1-alpha) can increase after the administration of certain cytoprotective agents, and amifostine (ethyol) is known to have protective effects against cytotoxicity and radiation damage, which could be associated with HIF-1α stabilization and increase.\n2. UNKNOWN: The statement about HIF-1α protein levels increasing transiently during the G1 phase of the cell cycle is specific and would require scientific evidence to confirm or refute. Without specific context or reference, the truth of this statement cannot be determined.\n3. UNKNOWN: The dependency of HIF-1α protein level increase on AMP-activated protein kinase (AMPK) is a specific biochemical pathway relationship that would require scientific evidence to confirm. Without additional context or reference, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, Set7 deposits H3K4 methylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is responsible for depositing H3K4 methylation.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is responsible for depositing H3K4 methylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the localization of the protein encoded by the gene DNAJC11 is likely to be in the neurons of the hippocampus and associated neocortex, which are the regions affected in Alzheimer's disease (AD). The protein folding problem mentioned in the passage is a major issue in AD, and the localization of the DNAJC11 protein in these regions suggests that it may play a role in the formation of tau neurofibrillary tangles, which are a hallmark of AD.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized in the neurons of the hippocampus.\n2. The protein encoded by the gene DNAJC11 is also localized in the associated neocortex.\n3. The regions where the DNAJC11 protein is localized are affected in Alzheimer's disease.\n4. The DNAJC11 protein may play a role in the formation of tau neurofibrillary tangles.\n5. Tau neurofibrillary tangles are a hallmark of Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized in the neurons of the hippocampus.",
      "The protein encoded by the gene DNAJC11 is also localized in the associated neocortex.",
      "The regions where the DNAJC11 protein is localized are affected in Alzheimer's disease.",
      "The DNAJC11 protein may play a role in the formation of tau neurofibrillary tangles.",
      "Tau neurofibrillary tangles are a hallmark of Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that ultraconserved elements are depleted among copy number variants (CNVs). The document states that \"Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants.\" This suggests that ultraconserved elements are less likely to be found in regions of the genome that have undergone copy number variations, such as CNVs.\nUltraconserved elements are sequences that are highly conserved across different species and are thought to play important roles in regulating gene expression and other cellular processes. They are typically found in non-coding regions of the genome and are often associated with gene regulation and chromatin structure.\nCopy number variants, on the other hand, are changes in the number of copies of a particular sequence in the genome. These changes can occur in both coding and non-coding regions of the genome and can have a variety of effects on gene expression and cellular function.\nThe depletion of ultraconserved elements among CNVs suggests that these elements may be particularly sensitive to changes in the genome that can lead to copy number variations. This could be due to the fact that ultraconserved elements are often located in regions of the genome that are critical for proper gene expression and cellular function, and therefore are more likely to be affected by changes in the genome.\nIn summary, based on the information provided in Document 0, it appears that ultraconserved elements are depleted among copy number variants in the mammalian genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are strongly depleted among segmental duplications and copy number variants (CNVs).\n2. Ultraconserved elements are sequences that are highly conserved across different species.\n3. Ultraconserved elements are typically found in non-coding regions of the genome.\n4. Copy number variants (CNVs) are changes in the number of copies of a particular sequence in the genome.\n5. Ultraconserved elements are often associated with gene regulation and chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are strongly depleted among segmental duplications and copy number variants (CNVs).",
      "Ultraconserved elements are sequences that are highly conserved across different species.",
      "Ultraconserved elements are typically found in non-coding regions of the genome.",
      "Copy number variants (CNVs) are changes in the number of copies of a particular sequence in the genome.",
      "Ultraconserved elements are often associated with gene regulation and chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the substrate of the Haspin kinase during mitosis is likely to be histone H3. The document mentions that Haspin, not VRKs (Viral protein kinases), is the H3T3 kinase in mitosis, and Haspin has been shown to phosphorylate histone H3 on various residues. This suggests that Haspin plays a critical role in regulating the phosphorylation of histone H3 during mitosis, which is essential for proper chromatin dynamics and cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is histone H3.\n2. Haspin kinase phosphorylates histone H3 on various residues.\n3. The phosphorylation of histone H3 by Haspin kinase is essential for proper chromatin dynamics and cell division during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is histone H3.",
      "Haspin kinase phosphorylates histone H3 on various residues.",
      "The phosphorylation of histone H3 by Haspin kinase is essential for proper chromatin dynamics and cell division during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Haspin kinase specifically phosphorylates histone H3 at threonine 3 (H3T3).\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Thank you for providing the information! Based on the details provided, the mechanism of viroid replication appears to involve an RNA-based rolling-circle mechanism with three steps that occur in both polarity strands.\nHere's a simplified explanation of the mechanism:\nStep 1: Synthesis of longer-than-unit strands\nViroid replication begins with the synthesis of longer-than-unit strands of RNA, catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase. These enzymes are redirected to transcribe RNA templates that are complementary to the viroid RNA.\nStep 2: Circularization of the RNA\nOnce the longer-than-unit strands are synthesized, they are circularized through an RNA-dependent RNA polymerase reaction. This results in the formation of a circular RNA molecule that serves as a template for the next step of replication.\nStep 3: Replication of the circular RNA\nThe circular RNA template is then replicated through an RNA-dependent RNA polymerase reaction, resulting in the production of additional viroid RNA molecules. This process is continuous, allowing the viroid to rapidly amplify its genetic material.\nIt's worth noting that the exact mechanisms of viroid replication can vary depending on the specific viroid and the organism in which it is found. However, the general RNA-based rolling-circle mechanism is a common feature among viroids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroid replication involves an RNA-based rolling-circle mechanism.\n2. The replication process begins with the synthesis of longer-than-unit strands of RNA.\n3. The synthesis of longer-than-unit strands is catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.\n4. The longer-than-unit strands are circularized through an RNA-dependent RNA polymerase reaction.\n5. The circular RNA template is replicated to produce additional viroid RNA molecules.",
    "llama-2-7b-chat-hf_fact": [
      "Viroid replication involves an RNA-based rolling-circle mechanism.",
      "The replication process begins with the synthesis of longer-than-unit strands of RNA.",
      "The synthesis of longer-than-unit strands is catalyzed by either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase.",
      "The longer-than-unit strands are circularized through an RNA-dependent RNA polymerase reaction.",
      "The circular RNA template is replicated to produce additional viroid RNA molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The longer-than-unit strands are cleaved and circularized through host cell enzymes, not an RNA-dependent RNA polymerase reaction.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy (DMD). The document states that fibronectin was chosen for follow-up based on differences in peptide spectral counts and sequence coverage observed between the DMD and control groups. This suggests that there are differences in the expression or modification of fibronectin between individuals with DMD and healthy controls, but it does not provide conclusive evidence that fibronectin can be used as a biomarker for DMD. Therefore, I must advise against using fibronectin as a serum biomarker for DMD without further investigation and validation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin was chosen for follow-up based on differences in peptide spectral counts and sequence coverage observed between Duchenne muscular dystrophy (DMD) patients and control groups.\n2. There are differences in the expression or modification of fibronectin between individuals with DMD and healthy controls.\n3. Fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy based on the provided information.\n4. The document advises against using fibronectin as a serum biomarker for DMD without further investigation and validation.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin was chosen for follow-up based on differences in peptide spectral counts and sequence coverage observed between Duchenne muscular dystrophy (DMD) patients and control groups.",
      "There are differences in the expression or modification of fibronectin between individuals with DMD and healthy controls.",
      "Fibronectin does not constitute a serum biomarker for Duchenne muscular dystrophy based on the provided information.",
      "The document advises against using fibronectin as a serum biomarker for DMD without further investigation and validation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The statement suggests that fibronectin could potentially constitute a serum biomarker for Duchenne muscular dystrophy based on the observed differences in peptide spectral counts and sequence coverage between DMD patients and control groups.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the major epigenome projects whose data are contained in the DeepBlue epigenomic data server are:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. ROADMAP (Roadmap Epigenomics Consortium)\n3. BLUEPRINT (Blueprint Epigenomics Project)\n4. DEEP (Deep Epigenomics Project)\nThese projects are some of the largest and most comprehensive epigenomics initiatives to date, and their data are now available through the DeepBlue data server for easy access and analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The DeepBlue epigenomic data server contains data from the ROADMAP Epigenomics Consortium.\n3. The DeepBlue epigenomic data server contains data from the Blueprint Epigenomics Project.\n4. The DeepBlue epigenomic data server contains data from the DEEP Epigenomics Project.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The DeepBlue epigenomic data server contains data from the ROADMAP Epigenomics Consortium.",
      "The DeepBlue epigenomic data server contains data from the Blueprint Epigenomics Project.",
      "The DeepBlue epigenomic data server contains data from the DEEP Epigenomics Project."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe DeepBlue epigenomic data server is known to aggregate and provide access to a variety of epigenomic datasets, including those from large-scale projects such as ENCODE, ROADMAP Epigenomics, Blueprint Epigenomics, and the DEEP Epigenomics Project.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the tool that employs self-organizing maps for analyzing synonymous codon usage is called \"CodonUsage\".",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MINDY-1 is a member of a new family of deubiquitinating enzymes that is evolutionarily conserved and structurally distinct. According to the document, MINDY-1 is an enzyme that removes ubiquitin, a small protein that is attached to other proteins to modulate their function, from target proteins. The document suggests that MINDY-1 is a key regulator of protein deubiquitination and is involved in various cellular processes, including cell signaling and protein degradation.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a deubiquitinating enzyme.\n2. MINDY-1 is evolutionarily conserved.\n3. MINDY-1 is structurally distinct from other enzymes.\n4. MINDY-1 removes ubiquitin from target proteins.\n5. MINDY-1 is involved in cellular processes such as cell signaling and protein degradation.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a deubiquitinating enzyme.",
      "MINDY-1 is evolutionarily conserved.",
      "MINDY-1 is structurally distinct from other enzymes.",
      "MINDY-1 removes ubiquitin from target proteins.",
      "MINDY-1 is involved in cellular processes such as cell signaling and protein degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is PHYLUCE. According to the document, PHYLUCE is a software package for the analysis of conserved genomic loci, and it was published in 2016 in the journal Bioinformatics. Therefore, it is the most relevant software package for analyzing conserved genomic loci based on the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "1. PHYLUCE is a software package for the analysis of conserved genomic loci.\n2. PHYLUCE was published in 2016.\n3. The journal in which PHYLUCE was published is Bioinformatics.",
    "llama-2-7b-chat-hf_fact": [
      "PHYLUCE is a software package for the analysis of conserved genomic loci.",
      "PHYLUCE was published in 2016.",
      "The journal in which PHYLUCE was published is Bioinformatics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PHYLUCE was first published in 2013.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, here are 3 diseases associated with the PIEZO2 gene:\n1. Autosomal recessive congenital lymphatic dysplasia: Loss-of-function mutations in the PIEZO1 gene, which is encoded by the PIEZO2 gene, can cause this rare genetic disorder. It is characterized by abnormal development of the lymphatic system, leading to lymphedema, infections, and other complications.\n2. Primary axonal dystonia: Gain-of-function mutations in the PIEZO1 gene have been associated with primary axonal dystonia, a rare neurological disorder that affects movement and muscle control.\n3. Charcot-Marie-Tooth disease: Some mutations in the PIEZO1 gene have been linked to Charcot-Marie-Tooth disease, a group of inherited disorders that affect the peripheral nervous system. These mutations are thought to disrupt the function of the mechanosensitive cation channels encoded by the PIEZO1 and PIEZO2 genes, leading to nerve damage and muscle weakness.",
    "llama-2-7b-chat-hf_fact_raw": "1. Loss-of-function mutations in the PIEZO1 gene can cause autosomal recessive congenital lymphatic dysplasia.\n2. Gain-of-function mutations in the PIEZO1 gene have been associated with primary axonal dystonia.\n3. Some mutations in the PIEZO1 gene have been linked to Charcot-Marie-Tooth disease.",
    "llama-2-7b-chat-hf_fact": [
      "Loss-of-function mutations in the PIEZO1 gene can cause autosomal recessive congenital lymphatic dysplasia.",
      "Gain-of-function mutations in the PIEZO1 gene have been associated with primary axonal dystonia.",
      "Some mutations in the PIEZO1 gene have been linked to Charcot-Marie-Tooth disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Gain-of-function mutations in the PIEZO1 gene have been associated with dehydrated hereditary stomatocytosis (also known as xerocytosis), not primary axonal dystonia.\n3. FALSE [correction]: Mutations in the PIEZO1 gene have not been linked to Charcot-Marie-Tooth disease; instead, mutations in other genes, such as PMP22, MFN2, and GJB1, are commonly associated with Charcot-Marie-Tooth disease.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it can be inferred that ERAP1-ERAP2 dimerization promotes the modulation of ERAP1/2 activity, which is a novel immunological strategy for cancer immunotherapy.\nERAP1 and ERAP2 are endoplasmic reticulum aminopeptidases that play a crucial role in the degradation of extracellular matrix proteins and the regulation of immune responses. The dimerization of ERAP1 and ERAP2 has been shown to modulate their activity, leading to the degradation of specific proteins involved in cancer progression. By targeting these proteins, the immune response can be modulated to recognize and attack cancer cells, making ERAP1-ERAP2 dimerization a promising strategy for cancer immunotherapy.\nIn summary, ERAP1-ERAP2 dimerization promotes the modulation of ERAP1/2 activity, which is a novel immunological strategy for cancer immunotherapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1 and ERAP2 are endoplasmic reticulum aminopeptidases.\n2. ERAP1-ERAP2 dimerization modulates the activity of ERAP1/2.\n3. The modulation of ERAP1/2 activity through dimerization leads to the degradation of specific proteins involved in cancer progression.\n4. ERAP1-ERAP2 dimerization is considered a strategy for cancer immunotherapy.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1 and ERAP2 are endoplasmic reticulum aminopeptidases.",
      "ERAP1-ERAP2 dimerization modulates the activity of ERAP1/2.",
      "The modulation of ERAP1/2 activity through dimerization leads to the degradation of specific proteins involved in cancer progression.",
      "ERAP1-ERAP2 dimerization is considered a strategy for cancer immunotherapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The modulation of ERAP1/2 activity through dimerization affects the generation of peptides for presentation by MHC class I molecules, which is important for immune surveillance, rather than directly leading to the degradation of specific proteins involved in cancer progression.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, R-spondin 1 and noggin play a crucial role in the function of non-damaged gallbladders. Specifically, these two growth factors stimulate the growth of gallbladder-derived organoids, which are stem/progenitor cells that are capable of differentiating into various cell types, including hepatocytes.\nIn non-damaged gallbladders, the presence of R-spondin 1 and noggin promotes the proliferation and differentiation of gallbladder-derived organoids, leading to their expansion and maintenance. Without these growth factors, the organoids may undergo partial differentiation towards the hepatocyte fate, but their growth and maintenance are impaired.\nIt is worth noting that the function of R-spondin 1 and noggin in non-damaged gallbladders is distinct from their role in the regulation of gallbladder development and function during embryonic development. During embryonic development, R-spondin 1 and noggin play a critical role in the formation and differentiation of the gallbladder and bile ducts.\nIn summary, R-spondin 1 and noggin are essential for the growth and maintenance of gallbladder-derived organoids in non-damaged gallbladders, and their loss leads to impaired differentiation and growth of these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids in non-damaged gallbladders.\n2. Gallbladder-derived organoids are stem/progenitor cells capable of differentiating into various cell types, including hepatocytes.\n3. The presence of R-spondin 1 and noggin promotes the proliferation and differentiation of gallbladder-derived organoids.\n4. Without R-spondin 1 and noggin, gallbladder-derived organoids may undergo partial differentiation towards the hepatocyte fate, but their growth and maintenance are impaired.\n5. R-spondin 1 and noggin have a distinct role in non-damaged gallbladders compared to their function during embryonic development, where they are critical for the formation and differentiation of the gallbladder and bile ducts.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids in non-damaged gallbladders.",
      "Gallbladder-derived organoids are stem/progenitor cells capable of differentiating into various cell types, including hepatocytes.",
      "The presence of R-spondin 1 and noggin promotes the proliferation and differentiation of gallbladder-derived organoids.",
      "Without R-spondin 1 and noggin, gallbladder-derived organoids may undergo partial differentiation towards the hepatocyte fate, but their growth and maintenance are impaired.",
      "R-spondin 1 and noggin have a distinct role in non-damaged gallbladders compared to their function during embryonic development, where they are critical for the formation and differentiation of the gallbladder and bile ducts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the field of developmental biology and organoid research. Without access to the specific scientific literature or studies that these statements are based on, it is not possible to accurately determine the truthfulness of these claims. These statements would require specialized knowledge in the field and access to the relevant research data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that NOX5, also known as NADPH oxidase 5, does require a subunit for function. The document states that NOX5 contains four Ca2+ binding domains at the N-terminus, which suggests that it may be a multi-subunit enzyme. Additionally, the document states that the activity of NOX5 is regulated by the intracellular concentration of Ca2+, which further supports the idea that NOX5 is a multi-subunit enzyme.\nTherefore, based on the information provided in Document 0, the answer to the user's question is yes, NOX5 requires a subunit for function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires a subunit for function.\n2. NOX5 contains four Ca2+ binding domains at the N-terminus.\n3. The activity of NOX5 is regulated by the intracellular concentration of Ca2+.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires a subunit for function.",
      "NOX5 contains four Ca2+ binding domains at the N-terminus.",
      "The activity of NOX5 is regulated by the intracellular concentration of Ca2+."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require a subunit for function; it is calcium-dependent and functions independently of cytosolic subunits.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there appears to be a connection between furin and hepcidin in the context of iron metabolism.\nFurin is a protease enzyme that is involved in the processing and activation of various proteins in the body. One of the proteins that furin is known to process is hepcidin. Hepcidin is a hormone that regulates iron metabolism by binding to ferroportin (FPN), an iron export protein, and inducing its internalization and degradation. This limits the amount of iron that is released into the bloodstream, thereby regulating iron homeostasis.\nTherefore, it can be inferred that furin plays a role in the regulation of hepcidin activity by processing and activating hepcidin. This may be an important mechanism for regulating iron metabolism in the body, particularly in response to changes in iron stores, hypoxia, inflammation, and erythropoiesis.\nIn summary, the connection between furin and hepcidin is that furin processes and activates hepcidin, which in turn regulates iron metabolism by limiting the amount of iron that is released into the bloodstream.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the processing and activation of various proteins in the body.\n2. Hepcidin is a hormone that regulates iron metabolism.\n3. Hepcidin functions by binding to ferroportin, an iron export protein, and inducing its internalization and degradation.\n4. Furin processes and activates hepcidin.\n5. The regulation of hepcidin by furin affects the amount of iron released into the bloodstream.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the processing and activation of various proteins in the body.",
      "Hepcidin is a hormone that regulates iron metabolism.",
      "Hepcidin functions by binding to ferroportin, an iron export protein, and inducing its internalization and degradation.",
      "Furin processes and activates hepcidin.",
      "The regulation of hepcidin by furin affects the amount of iron released into the bloodstream."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Furin does not process and activate hepcidin. Hepcidin is regulated by different mechanisms, primarily by the liver in response to iron levels, inflammation, and erythropoiesis.\n5. FALSE [correction]: Since furin does not process and activate hepcidin, it does not directly affect the regulation of hepcidin or the amount of iron released into the bloodstream. The regulation of hepcidin and thus iron homeostasis is controlled by other factors such as iron stores, inflammation, and erythropoietic activity.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, the largest metabolic gene cluster in yeast is the DAL cluster. The DAL cluster consists of six adjacent genes that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. This cluster is the largest metabolic gene cluster in yeast, and it plays a crucial role in the yeast's ability to utilize allantoin as a nitrogen source.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the DAL cluster.\n2. The DAL cluster consists of six adjacent genes.\n3. This gene cluster allows Saccharomyces cerevisiae to use allantoin as a nitrogen source.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the DAL cluster.",
      "The DAL cluster consists of six adjacent genes.",
      "This gene cluster allows Saccharomyces cerevisiae to use allantoin as a nitrogen source."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The DAL cluster consists of seven adjacent genes.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the role of LIMT lncRNA (Long Interspersed Nuclear Elements in the Midline of T cells) is not explicitly mentioned. However, the document you provided suggests that the lncRNA TERC (Telomerase RNA Template Component) plays a crucial role in telomere maintenance, which is a vital cellular function.\nTelomeres are repetitive DNA sequences located at the ends of chromosomes that shorten with each cell division. To maintain telomere length, cells have evolved mechanisms to elongate them, one of which involves the action of telomerase, an enzyme that adds nucleotides to the telomere repeats. TERC is a key component of telomerase, serving as the RNA template for the enzyme to work on.\nSince TERC is essential for telomere maintenance, it is likely that other lncRNAs, such as LIMT, may also play important roles in this process. However, without further information, it is difficult to determine the specific role of LIMT lncRNA in telomere maintenance or any other cellular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA stands for Long Interspersed Nuclear Elements in the Midline of T cells.\n2. TERC (Telomerase RNA Template Component) plays a crucial role in telomere maintenance.\n3. Telomeres are repetitive DNA sequences located at the ends of chromosomes.\n4. Telomeres shorten with each cell division.\n5. Telomerase is an enzyme that adds nucleotides to telomere repeats, and TERC serves as the RNA template for this enzyme.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA stands for Long Interspersed Nuclear Elements in the Midline of T cells.",
      "TERC (Telomerase RNA Template Component) plays a crucial role in telomere maintenance.",
      "Telomeres are repetitive DNA sequences located at the ends of chromosomes.",
      "Telomeres shorten with each cell division.",
      "Telomerase is an enzyme that adds nucleotides to telomere repeats, and TERC serves as the RNA template for this enzyme."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: LIMT lncRNA stands for Long Intergenic Noncoding RNA Mediating Interferon Response by Targeting miR-451.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package used for performing SNP enrichment analysis is \"traseR\".",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package \"traseR\" is used for performing SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package \"traseR\" is used for performing SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package \"traseR\" is used for trajectory analysis of single-cell RNA-seq data, not for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the key players on radial glial specification to ependymal cells are Mcidas and GemC1/Lynkeas. These two proteins were found to be key players in the radial glial specification to ependymal cells, as they were initially described as cell cycle regulators and have sequence similarity to Geminin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mcidas is a key player in radial glial specification to ependymal cells.\n2. GemC1/Lynkeas is a key player in radial glial specification to ependymal cells.\n3. Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.\n4. Mcidas and GemC1/Lynkeas have sequence similarity to Geminin.",
    "llama-2-7b-chat-hf_fact": [
      "Mcidas is a key player in radial glial specification to ependymal cells.",
      "GemC1/Lynkeas is a key player in radial glial specification to ependymal cells.",
      "Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.",
      "Mcidas and GemC1/Lynkeas have sequence similarity to Geminin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, triple negative gliomas are characterized as glioblastomas that lack all three major alterations, which are:\n1. TP53 mutation\n2. PTEN mutation\n3. EGFR mutation\nTriple negative gliomas are so named because they do not have any of these three mutations, which are commonly found in other types of gliomas, such as glioblastoma. These tumors are often aggressive and difficult to treat, but research is ongoing to develop new and more effective therapies.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack the TP53 mutation.\n2. Triple negative gliomas lack the PTEN mutation.\n3. Triple negative gliomas lack the EGFR mutation.\n4. These mutations (TP53, PTEN, EGFR) are commonly found in other types of gliomas.\n5. Triple negative gliomas are often aggressive and difficult to treat.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack the TP53 mutation.",
      "Triple negative gliomas lack the PTEN mutation.",
      "Triple negative gliomas lack the EGFR mutation.",
      "These mutations (TP53, PTEN, EGFR) are commonly found in other types of gliomas.",
      "Triple negative gliomas are often aggressive and difficult to treat."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas often have the TP53 mutation.\n2. FALSE [correction]: Triple negative gliomas often have the PTEN mutation.\n3. FALSE [correction]: Triple negative gliomas often have the EGFR mutation.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, TOPAZ1 appears to be a clinical trial evaluating the use of durvalumab, a monoclonal antibody, in combination with chemotherapy, for the treatment of advanced biliary tract cancer. The trial, known as TOPAZ-1, was conducted by the National Cancer Institute (NCI) and was published in the Journal of Clinical Oncology in 2019.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a clinical trial.\n2. The trial evaluated the use of durvalumab in combination with chemotherapy.\n3. The treatment was for advanced biliary tract cancer.\n4. The National Cancer Institute conducted the TOPAZ-1 trial.\n5. The results of the TOPAZ-1 trial were published in the Journal of Clinical Oncology in 2019.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a clinical trial.",
      "The trial evaluated the use of durvalumab in combination with chemotherapy.",
      "The treatment was for advanced biliary tract cancer.",
      "The National Cancer Institute conducted the TOPAZ-1 trial.",
      "The results of the TOPAZ-1 trial were published in the Journal of Clinical Oncology in 2019."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The TOPAZ-1 trial was conducted by a collaboration of various institutions and researchers, not solely by the National Cancer Institute.\n5. FALSE [correction]: The results of the TOPAZ-1 trial would not have been published in the Journal of Clinical Oncology in 2019, as the trial was still ongoing at that time. The exact publication date would need to be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the gene that controls the expression of GATA-1 isoforms is likely to be a transcription factor that regulates hematopoietic development. GATA-1 is a transcription factor that plays a crucial role in the regulation of hematopoietic cell fate and differentiation. There are several isoforms of GATA-1, each with distinct functions in different stages of hematopoiesis.\nThe expression of GATA-1 isoforms is tightly regulated during hematopoietic development, and several transcription factors have been identified that control the expression of these isoforms. For example, the transcription factor PU.1 has been shown to regulate the expression of GATA-1 isoforms in myeloid cells, while the transcription factor NF-E2 has been shown to regulate the expression of GATA-1 isoforms in erythroid cells.\nTherefore, based on the information provided in Document 0, the gene that controls the expression of GATA-1 isoforms is likely to be one of these transcription factors, such as PU.1 or NF-E2.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 is a transcription factor that plays a crucial role in the regulation of hematopoietic cell fate and differentiation.\n2. There are several isoforms of GATA-1, each with distinct functions in different stages of hematopoiesis.\n3. The expression of GATA-1 isoforms is regulated during hematopoietic development.\n4. The transcription factor PU.1 regulates the expression of GATA-1 isoforms in myeloid cells.\n5. The transcription factor NF-E2 regulates the expression of GATA-1 isoforms in erythroid cells.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 is a transcription factor that plays a crucial role in the regulation of hematopoietic cell fate and differentiation.",
      "There are several isoforms of GATA-1, each with distinct functions in different stages of hematopoiesis.",
      "The expression of GATA-1 isoforms is regulated during hematopoietic development.",
      "The transcription factor PU.1 regulates the expression of GATA-1 isoforms in myeloid cells.",
      "The transcription factor NF-E2 regulates the expression of GATA-1 isoforms in erythroid cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The transcription factor PU.1 does not regulate the expression of GATA-1 isoforms in myeloid cells; instead, PU.1 is involved in the regulation of genes necessary for myeloid and B-lymphoid cell development and functions antagonistically with GATA-1 in myeloid cells.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "Great, thank you for providing the information! Based on the information provided, MIRA-seq is a method used to enrich regions with methylated CpG dinucleotides in genomic DNA. It uses the high affinity of a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich these regions, which can be applied to both array-based DNA analysis and next-generation sequencing (NGS). In the MIRA procedure, the fragmented genomic DNA is first bound by the MBD2B and MBD3L1 complex, which then recognizes and binds to methylated CpG dinucleotides. The enriched DNA is then used for further analysis, such as array-based hybridization or NGS sequencing.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a method used to enrich regions with methylated CpG dinucleotides in genomic DNA.\n2. MIRA-seq uses a complex of methylated-CpG-binding proteins, specifically MBD2B and MBD3L1, to enrich these regions.\n3. The MIRA-seq method can be applied to both array-based DNA analysis and next-generation sequencing (NGS).\n4. In the MIRA procedure, fragmented genomic DNA is first bound by the MBD2B and MBD3L1 complex.\n5. The MBD2B and MBD3L1 complex recognizes and binds to methylated CpG dinucleotides during the MIRA-seq process.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a method used to enrich regions with methylated CpG dinucleotides in genomic DNA.",
      "MIRA-seq uses a complex of methylated-CpG-binding proteins, specifically MBD2B and MBD3L1, to enrich these regions.",
      "The MIRA-seq method can be applied to both array-based DNA analysis and next-generation sequencing (NGS).",
      "In the MIRA procedure, fragmented genomic DNA is first bound by the MBD2B and MBD3L1 complex.",
      "The MBD2B and MBD3L1 complex recognizes and binds to methylated CpG dinucleotides during the MIRA-seq process."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indication of ARCALYST is to treat symptoms of rare genetic conditions such as Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS). These conditions are inflammatory disorders that cause symptoms such as joint pain, swelling, and stiffness, as well as fever and fatigue, in response to cold, heat, stress, or tiredness. ARCALYST is a prescription medication that is used to treat these symptoms in adults and children aged 12 years and older.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is indicated for the treatment of symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS).\n2. ARCALYST is indicated for the treatment of symptoms of Muckle-Wells Syndrome (MWS).\n3. FCAS and MWS are inflammatory disorders that can cause joint pain, swelling, and stiffness.\n4. FCAS and MWS can also cause fever and fatigue in response to cold, heat, stress, or tiredness.\n5. ARCALYST is a prescription medication used in adults and children aged 12 years and older.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is indicated for the treatment of symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS).",
      "ARCALYST is indicated for the treatment of symptoms of Muckle-Wells Syndrome (MWS).",
      "FCAS and MWS are inflammatory disorders that can cause joint pain, swelling, and stiffness.",
      "FCAS and MWS can also cause fever and fatigue in response to cold, heat, stress, or tiredness.",
      "ARCALYST is a prescription medication used in adults and children aged 12 years and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: ARCALYST is a prescription medication used in adults and children aged 12 years and older for some indications, but for others, it may be approved for use in younger children as well. For example, for the treatment of FCAS and MWS, it is approved for use in adults and children aged 4 years and older.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the human acrocentric chromosomes involved in Robertsonian translocations are:\n1. Chromosome 13\n2. Chromosome 14\n3. Chromosome 15\n4. Chromosome 21\n5. Chromosome 22\nThese chromosomes are acrocentric because they have a short arm that is much shorter than their long arm. Additionally, the short arms of these chromosomes contain numerous copies of the genes coding for ribosomal RNA. Robertsonian translocations occur when a portion of one acrocentric chromosome breaks off and attaches to another acrocentric chromosome, resulting in a change in the number or structure of the chromosomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocations.\n2. Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.\n3. Chromosome 15 is an acrocentric chromosome involved in Robertsonian translocations.\n4. Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocations.\n5. Chromosome 22 is an acrocentric chromosome involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 14 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 15 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 21 is an acrocentric chromosome involved in Robertsonian translocations.",
      "Chromosome 22 is an acrocentric chromosome involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll five statements are true. Chromosomes 13, 14, 15, 21, and 22 are indeed acrocentric chromosomes, which means their centromeres are located near one end of the chromosome, resulting in a long arm and a very short arm. These chromosomes are known to be involved in Robertsonian translocations, a type of chromosomal rearrangement that occurs when the long arms of two acrocentric chromosomes fuse at the centromere, forming a single chromosome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that could be used for the identification of pediatric brain tumors is \"MethPed\". The MethPed package is a Bioconductor package that efficiently classifies pediatric brain tumors using a developed classifier. The package is available for use on the Bioconductor platform.\nAccording to the information provided, the MethPed package uses gene expression data to identify tumor specific gene and protein signatures, which are used to classify pediatric brain tumors. This suggests that the package is designed to analyze gene expression data and identify patterns that are associated with pediatric brain tumors, which could be useful for identifying and classifying these tumors.\nIt is important to note that the accuracy of the MethPed package may depend on the quality and quantity of the gene expression data used, as well as the specific type of pediatric brain tumor being analyzed. Therefore, it is recommended to consult the package documentation and relevant literature to determine the appropriate use and limitations of the package.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"MethPed\" can be used for the identification of pediatric brain tumors.\n2. MethPed is a Bioconductor package.\n3. The MethPed package classifies pediatric brain tumors using a developed classifier.\n4. MethPed uses gene expression data to identify tumor-specific gene and protein signatures.\n5. The accuracy of the MethPed package may depend on the quality and quantity of the gene expression data used.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"MethPed\" can be used for the identification of pediatric brain tumors.",
      "MethPed is a Bioconductor package.",
      "The MethPed package classifies pediatric brain tumors using a developed classifier.",
      "MethPed uses gene expression data to identify tumor-specific gene and protein signatures.",
      "The accuracy of the MethPed package may depend on the quality and quantity of the gene expression data used."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: MethPed is not a Bioconductor package; it is available on CRAN (The Comprehensive R Archive Network).\n3. TRUE\n4. FALSE [correction]: MethPed uses DNA methylation data, not gene expression data, to identify tumor-specific signatures.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the answer to the user's question is yes, NEMO is a zinc finger protein. The article states that the zinc finger of NEMO is a functional ubiquitin-binding domain, which suggests that NEMO contains a zinc finger protein domain. Zinc finger proteins are a class of proteins that contain a specific sequence of amino acids that are responsible for binding to zinc ions, and they play important roles in various cellular processes, including signal transduction and gene regulation. Therefore, based on the information provided, it can be concluded that NEMO is a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is a zinc finger protein.\n2. The zinc finger of NEMO is a functional ubiquitin-binding domain.\n3. Zinc finger proteins contain a specific sequence of amino acids responsible for binding to zinc ions.\n4. Zinc finger proteins play important roles in cellular processes such as signal transduction and gene regulation.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is a zinc finger protein.",
      "The zinc finger of NEMO is a functional ubiquitin-binding domain.",
      "Zinc finger proteins contain a specific sequence of amino acids responsible for binding to zinc ions.",
      "Zinc finger proteins play important roles in cellular processes such as signal transduction and gene regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO (NF-kappaB essential modulator) is not a zinc finger protein; it is an essential regulatory protein involved in the NF-kappaB signaling pathway.\n2. FALSE [correction]: Since NEMO is not a zinc finger protein, it does not have a zinc finger domain for binding ubiquitin. NEMO does interact with ubiquitin, but through a different domain known as the UBAN (ubiquitin-binding domain in ABIN proteins and NEMO).\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIIS) can affect nucleosome positioning. According to the information provided in Document 0, the lack of TFIIS leads to changes in nucleosome occupancy across the genome, particularly in gene bodies and promoter regions. This effect is most pronounced in genes that contain a canonical TATA box (TATA genes), which are also more strongly affected by sequence-bias correction. These findings suggest that TFIIS plays a role in shaping the chromatin landscape and influencing nucleosome positioning, which in turn can impact gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS can affect nucleosome positioning.\n2. The absence of TFIIS leads to changes in nucleosome occupancy across the genome.\n3. Changes in nucleosome occupancy are particularly notable in gene bodies and promoter regions due to the lack of TFIIS.\n4. Genes containing a canonical TATA box are more strongly affected by the absence of TFIIS.\n5. TFIIS influences gene expression by shaping the chromatin landscape.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS can affect nucleosome positioning.",
      "The absence of TFIIS leads to changes in nucleosome occupancy across the genome.",
      "Changes in nucleosome occupancy are particularly notable in gene bodies and promoter regions due to the lack of TFIIS.",
      "Genes containing a canonical TATA box are more strongly affected by the absence of TFIIS.",
      "TFIIS influences gene expression by shaping the chromatin landscape."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: TFIIS is known to be involved in transcription elongation and can affect chromatin structure, which includes nucleosome positioning.\n2. TRUE: The absence of TFIIS can lead to transcription elongation defects, which can in turn affect nucleosome occupancy across the genome.\n3. TRUE: Nucleosome occupancy changes are often most notable in gene bodies and promoter regions, which are key areas for the regulation of gene expression and can be affected by transcription elongation factors like TFIIS.\n4. UNKNOWN: Without specific evidence or data from the passage, it is difficult to determine whether genes with a canonical TATA box are more strongly affected by the absence of TFIIS than other genes.\n5. TRUE: TFIIS influences gene expression, and one of the ways it can do so is by affecting the chromatin landscape, which includes nucleosome positioning and other aspects of chromatin structure.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that origins of replication close to yeast centromeres fire early.\nCentromeres are specialized regions of DNA that play a crucial role in the separation of chromosomes during cell division. In eukaryotic cells, including yeast, DNA replication begins at multiple origins of replication (ORIs) located throughout the genome. These ORIs are thought to fire at different times during the cell cycle, with some firing earlier than others.\nStudies have shown that the distance between an origin of replication and the centromere can influence the timing of replication initiation. In general, origins of replication located closer to the centromere tend to fire earlier in the cell cycle than those located farther away. This is because the proximity of the origin to the centromere allows for more efficient loading of the replication machinery, leading to earlier initiation of replication.\nIn the case of yeast, the centromere is located near the origin of replication known as the \"A\" origin, which fires around the G1/S checkpoint of the cell cycle. This suggests that origins of replication close to the yeast centromere may fire early in the cell cycle.\nIt is worth noting, however, that the timing of origin firing can vary depending on a variety of factors, including the specific cell type, the presence of certain regulatory proteins, and the overall cellular environment. Therefore, while it is likely that origins of replication close to yeast centromeres fire early, the exact timing may depend on a variety of factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Centromeres are specialized regions of DNA that play a crucial role in the separation of chromosomes during cell division.\n2. In eukaryotic cells, including yeast, DNA replication begins at multiple origins of replication located throughout the genome.\n3. Origins of replication located closer to the centromere tend to fire earlier in the cell cycle than those located farther away.\n4. The proximity of the origin to the centromere allows for more efficient loading of the replication machinery, leading to earlier initiation of replication.\n5. The \"A\" origin of replication in yeast fires around the G1/S checkpoint of the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Centromeres are specialized regions of DNA that play a crucial role in the separation of chromosomes during cell division.",
      "In eukaryotic cells, including yeast, DNA replication begins at multiple origins of replication located throughout the genome.",
      "Origins of replication located closer to the centromere tend to fire earlier in the cell cycle than those located farther away.",
      "The proximity of the origin to the centromere allows for more efficient loading of the replication machinery, leading to earlier initiation of replication.",
      "The \"A\" origin of replication in yeast fires around the G1/S checkpoint of the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The statement is not universally true. In some organisms, origins of replication closer to the centromere may fire earlier, but this is not a general rule across all eukaryotes. The timing of origin firing can be influenced by various factors and is subject to complex regulation.\n4. UNKNOWN: The efficiency of loading the replication machinery can be influenced by proximity to the centromere, but this is not the only factor that determines the initiation timing of replication. Other factors such as origin recognition complex availability and chromatin structure also play significant roles.\n5. UNKNOWN: The timing of the firing of specific origins of replication, such as the \"A\" origin in yeast, can vary and is subject to regulation by multiple factors. Without specific information about the \"A\" origin, it is not possible to confirm when it fires during the cell cycle.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the properties of mammalian GA-sequences are:\n1. Length: Mammalian GA-sequences are longer than 50 bases, but consist exclusively of G's and A's (i.e., they are composed of only G and A nucleotides).\n2. Frequency of incidence: Although their frequency of incidence should be 10^-16 or smaller, mammalian GA-sequences are found in many tens of thousands of locations along the chromosomes of various mammalian species, including humans, chimpanzees, dogs, cats, rats, and mice.\n3. Species-dependent distribution: The frequency and distribution of GA-sequences vary among different mammalian species, with some species having more GA-sequences than others.\nIt is important to note that these properties are based on the information provided in Document 0 and may not be applicable to all mammalian GA-sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are longer than 50 bases.\n2. Mammalian GA-sequences consist exclusively of G's and A's nucleotides.\n3. The expected frequency of incidence for mammalian GA-sequences should be 10^-16 or smaller.\n4. Mammalian GA-sequences are found in many tens of thousands of locations along the chromosomes of various mammalian species.\n5. The frequency and distribution of GA-sequences vary among different mammalian species.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are longer than 50 bases.",
      "Mammalian GA-sequences consist exclusively of G's and A's nucleotides.",
      "The expected frequency of incidence for mammalian GA-sequences should be 10^-16 or smaller.",
      "Mammalian GA-sequences are found in many tens of thousands of locations along the chromosomes of various mammalian species.",
      "The frequency and distribution of GA-sequences vary among different mammalian species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is vague as it does not specify what is meant by \"GA-sequences.\" If it refers to specific genetic motifs or regions rich in guanine (G) and adenine (A), the length can vary widely, and without specific context, it's difficult to confirm or refute the length of these sequences.\n2. FALSE [correction]: Mammalian GA-sequences may be rich in guanine (G) and adenine (A) nucleotides, but they can also include other nucleotides such as cytosine (C) and thymine (T). The term \"GA-sequence\" does not imply that they consist exclusively of G's and A's.\n3. UNKNOWN: Without additional context, it's unclear what the basis for the expected frequency of incidence is. The calculation of such a frequency would depend on various factors, including the length of the sequence in question and the genomic context.\n4. TRUE: It is well-established that certain sequences, including GA-rich sequences, can be found at many locations along the chromosomes of various mammalian species.\n5. TRUE: The frequency and distribution of genetic sequences, including GA-sequences, do vary among different mammalian species due to evolutionary divergence and genetic variability.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there is one Groucho-related gene (GRG) contained in the mouse genome, specifically GRG5. The abstract mentions that GRG5 is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is one Groucho-related gene (GRG) in the mouse genome.\n2. The specific Groucho-related gene in the mouse genome is GRG5.\n3. GRG5 is a multifunctional protein.\n4. GRG5 has been implicated in late embryonic development in mice.\n5. GRG5 has been implicated in postnatal development in mice.",
    "llama-2-7b-chat-hf_fact": [
      "There is one Groucho-related gene (GRG) in the mouse genome.",
      "The specific Groucho-related gene in the mouse genome is GRG5.",
      "GRG5 is a multifunctional protein.",
      "GRG5 has been implicated in late embryonic development in mice.",
      "GRG5 has been implicated in postnatal development in mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are multiple Groucho-related genes (GRGs) in the mouse genome, not just one.\n2. FALSE [correction]: The specific Groucho-related genes in the mouse genome are usually referred to as Groucho/TLE genes, such as TLE1, TLE2, TLE3, and TLE4, not GRG5.\n3. TRUE: Groucho/TLE family proteins, including those in mice, are known to be multifunctional, involved in various cellular processes.\n4. TRUE: Groucho/TLE proteins have been implicated in embryonic development, including late embryonic development.\n5. TRUE: Groucho/TLE proteins are also implicated in postnatal development and various other processes throughout the life of the organism.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNA polymerase II does not have RNA cleavage activity. RNA cleavage activity is associated with enzymes like RNase III or the RNA-induced silencing complex (RISC), not with RNA polymerase II subunits. RNA polymerase II is primarily responsible for the synthesis of messenger RNA (mRNA) in eukaryotes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genetic basis of Ohdo syndrome is a variant of the SBBYS (Say-Barber-Biesecker-Young-Simpson) syndrome. This variant is caused by a mutation in a gene or genes that are responsible for the development and function of various body systems, including the reproductive, skeletal, and nervous systems.\nThe specific genetic cause of Ohdo syndrome is not specified in the information provided, but it is likely to be a mutation in a gene that is shared between the SBBYS and Ohdo syndromes. The SBBYS syndrome is caused by mutations in the PTEN gene, which is involved in the regulation of cell growth and division. The Ohdo syndrome, on the other hand, is caused by mutations in the TCOF1 gene, which is involved in the development and maintenance of the genitalia, kneecaps, and other body systems.\nIt is important to note that the genetic basis of Ohdo syndrome is still not fully understood, and more research is needed to determine the specific genetic causes of this condition. A genetic counselor or a medical professional can provide more information and guidance on the genetic basis of Ohdo syndrome and how it affects individuals with this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a variant of the Say-Barber-Biesecker-Young-Simpson (SBBYS) syndrome.\n2. Ohdo syndrome is caused by a mutation in a gene or genes.\n3. The PTEN gene is involved in the regulation of cell growth and division and is associated with mutations causing SBBYS syndrome.\n4. The TCOF1 gene is involved in the development and maintenance of the genitalia, kneecaps, and other body systems and is associated with mutations causing Ohdo syndrome.\n5. The genetic basis of Ohdo syndrome is not fully understood and requires more research.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a variant of the Say-Barber-Biesecker-Young-Simpson (SBBYS) syndrome.",
      "Ohdo syndrome is caused by a mutation in a gene or genes.",
      "The PTEN gene is involved in the regulation of cell growth and division and is associated with mutations causing SBBYS syndrome.",
      "The TCOF1 gene is involved in the development and maintenance of the genitalia, kneecaps, and other body systems and is associated with mutations causing Ohdo syndrome.",
      "The genetic basis of Ohdo syndrome is not fully understood and requires more research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The KAT6B gene, not the PTEN gene, is associated with mutations causing Say-Barber-Biesecker-Young-Simpson (SBBYS) syndrome.\n4. FALSE [correction]: The KAT6B gene is involved in the development of multiple body systems and is associated with mutations causing Ohdo syndrome. The TCOF1 gene is associated with Treacher Collins syndrome, not Ohdo syndrome.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is Psygenet2r. According to the documentation, Psygenet2r is especially suited for network medicine analysis of psychiatric disorders, making it a useful tool for analyzing genetic data related to psychiatric diseases. The package is implemented in R and is available under MIT license from Bioconductor, which is a comprehensive resource for R packages related to genomics and bioinformatics.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.\n2. Psygenet2r is designed for network medicine analysis of psychiatric disorders.\n3. Psygenet2r is implemented in the R programming language.\n4. The Psygenet2r package is available under the MIT license.\n5. Psygenet2r can be obtained from Bioconductor, a resource for genomics and bioinformatics R packages.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.",
      "Psygenet2r is designed for network medicine analysis of psychiatric disorders.",
      "Psygenet2r is implemented in the R programming language.",
      "The Psygenet2r package is available under the MIT license.",
      "Psygenet2r can be obtained from Bioconductor, a resource for genomics and bioinformatics R packages."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Psygenet2r package is available under the Artistic-2.0 license.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided, the swirl sign is a non-contrast CT appearance of acute extravasation of blood into a hematoma, such as an intracerebral hemorrhage, extradural hematoma, or subdural hematoma. This sign represents unclotted fresh blood that is of lower attenuation than the clotted blood that surrounds it. In other words, the swirl sign is a characteristic feature of bleeding in the brain that can help doctors diagnose and monitor the progression of certain neurological conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign is a non-contrast CT appearance of acute extravasation of blood into a hematoma.\n2. It can be observed in conditions such as intracerebral hemorrhage, extradural hematoma, or subdural hematoma.\n3. The swirl sign represents unclotted fresh blood.\n4. Unclotted fresh blood is of lower attenuation than the clotted blood that surrounds it.\n5. The swirl sign is used to help diagnose and monitor the progression of certain neurological conditions.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign is a non-contrast CT appearance of acute extravasation of blood into a hematoma.",
      "It can be observed in conditions such as intracerebral hemorrhage, extradural hematoma, or subdural hematoma.",
      "The swirl sign represents unclotted fresh blood.",
      "Unclotted fresh blood is of lower attenuation than the clotted blood that surrounds it.",
      "The swirl sign is used to help diagnose and monitor the progression of certain neurological conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it can be inferred that Arabidopsis ROF1 expression is induced by heat stress. The study shows that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain, which suggests that ROF1 is involved in the response to heat stress. Additionally, the study states that ROF1 expression is developmentally regulated, which means that it may also be induced by other factors during different stages of plant development. However, based on the information provided, heat stress is the most likely inducer of ROF1 expression in Arabidopsis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.\n3. ROF1 is involved in the response to heat stress in Arabidopsis.\n4. ROF1 expression is developmentally regulated in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.",
      "ROF1 is involved in the response to heat stress in Arabidopsis.",
      "ROF1 expression is developmentally regulated in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: While the statements provided are consistent with the general knowledge about Arabidopsis ROF1 and its role in heat stress response, without specific references to scientific literature, the responses are based on typical understanding of such genes in plant biology. Arabidopsis ROF1 (AtROF1) is known to be involved in heat stress response, and its expression can be induced by heat stress. It is known to interact with heat shock proteins such as HSP90 through its tetratricopeptide repeat (TPR) domain, and it plays a role in the heat stress response of Arabidopsis thaliana. Additionally, the expression of many genes, including ROF1, can be developmentally regulated in plants. However, for precise validation, specific scientific studies should be referenced.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most common cause of hereditary renal amyloidosis is likely to be alpha-2-macroglobulin (A2M). A2M is a protein that is commonly associated with hereditary amyloidosis, and it is the most common cause of renal amyloidosis.\nAccording to the information provided, amyloidosis is a rare disease that occurs when a protein called amyloid builds up in organs, leading to organ dysfunction. Hereditary amyloidosis refers to the inherited form of the disease, which can affect multiple organs, including the kidneys. Renal amyloidosis specifically refers to the buildup of amyloid in the kidneys, which can lead to chronic kidney disease and potentially kidney failure.\nAlpha-2-macroglobulin is a protein that is produced in the liver and is involved in the immune system. Mutations in the A2M gene can lead to the production of abnormal A2M proteins, which can accumulate in organs, including the kidneys, and cause amyloidosis. Hereditary renal amyloidosis caused by A2M mutations is the most common form of the disease, accounting for approximately 70% of all cases.\nTherefore, based on the information provided, the most common cause of hereditary renal amyloidosis is likely to be alpha-2-macroglobulin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is commonly associated with hereditary amyloidosis.\n2. A2M is the most common cause of renal amyloidosis.\n3. Amyloidosis occurs when a protein called amyloid builds up in organs, leading to organ dysfunction.\n4. Hereditary amyloidosis is an inherited form of the disease that can affect multiple organs, including the kidneys.\n5. Mutations in the A2M gene can lead to the production of abnormal A2M proteins that accumulate in organs and cause amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is commonly associated with hereditary amyloidosis.",
      "A2M is the most common cause of renal amyloidosis.",
      "Amyloidosis occurs when a protein called amyloid builds up in organs, leading to organ dysfunction.",
      "Hereditary amyloidosis is an inherited form of the disease that can affect multiple organs, including the kidneys.",
      "Mutations in the A2M gene can lead to the production of abnormal A2M proteins that accumulate in organs and cause amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not commonly associated with hereditary amyloidosis. Transthyretin (TTR), not A2M, is more commonly associated with hereditary amyloidosis.\n2. FALSE [correction]: A2M is not the most common cause of renal amyloidosis. The most common forms of amyloidosis affecting the kidneys are AL (light chain) and AA (secondary) amyloidosis.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the A2M gene are not typically associated with hereditary amyloidosis. It is mutations in other genes, such as the TTR gene, that can lead to hereditary amyloidosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of mice hippocampus has been analyzed in the document provided. The study analyzed the hippocampal proteome at two ages (5 and 10 months) to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus. This information suggests that the study has conducted a proteomic analysis of the hippocampus in mice, which is a brain region involved in memory and spatial navigation. The analysis likely involved techniques such as mass spectrometry or protein microarrays to identify and quantify proteins in the hippocampus at different ages.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of mice hippocampus has been analyzed.\n2. The study analyzed the hippocampal proteome at two ages: 5 and 10 months.\n3. The purpose of the study was to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.\n4. The hippocampus is a brain region involved in memory and spatial navigation.\n5. The analysis likely involved techniques such as mass spectrometry or protein microarrays.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of mice hippocampus has been analyzed.",
      "The study analyzed the hippocampal proteome at two ages: 5 and 10 months.",
      "The purpose of the study was to reveal the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.",
      "The hippocampus is a brain region involved in memory and spatial navigation.",
      "The analysis likely involved techniques such as mass spectrometry or protein microarrays."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the answer to the user's question is:\nYes, mouse chromosomes are acrocentric. According to Document 0, all chromosomes in mice are acrocentric, while other mammalian species carry a mixture of acrocentric and metacentric chromosomes. This suggests that mouse chromosomes have a characteristic acrocentric structure, which may play a role in the differences in telomeric structures observed between mice and other mammalian species.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. All chromosomes in mice are acrocentric.\n3. Other mammalian species carry a mixture of acrocentric and metacentric chromosomes.\n4. The acrocentric structure of mouse chromosomes may play a role in the differences in telomeric structures observed between mice and other mammalian species.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are acrocentric.",
      "All chromosomes in mice are acrocentric.",
      "Other mammalian species carry a mixture of acrocentric and metacentric chromosomes.",
      "The acrocentric structure of mouse chromosomes may play a role in the differences in telomeric structures observed between mice and other mammalian species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Not all chromosomes in mice are acrocentric; mice have both acrocentric and telocentric chromosomes.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is ALN-VSP02.",
    "llama-2-7b-chat-hf_fact_raw": "1. ALN-VSP02 is an siRNA-based drug.\n2. ALN-VSP02 is in clinical trials for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ALN-VSP02 is an siRNA-based drug.",
      "ALN-VSP02 is in clinical trials for the treatment of pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the HPG pore appears to be a toolkit for exploring and analyzing nanopore sequencing data. Nanopore sequencing is a single-molecule sequencing technique that uses a nanopore to read the sequence of nucleotides in a DNA molecule. The HPG pore toolkit is designed to help researchers analyze and make sense of the large amounts of data generated by nanopore sequencing. It can run on both individual computers and in the Hadoop distributed computing framework, which allows for easy scaling up to manage large amounts of data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data.\n2. Nanopore sequencing is a single-molecule sequencing technique.\n3. Nanopore sequencing involves using a nanopore to read the sequence of nucleotides in a DNA molecule.\n4. The HPG pore toolkit is designed to help researchers analyze large amounts of data generated by nanopore sequencing.\n5. The HPG pore can run on individual computers and in the Hadoop distributed computing framework.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data.",
      "Nanopore sequencing is a single-molecule sequencing technique.",
      "Nanopore sequencing involves using a nanopore to read the sequence of nucleotides in a DNA molecule.",
      "The HPG pore toolkit is designed to help researchers analyze large amounts of data generated by nanopore sequencing.",
      "The HPG pore can run on individual computers and in the Hadoop distributed computing framework."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore is not a toolkit; it is likely a confusion with a different tool. HPG stands for High-Performance Genomics, which could refer to various tools and frameworks for genomic data analysis, but \"HPG pore\" itself is not a recognized toolkit for nanopore sequencing data.\n2. TRUE\n3. TRUE\n4. UNKNOWN: Without specific information about the \"HPG pore\" toolkit, it is not possible to confirm whether it is designed to help researchers analyze large amounts of data generated by nanopore sequencing.\n5. UNKNOWN: Similarly, without accurate information about the \"HPG pore\" toolkit, it is not possible to confirm whether it can run on individual computers and in the Hadoop distributed computing framework.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale effort to sequence the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in a wide range of environments, including soil, plants, and animals. The initiative is inspired by the successful sequencing of the genome of the nematode Caenorhabditis elegans, which was a landmark achievement that ushered in a new era of whole-organism, systems-level analyses of this powerful model organism.\nThe 959 Nematode Genomes initiative is a collaborative effort involving researchers from around the world, and it is expected to provide a wealth of new insights into the biology and evolution of nematodes, as well as their interactions with their environments and hosts. The project will also provide a valuable resource for the development of new drugs and pesticides, as well as for improving crop yields and plant health.\nThe initiative is being led by the University of California, Davis, and is supported by a grant from the National Institutes of Health. The project is expected to be completed within the next few years, and the results will be made available to the scientific community through a variety of online resources.\nReferences:\n* Document 0: Toward 959 nematode genomes. (2014). Nature, 500(7401), 240-243. doi: 10.1038/nature12477\nNote: The information provided is based on the given document and my internal knowledge, but it is not a guarantee of accuracy or completeness.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.\n2. The initiative was inspired by the successful sequencing of the genome of the nematode Caenorhabditis elegans.\n3. The project is a collaborative effort involving researchers from around the world.\n4. The University of California, Davis is leading the 959 Nematode Genomes initiative.\n5. The initiative is supported by a grant from the National Institutes of Health.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.",
      "The initiative was inspired by the successful sequencing of the genome of the nematode Caenorhabditis elegans.",
      "The project is a collaborative effort involving researchers from around the world.",
      "The University of California, Davis is leading the 959 Nematode Genomes initiative.",
      "The initiative is supported by a grant from the National Institutes of Health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that has been developed for analyzing Non-invasive prenatal testing (NIPT) data is NIPTeR.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTeR.",
    "llama-2-7b-chat-hf_fact": [
      "The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTeR."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach syndrome is a rare medical condition characterized by recurring and painful bruising of the fingers or palm, without any underlying serious conditions. It is more common in middle-aged females, with a median age of onset of 48-50 years (range of 22-76 years). The exact cause of Achenbach syndrome is not known, but it is believed to be related to changes in blood vessels and vascular fragility.\nThe symptoms of Achenbach syndrome typically occur without any obvious trigger and can last for several days or weeks before resolving on their own. The affected fingers or palm may appear blue or purple due to the bruising, and the pain can range from mild to severe. In some cases, the bruising may be accompanied by swelling or redness.\nWhile Achenbach syndrome is not a life-threatening condition, it can significantly impact a person's quality of life due to the recurring nature of the symptoms and the associated pain. If you are experiencing symptoms of Achenbach syndrome, it is essential to consult with a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach syndrome is characterized by recurring and painful bruising of the fingers or palm.\n2. It is more common in middle-aged females.\n3. The median age of onset for Achenbach syndrome is between 48-50 years.\n4. The exact cause of Achenbach syndrome is unknown but is believed to be related to changes in blood vessels and vascular fragility.\n5. Symptoms of Achenbach syndrome typically resolve on their own after several days or weeks.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach syndrome is characterized by recurring and painful bruising of the fingers or palm.",
      "It is more common in middle-aged females.",
      "The median age of onset for Achenbach syndrome is between 48-50 years.",
      "The exact cause of Achenbach syndrome is unknown but is believed to be related to changes in blood vessels and vascular fragility.",
      "Symptoms of Achenbach syndrome typically resolve on their own after several days or weeks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the algorithm used for detection of long repeat expansions is likely to be a repeat-masking algorithm. These algorithms use a combination of computational methods to identify and mask repeat regions in a DNA sequence, including:\n1. Repeat-masking: This algorithm uses a combination of heuristics and statistical models to identify repeat regions in a DNA sequence. It works by comparing the sequence to a database of known repeat sequences and identifying regions that match.\n2. Repeat-finding: This algorithm uses a combination of sequence alignment and statistical models to identify repeat regions in a DNA sequence. It works by aligning the sequence to a reference genome and identifying regions that have a high degree of similarity to known repeat sequences.\n3. Repeat-assembly: This algorithm uses a combination of sequence assembly and statistical models to identify repeat regions in a DNA sequence. It works by assembling the sequence into contigs and scaffolds and identifying regions that have a high degree of similarity to known repeat sequences.\nSome examples of repeat-masking algorithms include:\n1. RepeatMasker: This is a widely used algorithm for detecting repeat regions in a DNA sequence. It uses a combination of heuristics and statistical models to identify repeat regions and can be used for both short-read and long-read sequencing data.\n2. RepeatFinder: This algorithm is similar to RepeatMasker but is specifically designed for detecting repeat regions in a DNA sequence. It uses a combination of sequence alignment and statistical models to identify repeat regions and can be used for both short-read and long-read sequencing data.\n3. RepeatAssembler: This algorithm is similar to RepeatFinder but is specifically designed for detecting repeat regions in a DNA sequence during the assembly process. It uses a combination of sequence assembly and statistical models to identify repeat regions and can be used for both short-read and long-read sequencing data.\nIt's important to note that these algorithms are not mutually exclusive, and many repeat-masking algorithms use a combination of different methods to identify repeat regions. Additionally, there are many other algorithms available for detecting repeat regions in a DNA sequence, and the choice of algorithm will depend on the specific requirements of the analysis and the characteristics of the data.",
    "llama-2-7b-chat-hf_fact_raw": "1. Repeat-masking algorithms are used for detection of long repeat expansions in DNA sequences.\n2. RepeatMasker is a widely used algorithm for detecting repeat regions in DNA sequences.\n3. RepeatFinder is designed for detecting repeat regions in DNA sequences and uses sequence alignment and statistical models.\n4. RepeatAssembler is designed for detecting repeat regions in DNA sequences during the assembly process.\n5. Repeat-masking algorithms can be used for both short-read and long-read sequencing data.",
    "llama-2-7b-chat-hf_fact": [
      "Repeat-masking algorithms are used for detection of long repeat expansions in DNA sequences.",
      "RepeatMasker is a widely used algorithm for detecting repeat regions in DNA sequences.",
      "RepeatFinder is designed for detecting repeat regions in DNA sequences and uses sequence alignment and statistical models.",
      "RepeatAssembler is designed for detecting repeat regions in DNA sequences during the assembly process.",
      "Repeat-masking algorithms can be used for both short-read and long-read sequencing data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, neuroligin-3 promotes the growth and progression of certain types of brain tumors, including:\n1. Glioblastoma: The document states that activity-dependent cleavage and secretion of neuroligin-3 (NLGN3) mediates the regulation of brain cancer, including glioblastoma.\n2. Medulloblastoma: The document also mentions that neuroligin-3 is involved in the regulation of medulloblastoma, another type of brain cancer.\nIt is important to note that these findings are based on in vitro and in vivo studies, and further research is needed to confirm the role of neuroligin-3 in brain tumorigenesis in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth and progression of glioblastoma.\n2. Neuroligin-3 is involved in the regulation of medulloblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth and progression of glioblastoma.",
      "Neuroligin-3 is involved in the regulation of medulloblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the approximate size of gas vesicles can be estimated to be:\nWidth: 0.045–0.2 μm (0.0000045–0.00002 μm)\nLength: 0.1–2 μm (0.000001–0.00002 μm)\nSo, the diameter of a gas vesicle is approximately between 0.0000045 and 0.00002 μm, and its length can range from 0.000001 to 0.00002 μm.",
    "llama-2-7b-chat-hf_fact_raw": "1. The width of gas vesicles is approximately between 0.045 and 0.2 μm.\n2. The length of gas vesicles can range from 0.1 to 2 μm.",
    "llama-2-7b-chat-hf_fact": [
      "The width of gas vesicles is approximately between 0.045 and 0.2 μm.",
      "The length of gas vesicles can range from 0.1 to 2 μm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided in Document 0, here are some of the BET proteins that have been identified:\n1. BRD4 (Bromodomain-Containing Protein 4): This is the most well-studied BET protein and is involved in various cellular processes, including cell cycle progression, neurogenesis, differentiation, and maturation of erythroids and spermatogenesis.\n2. BRD2 (Bromodomain-Containing Protein 2): Like BRD4, BRD2 is also involved in various cellular processes and has been implicated in various diseases, including cancer and inflammation.\n3. BRDT (Bromodomain-Containing Protein T): This protein is similar to BRD4 and BRD2 and has been shown to play a role in regulating gene expression and cellular differentiation.\n4. BRIL (Bromodomain-Containing Protein R): This protein is a less well-studied member of the BET family and has been implicated in the regulation of gene expression and cellular differentiation.\nIt's worth noting that there may be other BET proteins that have not been as extensively studied or identified, but these are some of the most well-characterized members of the family.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD4 is a BET protein involved in cell cycle progression, neurogenesis, differentiation, and maturation of erythroids and spermatogenesis.\n2. BRD2 is a BET protein implicated in various diseases, including cancer and inflammation.\n3. BRDT is a BET protein that plays a role in regulating gene expression and cellular differentiation.\n4. BRIL is a member of the BET protein family implicated in the regulation of gene expression and cellular differentiation.\n5. BRD4, BRD2, and BRDT are well-studied members of the BET protein family.",
    "llama-2-7b-chat-hf_fact": [
      "BRD4 is a BET protein involved in cell cycle progression, neurogenesis, differentiation, and maturation of erythroids and spermatogenesis.",
      "BRD2 is a BET protein implicated in various diseases, including cancer and inflammation.",
      "BRDT is a BET protein that plays a role in regulating gene expression and cellular differentiation.",
      "BRIL is a member of the BET protein family implicated in the regulation of gene expression and cellular differentiation.",
      "BRD4, BRD2, and BRDT are well-studied members of the BET protein family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRIL is not a member of the BET protein family. BET proteins include BRD2, BRD3, BRD4, and BRDT.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the algorithm developed for prediction of protein subcellular localization using deep learning is a prediction algorithm using deep neural networks.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MULTOVL appears to be an application suite designed to detect and analyze multiple overlaps of genomic regions in a fast and efficient manner. The package supports the detection of multiple region intersections, unions, and what it calls \"solitary\" genomic regions. The significance of actually observed overlaps is also discussed in the document.\nIn summary, MULTOVL is a tool designed to help analyze and understand the overlaps of genomic regions, which can provide valuable insights into the structure and function of genomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is an application suite designed for detecting and analyzing overlaps of genomic regions.\n2. MULTOVL can detect multiple region intersections and unions.\n3. MULTOVL has a feature to identify \"solitary\" genomic regions.\n4. The application suite discusses the significance of observed overlaps in genomic regions.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is an application suite designed for detecting and analyzing overlaps of genomic regions.",
      "MULTOVL can detect multiple region intersections and unions.",
      "MULTOVL has a feature to identify \"solitary\" genomic regions.",
      "The application suite discusses the significance of observed overlaps in genomic regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific information about the application suite named MULTOVL, it is not possible to verify the accuracy of these statements. If MULTOVL is a real and documented application suite, the details provided would need to be checked against authoritative sources or documentation related to MULTOVL to determine the truthfulness of each statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is possible that GDF15 could be used as a biomarker for metformin treatment. The document states that GDF15 is expressed in multiple cell types and can be increased by cellular stressors, including hypoxia, mitochondrial dysfunction, and metformin. This suggests that GDF15 levels may be affected by metformin treatment, and could potentially serve as a biomarker for its effectiveness.\nHowever, it is important to note that the relationship between GDF15 and metformin is complex and may depend on various factors, such as the dose and duration of metformin treatment, as well as individual differences in metformin metabolism and response. Further research is needed to fully understand the potential of GDF15 as a biomarker for metformin treatment.\nIn summary, while the information provided suggests that GDF15 may be a potential biomarker for metformin treatment, more research is needed to confirm this association and to fully understand its implications for clinical practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 is expressed in multiple cell types.\n2. GDF15 levels can be increased by cellular stressors, including hypoxia, mitochondrial dysfunction, and metformin.\n3. GDF15 levels may be affected by metformin treatment.\n4. The relationship between GDF15 and metformin depends on various factors such as dose and duration of treatment, and individual differences in metabolism and response.\n5. Further research is needed to fully understand the potential of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 is expressed in multiple cell types.",
      "GDF15 levels can be increased by cellular stressors, including hypoxia, mitochondrial dysfunction, and metformin.",
      "GDF15 levels may be affected by metformin treatment.",
      "The relationship between GDF15 and metformin depends on various factors such as dose and duration of treatment, and individual differences in metabolism and response.",
      "Further research is needed to fully understand the potential of GDF15 as a biomarker for metformin treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the statements provided are consistent with current scientific understanding regarding GDF15 (Growth Differentiation Factor 15) and its relationship with cellular stressors and metformin treatment. GDF15 is indeed expressed in various cell types and can be upregulated in response to different stressors, including those listed. The relationship between GDF15 levels and metformin treatment is complex and can be influenced by multiple factors. Further research is often needed to clarify the role of biomarkers like GDF15 in the context of specific treatments such as metformin.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, yes, recursive splicing is more common in short introns. Document 0 suggests that recursive splicing often involves non-canonical splicing elements positioned deep within introns, which are more prevalent in short introns compared to long introns. Additionally, the document mentions different mechanisms for the deployment of recursive splicing, which may be more pronounced in short introns. Therefore, it can be inferred that recursive splicing is more common in short introns than in long introns.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing often involves non-canonical splicing elements.\n2. Non-canonical splicing elements are more prevalent in short introns compared to long introns.\n3. Recursive splicing is more common in short introns than in long introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing often involves non-canonical splicing elements.",
      "Non-canonical splicing elements are more prevalent in short introns compared to long introns.",
      "Recursive splicing is more common in short introns than in long introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: Recursive splicing is more common in long introns than in short introns.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the TALE-iD method is used for genome editing. Specifically, the TALE-iD method is a genome editing technology that uses TALE (Transcription Activator-Like Effector) nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors to make targeted changes to the genome. The TALE-iD method is considered to be an easy-to-use genome editing technology and has been used in both agricultural and medical applications. The guidelines for TALEN design provided in the information suggest that the method can be used to create specific genetic modifications in an organism's genome. Overall, the TALE-iD method is a powerful tool for genome editing and has played a significant role in the genome editing revolution.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for genome editing.\n2. It utilizes TALE (Transcription Activator-Like Effector) nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors.\n3. The TALE-iD method is considered easy to use.\n4. The TALE-iD method has been applied in both agricultural and medical fields.\n5. The TALE-iD method allows for the creation of specific genetic modifications in an organism's genome.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for genome editing.",
      "It utilizes TALE (Transcription Activator-Like Effector) nucleases, activators, transposases, recombinases, epigenomic modifiers, and base editors.",
      "The TALE-iD method is considered easy to use.",
      "The TALE-iD method has been applied in both agricultural and medical fields.",
      "The TALE-iD method allows for the creation of specific genetic modifications in an organism's genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Lisp framework that has been developed for image processing is FunImageJ.",
    "llama-2-7b-chat-hf_fact_raw": "1. FunImageJ is a Lisp framework developed for image processing.",
    "llama-2-7b-chat-hf_fact": [
      "FunImageJ is a Lisp framework developed for image processing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it is estimated that approximately 10% of the genes in Saccharomyces cerevisiae (baker's yeast) are the result of an ancient whole genome duplication. This is suggested by the finding that many duplicate genes have been identified in S. cerevisiae, and these genes often appear to be phenotypically redundant.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 10% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. Many duplicate genes have been identified in Saccharomyces cerevisiae.\n3. The duplicate genes in Saccharomyces cerevisiae often appear to be phenotypically redundant.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 10% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "Many duplicate genes have been identified in Saccharomyces cerevisiae.",
      "The duplicate genes in Saccharomyces cerevisiae often appear to be phenotypically redundant."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the complex that is bound by estrogen-related receptor β (Esrrb) is the mesendoderm and extra-embryonic markers. Genetic inactivation of Esrrb leads to the illegitimate expression of these markers, which results in impaired formative expression and failure to self-organize in 3D.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) binds to the mesendoderm and extra-embryonic markers.\n2. Genetic inactivation of Esrrb leads to the illegitimate expression of mesendoderm and extra-embryonic markers.\n3. Impaired formative expression results from the genetic inactivation of Esrrb.\n4. Failure to self-organize in 3D is a consequence of the genetic inactivation of Esrrb.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) binds to the mesendoderm and extra-embryonic markers.",
      "Genetic inactivation of Esrrb leads to the illegitimate expression of mesendoderm and extra-embryonic markers.",
      "Impaired formative expression results from the genetic inactivation of Esrrb.",
      "Failure to self-organize in 3D is a consequence of the genetic inactivation of Esrrb."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements provided are highly specific to the field of genetics and developmental biology, and without the proper context or access to the specific scientific literature or passage from which these statements are derived, it is not possible to accurately determine their truthfulness. Corrections would require specific knowledge of the functions and effects of the Estrogen-related receptor β (Esrrb) gene.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ZCCHC17 appears to be a gene that is relevant to hepatocellular carcinoma (HCC), a type of malignant tumor. The abstract mentions that HCC has a poor prognosis and low five-year survival rate due to tumor recurrence and metastasis.\nZCCHC17 is a gene that has been identified as a potential oncogene in HCC. Studies have shown that ZCCHC17 is overexpressed in many types of cancer, including HCC, and that high levels of ZCCHC17 expression are associated with poor prognosis and increased risk of recurrence and metastasis.\nIn summary, the role of ZCCHC17 in HCC appears to be as an oncogene that promotes the growth and progression of cancer cells, leading to poor prognosis and low survival rates.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a gene that is relevant to hepatocellular carcinoma (HCC).\n2. Hepatocellular carcinoma (HCC) has a poor prognosis and low five-year survival rate.\n3. ZCCHC17 is identified as a potential oncogene in HCC.\n4. ZCCHC17 is overexpressed in many types of cancer, including HCC.\n5. High levels of ZCCHC17 expression are associated with poor prognosis and increased risk of recurrence and metastasis in HCC.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a gene that is relevant to hepatocellular carcinoma (HCC).",
      "Hepatocellular carcinoma (HCC) has a poor prognosis and low five-year survival rate.",
      "ZCCHC17 is identified as a potential oncogene in HCC.",
      "ZCCHC17 is overexpressed in many types of cancer, including HCC.",
      "High levels of ZCCHC17 expression are associated with poor prognosis and increased risk of recurrence and metastasis in HCC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that while these statements are generally consistent with scientific understanding, the specifics can vary based on the latest research. The statements provided do not contain enough detail to determine if there are any nuances or exceptions, so they are taken at face value as being true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the proteins that form the nuclear pore basket in human cells are:\n1. TNPO1 (Transthyretin-related protein 1) - Document 0 states that TNPO1 is preferentially involved in the transport of proteins related to nuclear division and tRNA ligases.\n2. HMG proteins (High-mobility group proteins) - Document 0 mentions that proteins related to DNA repair are also preferentially transported by TNPO1.\nTherefore, the nuclear pore basket in human cells is composed of TNPO1 and HMG proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. TNPO1 (Transthyretin-related protein 1) is involved in the transport of proteins related to nuclear division and tRNA ligases in human cells.\n2. HMG proteins (High-mobility group proteins) are related to DNA repair in human cells.\n3. The nuclear pore basket in human cells is composed of TNPO1 and HMG proteins.",
    "llama-2-7b-chat-hf_fact": [
      "TNPO1 (Transthyretin-related protein 1) is involved in the transport of proteins related to nuclear division and tRNA ligases in human cells.",
      "HMG proteins (High-mobility group proteins) are related to DNA repair in human cells.",
      "The nuclear pore basket in human cells is composed of TNPO1 and HMG proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TNPO1 (Transportin 1) is involved in the nuclear import of proteins with a specific nuclear localization signal, not specifically related to nuclear division and tRNA ligases.\n2. TRUE: HMG proteins (High-mobility group proteins) are indeed involved in several cellular processes, including DNA repair.\n3. FALSE [correction]: The nuclear pore basket is composed of proteins known as nucleoporins, not TNPO1 and HMG proteins.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, gepotidacin is a topoisomerase inhibitor. Specifically, it is a triazaacenaphthylene antibiotic, which is a type of topoisomerase inhibitor that is distinct from fluoroquinolones. Topoisomerase inhibitors are a class of antibiotics that work by interfering with the ability of bacteria to divide and replicate, ultimately leading to cell death. Gepotidacin's unique mechanism of action is not anticipated to have the same risks to bone growth as those of fluoroquinolones, which is a class of antibiotics that have been associated with adverse effects on bone development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. It is classified as a triazaacenaphthylene antibiotic.\n3. Gepotidacin has a mechanism of action distinct from fluoroquinolones.\n4. Topoisomerase inhibitors interfere with the ability of bacteria to divide and replicate.\n5. Fluoroquinolones, a different class of antibiotics, have been associated with adverse effects on bone development.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "It is classified as a triazaacenaphthylene antibiotic.",
      "Gepotidacin has a mechanism of action distinct from fluoroquinolones.",
      "Topoisomerase inhibitors interfere with the ability of bacteria to divide and replicate.",
      "Fluoroquinolones, a different class of antibiotics, have been associated with adverse effects on bone development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a software tool developed by Illumina for variant identification and filtering. It is designed to support a variety of family structures and provides a range of scoring and filtering options to automate and streamline the process of identifying de novo variants.\nCanvas SPW is available for download from GitHub, and users can contact the developers at sivakhno@illumina.com for more information or assistance with implementation.\nSome of the key features of Canvas SPW include:\n* Support for a variety of family structures, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations.\n* A wide range of scoring and filtering options to automate and streamline the variant identification process.\n* Integration with other Illumina software tools, such as BaseSpace, for seamless analysis and interpretation of genomic data.\n* Ability to handle large datasets and perform high-throughput analysis.\nOverall, Canvas SPW is a powerful tool for identifying and filtering de novo variants in genomic data, and it can be a valuable resource for researchers and clinicians working in the field of genomics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a software tool developed by Illumina for variant identification and filtering.\n2. Canvas SPW supports a variety of family structures, including SNPs, insertions, deletions, and copy number variations.\n3. The software offers a range of scoring and filtering options to automate the variant identification process.\n4. Canvas SPW is integrated with other Illumina software tools, such as BaseSpace.\n5. Canvas SPW is capable of handling large datasets and performing high-throughput analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a software tool developed by Illumina for variant identification and filtering.",
      "Canvas SPW supports a variety of family structures, including SNPs, insertions, deletions, and copy number variations.",
      "The software offers a range of scoring and filtering options to automate the variant identification process.",
      "Canvas SPW is integrated with other Illumina software tools, such as BaseSpace.",
      "Canvas SPW is capable of handling large datasets and performing high-throughput analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Canvas SPW supports a variety of variant types, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, but \"family structures\" is not the correct term for these variant types.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with a list of STING agonists based on the information provided in Document 0:\n1. STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response. STING agonists are molecules that activate STING, leading to the activation of interferon signaling pathways.\n2. Here are some examples of STING agonists:\na. Poly (I:C): Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING and leads to the production of interferons.\nb. Streptolysin O (SLO): SLO is a bacterial toxin that activates STING and induces the production of interferons.\nc. R848: R848 is a synthetic agonist of STING that has been shown to activate STING and induce the production of interferons in various cell types.\nd. IMQ: IMQ is a synthetic agonist of STING that has been shown to activate STING and induce the production of interferons in various cell types.\ne. Resiquimod (R837): Resiquimod is a synthetic agonist of STING that has been shown to activate STING and induce the production of interferons in various cell types.\nf. Toll-like receptor (TLR) agonists: TLR agonists, such as lipopolysaccharide (LPS) and flagellin, can also activate STING and induce the production of interferons.\ng. CpG oligonucleotides: CpG oligonucleotides are synthetic DNA molecules that contain the CpG motif, which is a common feature of bacterial DNA. CpG oligonucleotides can activate STING and induce the production of interferons.\nh. Anti-cancer drugs: Some anti-cancer drugs, such as cyclophosphamide and fludarabine, have been shown to activate STING and induce the production of interferons",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING.\n2. Streptolysin O (SLO) is a bacterial toxin that activates STING.\n3. R848 is a synthetic agonist of STING that induces the production of interferons in various cell types.\n4. Resiquimod (R837) is a synthetic agonist of STING that induces the production of interferons in various cell types.\n5. CpG oligonucleotides are synthetic DNA molecules that can activate STING.",
    "llama-2-7b-chat-hf_fact": [
      "Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING.",
      "Streptolysin O (SLO) is a bacterial toxin that activates STING.",
      "R848 is a synthetic agonist of STING that induces the production of interferons in various cell types.",
      "Resiquimod (R837) is a synthetic agonist of STING that induces the production of interferons in various cell types.",
      "CpG oligonucleotides are synthetic DNA molecules that can activate STING."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates TLR3 and MDA5, not STING.\n2. FALSE [correction]: Streptolysin O (SLO) is a bacterial toxin that can permeabilize membranes but is not known to directly activate STING.\n3. FALSE [correction]: R848 is a synthetic agonist of TLR7 and TLR8, not STING, and it induces the production of interferons in various cell types.\n4. FALSE [correction]: Resiquimod (R837) is a synthetic agonist of TLR7, not STING, and it induces the production of interferons in various cell types.\n5. FALSE [correction]: CpG oligonucleotides are synthetic DNA molecules that activate TLR9, not STING.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Single-molecule Localization with Improved CAGE) is a method used to generate a genome-wide promoterome (a comprehensive map of gene expression) using significantly less material than traditional CAGE (Cap Analysis of Gene Expression) methods.\nIn traditional CAGE, the process of isolating and sequencing RNA molecules from individual cells requires a large amount of material, typically on the order of millions of cells. This can be a challenge, particularly when working with rare or precious samples, such as those from embryonic tissues.\nSLIC-CAGE addresses this challenge by using a combination of single-molecule localization and CAGE techniques. By using a complex, high-quality library generated from mouse embryonic day 11.5 primordial germ cells, SLIC-CAGE is able to generate a genome-wide promoterome with 1000-fold less material than required by existing CAGE methods.\nIn essence, SLIC-CAGE is a more efficient and cost-effective way to map gene expression at the single-cell level, allowing researchers to study the regulation of gene expression in a wider range of samples and under a greater variety of conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a method used to generate a genome-wide promoterome.\n2. SLIC-CAGE requires significantly less material than traditional CAGE methods.\n3. Traditional CAGE typically requires material from millions of cells.\n4. SLIC-CAGE combines single-molecule localization with CAGE techniques.\n5. SLIC-CAGE can generate a genome-wide promoterome with 1000-fold less material than traditional CAGE methods.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a method used to generate a genome-wide promoterome.",
      "SLIC-CAGE requires significantly less material than traditional CAGE methods.",
      "Traditional CAGE typically requires material from millions of cells.",
      "SLIC-CAGE combines single-molecule localization with CAGE techniques.",
      "SLIC-CAGE can generate a genome-wide promoterome with 1000-fold less material than traditional CAGE methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: SLIC-CAGE combines single-cell analysis with CAGE techniques, not single-molecule localization.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, LEM-3 appears to play a role in the processing and resolution of chromatin bridges. Chromatin bridges are structures that form when chromosomes fail to separate properly during cell division, leading to the attachment of one chromosome to another. LEM-3 is involved in the local processing of these bridges, which is necessary for proper chromosome segregation and the prevention of genetic abnormalities.\nSpecifically, LEM-3 is involved in the proper formation and maintenance of the midbody, which is a structure that forms during cell division and plays a crucial role in the separation of chromosomes. LEM-3 helps to ensure that the midbody is properly formed and that chromosomes are properly separated during cell division, which is essential for maintaining the integrity of the genetic material.\nIn addition to its role in chromatin bridge processing and midbody formation, LEM-3 has also been implicated in the regulation of other cellular processes, including the cell cycle and the maintenance of genome stability.\nIn summary, the roles of LEM-3 include:\n1. Processing of chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure.\n2. Proper formation and maintenance of the midbody during cell division.\n3. Regulation of other cellular processes, including the cell cycle and the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 plays a role in the processing and resolution of chromatin bridges during cell division.\n2. Chromatin bridges form when chromosomes fail to separate properly, leading to the attachment of one chromosome to another.\n3. LEM-3 is involved in the proper formation and maintenance of the midbody, a structure crucial for chromosome separation during cell division.\n4. LEM-3 helps ensure proper chromosome segregation and prevents genetic abnormalities.\n5. LEM-3 has been implicated in the regulation of the cell cycle and the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 plays a role in the processing and resolution of chromatin bridges during cell division.",
      "Chromatin bridges form when chromosomes fail to separate properly, leading to the attachment of one chromosome to another.",
      "LEM-3 is involved in the proper formation and maintenance of the midbody, a structure crucial for chromosome separation during cell division.",
      "LEM-3 helps ensure proper chromosome segregation and prevents genetic abnormalities.",
      "LEM-3 has been implicated in the regulation of the cell cycle and the maintenance of genome stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the releases of tmVar are:\n1. tmVar 3.0 - as mentioned in the question, this release provides advanced variant normalization options such as allele-specific identifiers from the ClinGen Allele Registry, and exhibits state-of-the-art performance with over 90% in F-measure for variant recognition and normalization, when evaluated on three independent benchmarking datasets.\nTherefore, the answer to the user's question is:\ntmVar 3.0",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, the database of somatic mutations in normal cells is likely to be Document 0: DSMNC. As you mentioned, DSMNC serves as a timely and valuable collection of somatic mutations in individual normal cells, which allows for the analysis of the burdens and signatures of somatic mutations in various types of heterogeneous normal cells. This information is likely to be useful for understanding the genetic changes that occur in normal cells and how they may contribute to disease. Is there anything else I can help with?",
    "llama-2-7b-chat-hf_fact_raw": "1. DSMNC is a database of somatic mutations in normal cells.\n2. DSMNC allows for the analysis of the burdens and signatures of somatic mutations in various types of heterogeneous normal cells.\n3. The information in DSMNC is useful for understanding the genetic changes that occur in normal cells.\n4. DSMNC can contribute to the understanding of how genetic changes in normal cells may contribute to disease.",
    "llama-2-7b-chat-hf_fact": [
      "DSMNC is a database of somatic mutations in normal cells.",
      "DSMNC allows for the analysis of the burdens and signatures of somatic mutations in various types of heterogeneous normal cells.",
      "The information in DSMNC is useful for understanding the genetic changes that occur in normal cells.",
      "DSMNC can contribute to the understanding of how genetic changes in normal cells may contribute to disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are a few options:\n1. JGraphT: JGraphT is a Java implementation of the igraph library, which is a popular graph kernel library. JGraphT provides a Java interface to the igraph library, allowing users to use the graph kernel functions in their Java programs.\n2. GraphKernel: GraphKernel is a Java library for graph kernel computation. It provides a simple and efficient way to compute graph kernels using various algorithms, including spectral, spectral-based, and machine learning-based methods.\n3. Java Graph Kernel Library (JGKL): JGKL is a Java library for graph kernel computation and analysis. It provides a comprehensive set of graph kernel functions, including spectral, spectral-based, and machine learning-based methods, as well as tools for graph visualization and analysis.\n4. GraphKernelMatrix: GraphKernelMatrix is a Java library for computing graph kernels using the matrix kernel method. It provides a simple and efficient way to compute graph kernels using the matrix kernel method, which is based on the eigendecomposition of the graph Laplacian matrix.\nAll of these libraries are available on GitHub, and they can be easily integrated into Java programs using the appropriate dependencies.\nTo use any of these libraries, you will need to include the relevant header files in your program, as mentioned in the information provided. For example, to use JGraphT, you will need to include the \"jgrapht.h\" header file. To use GraphKernel, you will need to include the \"graphkernel.h\" header file.\nOnce you have included the header file, you can use the library functions to compute the graph kernel matrix. For example, to compute the graph kernel matrix using JGraphT, you can use the \"jgrapht.GraphKernel\" class, which provides a simple and efficient way to compute the graph kernel matrix.\nHere is an example of how to use JGraphT to compute the graph kernel matrix:\n```\nimport jgrapht.Graph;\nimport jgrapht.GraphKernel;\n// Create a graph object\nGraph g = new Graph();\n// Add vertices and edges to the graph\ng.addVertex(0);\ng.addVertex(1);\ng.addEdge(0,",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java implementation of the igraph library.\n2. GraphKernel is a Java library for graph kernel computation that includes various algorithms.\n3. Java Graph Kernel Library (JGKL) provides a set of graph kernel functions and tools for graph visualization and analysis.\n4. GraphKernelMatrix is a Java library that computes graph kernels using the matrix kernel method based on the eigendecomposition of the graph Laplacian matrix.\n5. All the mentioned libraries (JGraphT, GraphKernel, JGKL, GraphKernelMatrix) are available on GitHub.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java implementation of the igraph library.",
      "GraphKernel is a Java library for graph kernel computation that includes various algorithms.",
      "Java Graph Kernel Library (JGKL) provides a set of graph kernel functions and tools for graph visualization and analysis.",
      "GraphKernelMatrix is a Java library that computes graph kernels using the matrix kernel method based on the eigendecomposition of the graph Laplacian matrix.",
      "All the mentioned libraries (JGraphT, GraphKernel, JGKL, GraphKernelMatrix) are available on GitHub."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JGraphT is a Java library that provides a mathematical graph-theory objects and algorithms, but it is not an implementation of the igraph library, which is primarily written in C.\n2. TRUE\n3. UNKNOWN: Without more specific information about a library named \"Java Graph Kernel Library (JGKL),\" it is not possible to confirm the accuracy of this statement. There is no widely recognized library by this name as of my knowledge cutoff date.\n4. UNKNOWN: Similar to statement 3, without more specific information about a library named \"GraphKernelMatrix,\" it is not possible to confirm the accuracy of this statement. There is no widely recognized library by this name as of my knowledge cutoff date.\n5. UNKNOWN: While JGraphT is available on GitHub, without specific information about the other libraries mentioned (GraphKernel, JGKL, GraphKernelMatrix), it is not possible to confirm whether all of them are available on GitHub.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the four advances integrated into the SHERLOCKv2 platform are:\n1. The use of the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.\n2. The development of a detection platform called SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) for rapid and portable sensing of nucleic acids.\n3. The integration of multiplexing capabilities into the SHERLOCKv2 platform, allowing for the detection of multiple targets in a single reaction.\n4. The use of a novel reporter system that provides a high sensitivity and specificity for detecting nucleic acid targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform uses the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.\n2. The SHERLOCKv2 platform includes a detection platform called SHERLOCK for rapid and portable sensing of nucleic acids.\n3. The SHERLOCKv2 platform has integrated multiplexing capabilities, allowing for the detection of multiple targets in a single reaction.\n4. The SHERLOCKv2 platform utilizes a novel reporter system to achieve high sensitivity and specificity for detecting nucleic acid targets.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform uses the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection.",
      "The SHERLOCKv2 platform includes a detection platform called SHERLOCK for rapid and portable sensing of nucleic acids.",
      "The SHERLOCKv2 platform has integrated multiplexing capabilities, allowing for the detection of multiple targets in a single reaction.",
      "The SHERLOCKv2 platform utilizes a novel reporter system to achieve high sensitivity and specificity for detecting nucleic acid targets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe SHERLOCKv2 platform indeed uses the RNA-targeting CRISPR-associated enzyme Cas13 for nucleic acid detection, includes a detection platform called SHERLOCK for rapid and portable sensing of nucleic acids, has integrated multiplexing capabilities allowing for the detection of multiple targets in a single reaction, and utilizes a novel reporter system to achieve high sensitivity and specificity for detecting nucleic acid targets.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a clustering algorithm specifically designed for counting high-complexity deeply sequenced barcode reads. According to Document 0, Bartender is the most accurate clustering algorithm in this regard, with a comparable speed to other existing algorithms.\nThe key innovation of the Bartender algorithm is a new statistical test schema that uses both nucleotide sequence and cluster size information to prevent over-clustering and improve accuracy. This allows Bartender to identify and separate closely related sequences with high accuracy, even in the presence of high levels of noise or complexity in the data.\nIn summary, the Bartender algorithm is a powerful tool for clustering and analyzing deeply sequenced barcode reads, offering a balance of accuracy and speed that makes it a valuable resource for researchers in the field.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is designed for counting high-complexity deeply sequenced barcode reads.\n2. Bartender is considered the most accurate clustering algorithm for this purpose, according to Document 0.\n3. The Bartender algorithm has a comparable speed to other existing clustering algorithms.\n4. The Bartender algorithm uses a new statistical test schema that incorporates nucleotide sequence and cluster size information.\n5. The Bartender algorithm is capable of separating closely related sequences with high accuracy.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is designed for counting high-complexity deeply sequenced barcode reads.",
      "Bartender is considered the most accurate clustering algorithm for this purpose, according to Document 0.",
      "The Bartender algorithm has a comparable speed to other existing clustering algorithms.",
      "The Bartender algorithm uses a new statistical test schema that incorporates nucleotide sequence and cluster size information.",
      "The Bartender algorithm is capable of separating closely related sequences with high accuracy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (The accuracy of the Bartender algorithm being the most accurate according to \"Document 0\" cannot be verified without access to the specific document.)\n3. UNKNOWN (Without specific comparative speed data or a reference, it's not possible to confirm the speed of the Bartender algorithm relative to other clustering algorithms.)\n4. TRUE (The statement is consistent with the description of an algorithm that would incorporate multiple types of data for clustering, which is plausible for a complex algorithm like Bartender.)\n5. TRUE (This statement aligns with the purpose of a high-complexity barcode reading algorithm, which would need to differentiate closely related sequences accurately.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several web-based pedigree editors available, including:\n1. Pedigreejs: As you mentioned, Pedigreejs is an open-source, lightweight, and easily configurable pedigree editor that uses an open-source Javascript library to define a hierarchical layout and produce images in SVG format.\n2. Pedigree.js: Another web-based pedigree editor that uses JavaScript to create interactive and customizable family trees. It offers features such as drag-and-drop functionality, customizable layouts, and integration with popular genealogy databases.\n3. Family Tree Builder: This is a web-based tool that allows users to create and share their family trees online. It offers a user-friendly interface and a range of features, including the ability to add photos, stories, and sources to each person in the tree.\n4. GenoPro: This is a comprehensive genealogy software that includes a web-based pedigree editor. It offers a range of features, including the ability to create detailed family trees, add sources and photos, and collaborate with other researchers.\n5. Legacy Family Tree: This is a popular genealogy software that includes a web-based pedigree editor. It offers a range of features, including the ability to create detailed family trees, add sources and photos, and collaborate with other researchers.\nThese are just a few examples of the many web-based pedigree editors available. Each one has its own unique features and capabilities, so it's worth exploring each option to determine which one best meets your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigreejs is an open-source, lightweight, and easily configurable pedigree editor.\n2. Pedigree.js is a web-based pedigree editor that uses JavaScript to create interactive and customizable family trees.\n3. Family Tree Builder is a web-based tool that allows users to create and share their family trees online.\n4. GenoPro includes a web-based pedigree editor and offers features for creating detailed family trees and adding sources and photos.\n5. Legacy Family Tree is a genealogy software that includes a web-based pedigree editor with features for creating detailed family trees and collaboration.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigreejs is an open-source, lightweight, and easily configurable pedigree editor.",
      "Pedigree.js is a web-based pedigree editor that uses JavaScript to create interactive and customizable family trees.",
      "Family Tree Builder is a web-based tool that allows users to create and share their family trees online.",
      "GenoPro includes a web-based pedigree editor and offers features for creating detailed family trees and adding sources and photos.",
      "Legacy Family Tree is a genealogy software that includes a web-based pedigree editor with features for creating detailed family trees and collaboration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GenoPro is not primarily web-based; it is a genealogy software that requires installation on a user's computer and offers features for creating detailed family trees and adding sources and photos.\n5. FALSE [correction]: Legacy Family Tree is a genealogy software that requires installation on a user's computer, not a web-based pedigree editor, and it includes features for creating detailed family trees and collaboration.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Based on the information provided, there are several curated databases that contain information on spider-venom toxins. Here are a few examples:\n1. ArachnoServer (www.arachnoserver.org): As you mentioned, this is a manually curated database that provides information on the sequence, structure, and biological activity of protein toxins from spider venoms. It is a comprehensive resource that covers a wide range of spider species and includes information on the toxins' properties, functions, and potential applications.\n2. SpiderBase (www.spiderbase.org): This is a curated database that contains information on the venomous spiders of the world, including their taxonomy, distribution, and venom composition. It also includes data on the toxins' structure, function, and potential uses in medicine and other fields.\n3. VenomDB (www.venomdb.org): This is a comprehensive database that contains information on the venomous animals of the world, including spiders, snakes, scorpions, and insects. It includes data on the toxins' structure, function, and potential uses in medicine and other fields, as well as information on the animals' taxonomy, distribution, and evolutionary history.\n4. ToxinDB (www.toxindb.org): This is a database that contains information on the toxins found in various organisms, including spiders. It includes data on the toxins' structure, function, and potential uses in medicine and other fields, as well as information on the organisms' taxonomy, distribution, and evolutionary history.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ArachnoServer is a manually curated database that provides information on protein toxins from spider venoms.\n2. SpiderBase is a curated database that contains information on venomous spiders, including their taxonomy, distribution, and venom composition.\n3. VenomDB is a comprehensive database that includes information on venomous animals such as spiders, snakes, scorpions, and insects.\n4. ToxinDB is a database that contains information on toxins found in various organisms, including spiders.",
    "llama-2-7b-chat-hf_fact": [
      "ArachnoServer is a manually curated database that provides information on protein toxins from spider venoms.",
      "SpiderBase is a curated database that contains information on venomous spiders, including their taxonomy, distribution, and venom composition.",
      "VenomDB is a comprehensive database that includes information on venomous animals such as spiders, snakes, scorpions, and insects.",
      "ToxinDB is a database that contains information on toxins found in various organisms, including spiders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SpiderBase is not a known curated database for venomous spiders. However, there is a database called ArachnoServer that provides information on spider toxins, and the World Spider Catalog, which is a comprehensive database of spider taxonomy and distribution.\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited evidence to suggest that Axitinib prolongs survival in patients with pancreatic cancer, specifically those with localized pancreatic ductal adenocarcinoma (PDAC).\nDocument 0 mentions that patients with localized PDAC are best treated with surgical resection of the primary tumor and systemic chemotherapy, which provides considerably longer overall survival compared to chemotherapy alone. However, there is no mention of Axitinib as a treatment option for PDAC patients.\nAxitinib is a tyrosine kinase inhibitor that has been approved for the treatment of advanced renal cell carcinoma. While there have been some studies investigating the use of Axitinib in various types of cancer, including pancreatic cancer, the evidence is limited and inconclusive.\nA systematic review and meta-analysis published in 2020 found that Axitinib had a modest effect on overall survival in patients with advanced pancreatic cancer, but the quality of the evidence was low due to the small number of studies included and the variability in patient populations. Another study published in 2019 found that Axitinib was associated with improved progression-free survival in patients with metastatic pancreatic cancer, but the study was small and had limited follow-up.\nIn summary, while there is some evidence to suggest that Axitinib may have a modest effect on overall survival in patients with advanced pancreatic cancer, the evidence is limited and inconclusive. Further research is needed to determine the efficacy and safety of Axitinib in this patient population.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma.\n2. Patients with localized pancreatic ductal adenocarcinoma (PDAC) are typically treated with surgical resection of the primary tumor and systemic chemotherapy.\n3. A systematic review and meta-analysis published in 2020 found that Axitinib had a modest effect on overall survival in patients with advanced pancreatic cancer.\n4. A study published in 2019 associated Axitinib with improved progression-free survival in patients with metastatic pancreatic cancer.\n5. The quality of evidence for Axitinib's effect on overall survival in advanced pancreatic cancer patients was considered low due to the small number of studies and variability in patient populations.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma.",
      "Patients with localized pancreatic ductal adenocarcinoma (PDAC) are typically treated with surgical resection of the primary tumor and systemic chemotherapy.",
      "A systematic review and meta-analysis published in 2020 found that Axitinib had a modest effect on overall survival in patients with advanced pancreatic cancer.",
      "A study published in 2019 associated Axitinib with improved progression-free survival in patients with metastatic pancreatic cancer.",
      "The quality of evidence for Axitinib's effect on overall survival in advanced pancreatic cancer patients was considered low due to the small number of studies and variability in patient populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: A systematic review and meta-analysis published in 2020 found that Axitinib had a modest effect on overall survival in patients with advanced renal cell carcinoma, not pancreatic cancer.\n4. FALSE [correction]: Without specific details of the study, it is not possible to confirm the accuracy of this statement. Axitinib is primarily used for renal cell carcinoma, and there is no widely recognized evidence of its efficacy in metastatic pancreatic cancer as of my knowledge cutoff date.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through protein interaction with the actin-binding protein, Myosin. Myosin is a key regulator of actin dynamics, and MLP's interaction with Myosin helps to regulate the production of forces in cells by controlling the phosphorylation state of Myosin. Specifically, MLP dephosphorylates Myosin, which leads to the activation of Myosin and the generation of forces in cells. Therefore, MLP regulates F-actin dynamics through its interaction with Myosin.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through interaction with the actin-binding protein, Myosin.\n2. Myosin is a key regulator of actin dynamics.\n3. MLP's interaction with Myosin helps to regulate the production of forces in cells.\n4. MLP dephosphorylates Myosin, leading to the activation of Myosin.\n5. The activation of Myosin by MLP contributes to the generation of forces in cells.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through interaction with the actin-binding protein, Myosin.",
      "Myosin is a key regulator of actin dynamics.",
      "MLP's interaction with Myosin helps to regulate the production of forces in cells.",
      "MLP dephosphorylates Myosin, leading to the activation of Myosin.",
      "The activation of Myosin by MLP contributes to the generation of forces in cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP (Myosin Light Chain Phosphatase) does not regulate F-actin dynamics through interaction with the actin-binding protein, Myosin. Instead, MLP dephosphorylates myosin light chains, which affects myosin's interaction with actin.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MLP dephosphorylates Myosin, leading to the inactivation of Myosin. Dephosphorylation typically reduces myosin's ability to interact with actin, thus decreasing contractility.\n5. FALSE [correction]: The dephosphorylation of Myosin by MLP actually leads to a decrease in myosin's activity, which can relax muscles and decrease the generation of forces in cells.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are approximately 518 protein kinases in the human kinome. Of these, 478 contain a eukaryotic protein kinase (ePK) domain, while the remaining 40 lack sequence similarity to the ePK domain. Therefore, there are approximately 478 protein kinases in the human kinome that contain the ePK domain.\nIt is worth noting that the term \"pseudokinase\" is not used in the document, and the term \"lipid kinase\" is used to refer to proteins that phosphorylate lipids. Therefore, the answer to the user's question is 478.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 518 protein kinases in the human kinome.\n2. Out of these, 478 protein kinases contain a eukaryotic protein kinase (ePK) domain.\n3. The remaining 40 protein kinases lack sequence similarity to the ePK domain.\n4. The term \"pseudokinase\" is not used in the provided document.\n5. The term \"lipid kinase\" refers to proteins that phosphorylate lipids according to the document.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 518 protein kinases in the human kinome.",
      "Out of these, 478 protein kinases contain a eukaryotic protein kinase (ePK) domain.",
      "The remaining 40 protein kinases lack sequence similarity to the ePK domain.",
      "The term \"pseudokinase\" is not used in the provided document.",
      "The term \"lipid kinase\" refers to proteins that phosphorylate lipids according to the document."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Certainly! Based on the information provided in Document 0, here are three apoE mimetics:\n1. ApoE-mimetic peptide PF-04492324: This peptide is a synthetic mimic of the apoE protein and has been shown to have cholesterol-lowering effects in preclinical studies. It is being developed as a potential treatment for high cholesterol and cardiovascular disease.\n2. ApoE-mimetic peptide AZD7207: This peptide is a small molecule mimic of apoE that has been shown to have anti-inflammatory and cholesterol-lowering effects in preclinical studies. It is being developed as a potential treatment for atherosclerosis and other cardiovascular diseases.\n3. ApoE-mimetic peptide GW3965: This peptide is a synthetic mimic of apoE that has been shown to have cholesterol-lowering effects in preclinical studies. It is being developed as a potential treatment for high cholesterol and cardiovascular disease.\nI hope this information is helpful! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE-mimetic peptide PF-04492324 is being developed as a potential treatment for high cholesterol and cardiovascular disease.\n2. ApoE-mimetic peptide AZD7207 is being developed as a potential treatment for atherosclerosis and other cardiovascular diseases.\n3. ApoE-mimetic peptide GW3965 is being developed as a potential treatment for high cholesterol and cardiovascular disease.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE-mimetic peptide PF-04492324 is being developed as a potential treatment for high cholesterol and cardiovascular disease.",
      "ApoE-mimetic peptide AZD7207 is being developed as a potential treatment for atherosclerosis and other cardiovascular diseases.",
      "ApoE-mimetic peptide GW3965 is being developed as a potential treatment for high cholesterol and cardiovascular disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: GW3965 is not an ApoE-mimetic peptide; it is a liver X receptor (LXR) agonist that has been studied for its potential effects on cholesterol and cardiovascular disease.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are sex differences in SAMHD1 activity, with higher activity observed in macrophages from female donors compared to male donors. Specifically, the study found that SAMHD1 activity was increased in female-derived macrophages, which correlated with and explained the lower infectivity of HIV-1 in these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are sex differences in SAMHD1 activity.\n2. Macrophages from female donors have higher SAMHD1 activity compared to those from male donors.\n3. Increased SAMHD1 activity in female-derived macrophages correlates with lower HIV-1 infectivity in these cells.",
    "llama-2-7b-chat-hf_fact": [
      "There are sex differences in SAMHD1 activity.",
      "Macrophages from female donors have higher SAMHD1 activity compared to those from male donors.",
      "Increased SAMHD1 activity in female-derived macrophages correlates with lower HIV-1 infectivity in these cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the answer to the user's question is:\nRUNX2 does not inhibit astrocyte differentiation. In fact, the document suggests that RUNX2 promotes astrocyte maturation. The transcription factors NFIA and ATF3 are identified as drivers of astrocyte differentiation from neural precursor cells, while RUNX2 is involved in the maturation of astrocytes.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 does not inhibit astrocyte differentiation.\n2. RUNX2 promotes astrocyte maturation.\n3. The transcription factors NFIA and ATF3 drive astrocyte differentiation from neural precursor cells.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 does not inhibit astrocyte differentiation.",
      "RUNX2 promotes astrocyte maturation.",
      "The transcription factors NFIA and ATF3 drive astrocyte differentiation from neural precursor cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nRUNX2, also known as Runt-related transcription factor 2, is known for its role in bone development. However, in the context of neural differentiation, it has been shown that RUNX2 can inhibit the differentiation of neural precursor cells into astrocytes, thus promoting the maturation of non-astrocytic lineages. Therefore, the first statement is true.\n\nThe second statement is also true as RUNX2, by inhibiting astrocyte differentiation, indirectly promotes the maturation of other cell types, which could include maturation within the osteogenic lineage, given RUNX2's role in bone development.\n\nThe third statement is true as well. NFIA (Nuclear Factor I/A) and ATF3 (Activating Transcription Factor 3) are transcription factors that have been implicated in the regulation of astrocyte differentiation from neural precursor cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Cobb-Stainsby excision arthroplasty would typically be performed in the foot, specifically in the metatarsophalangeal joint. This is because the procedure combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb), which suggests that the procedure is focused on the metatarsophalangeal joint.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed in the foot.\n2. The procedure is focused on the metatarsophalangeal joint.\n3. The Cobb-Stainsby excision arthroplasty combines partial phalangectomy with extensor tendon transfer to the metatarsal head.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed in the foot.",
      "The procedure is focused on the metatarsophalangeal joint.",
      "The Cobb-Stainsby excision arthroplasty combines partial phalangectomy with extensor tendon transfer to the metatarsal head."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed in the hip, not the foot.\n2. FALSE [correction]: Since the procedure is not performed in the foot, it is not focused on the metatarsophalangeal joint.\n3. FALSE [correction]: The Cobb-Stainsby excision arthroplasty involves the removal of the femoral head and neck, as well as the interposition of soft tissue, in the hip joint. It does not combine partial phalangectomy with extensor tendon transfer to the metatarsal head, as this description pertains to a different type of surgery.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT), which is a process that involves the loss of epithelial characteristics and the acquisition of mesenchymal properties.\nThe document states that GRHL2 is a transcription factor that plays a crucial role in the regulation of epithelial genes during EMT/MET. EMT/MET is a process that involves the transformation of epithelial cells into mesenchymal cells, which are characterized by increased mobility, invasiveness, and the ability to differentiate into various cell types.\nThe document also suggests that GRHL2 over-expression can lead to the repression of epithelial genes and the activation of mesenchymal genes, which is consistent with the idea that GRHL2 promotes EMT.\nTherefore, based on the information provided in Document 0, it can be concluded that GRHL2 over-expression can lead to EMT.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT).\n2. GRHL2 is a transcription factor involved in the regulation of epithelial genes during EMT/MET.\n3. EMT/MET involves the transformation of epithelial cells into mesenchymal cells.\n4. Mesenchymal cells are characterized by increased mobility, invasiveness, and the ability to differentiate into various cell types.\n5. GRHL2 over-expression can result in the repression of epithelial genes and the activation of mesenchymal genes.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT).",
      "GRHL2 is a transcription factor involved in the regulation of epithelial genes during EMT/MET.",
      "EMT/MET involves the transformation of epithelial cells into mesenchymal cells.",
      "Mesenchymal cells are characterized by increased mobility, invasiveness, and the ability to differentiate into various cell types.",
      "GRHL2 over-expression can result in the repression of epithelial genes and the activation of mesenchymal genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nExplanation:\n1. GRHL2 (Grainyhead-like 2) is known to play a role in epithelial-to-mesenchymal transition (EMT), a process where epithelial cells lose their characteristics and gain mesenchymal properties.\n2. GRHL2 is indeed a transcription factor that is involved in the regulation of epithelial genes during the processes of EMT and the reverse process, mesenchymal-to-epithelial transition (MET).\n3. EMT/MET involves the transformation of epithelial cells, which are usually polarized and form tight junctions, into mesenchymal cells, which are more migratory and can invade tissues.\n4. Mesenchymal cells are indeed characterized by increased mobility, invasiveness, and the ability to differentiate into a variety of cell types, which is a hallmark of the EMT process.\n5. Over-expression of GRHL2 can lead to the repression of mesenchymal genes and the activation of epithelial genes, which is consistent with its role in maintaining epithelial characteristics and inhibiting EMT.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following T-UCRs have been implicated in lung cancer:\n1. uc.339 - identified as an oncogene in lung cancer by the authors.\nThe authors of Document 0 provide evidence that uc.339 is overexpressed in lung cancer tissues and promotes the proliferation and migration of lung cancer cells. They also suggest that uc.339 may play a role in the development and progression of lung cancer.\nIt is important to note that this information is based on the authors' findings and has not been extensively replicated or validated in other studies. Further research is needed to confirm the role of uc.339 in lung cancer and to better understand its underlying mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCR uc.339 has been implicated in lung cancer.\n2. uc.339 is identified as an oncogene in lung cancer by the authors of Document 0.\n3. uc.339 is overexpressed in lung cancer tissues according to the authors of Document 0.\n4. uc.339 promotes the proliferation and migration of lung cancer cells as per the findings in Document 0.\n5. The role of uc.339 in lung cancer has not been extensively replicated or validated in other studies.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCR uc.339 has been implicated in lung cancer.",
      "uc.339 is identified as an oncogene in lung cancer by the authors of Document 0.",
      "uc.339 is overexpressed in lung cancer tissues according to the authors of Document 0.",
      "uc.339 promotes the proliferation and migration of lung cancer cells as per the findings in Document 0.",
      "The role of uc.339 in lung cancer has not been extensively replicated or validated in other studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific content of \"Document 0\" or additional information on T-UCR uc.339, it is not possible to verify the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, here is what is known about the orphan receptor GPR151:\nGPR151, also known as the free fatty acid receptor 2 (FFA2), is an orphan G protein-coupled receptor that is primarily expressed in the habenula, a small brain region involved in aversion and emotion regulation. Unlike the well-studied mu opioid receptor (MOR), which is activated by endogenous opioid peptides, GPR151 is activated by free fatty acids, such as arachidonic acid and eicosatetraenoic acid.\nStudies have shown that GPR151 is involved in the regulation of a variety of physiological processes, including pain modulation, mood regulation, and cognitive function. For example, activation of GPR151 has been shown to produce analgesic effects in animal models of pain, while inhibition of GPR151 has been linked to depression-like behavior.\nGPR151 has also been implicated in the development and progression of certain neurological disorders, including epilepsy and Parkinson's disease. For example, studies have shown that GPR151 is upregulated in the brains of individuals with epilepsy, and that inhibition of GPR151 can reduce seizure frequency.\nOverall, while GPR151 is an orphan receptor in the sense that it does not have a well-defined endogenous ligand, it is an important regulator of a variety of physiological processes and has potential as a therapeutic target for a range of neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is also known as the free fatty acid receptor 2 (FFA2).\n2. GPR151 is primarily expressed in the habenula, a brain region involved in aversion and emotion regulation.\n3. GPR151 is activated by free fatty acids, such as arachidonic acid and eicosatetraenoic acid.\n4. Activation of GPR151 has been shown to produce analgesic effects in animal models of pain.\n5. GPR151 has been implicated in the development and progression of neurological disorders, including epilepsy and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is also known as the free fatty acid receptor 2 (FFA2).",
      "GPR151 is primarily expressed in the habenula, a brain region involved in aversion and emotion regulation.",
      "GPR151 is activated by free fatty acids, such as arachidonic acid and eicosatetraenoic acid.",
      "Activation of GPR151 has been shown to produce analgesic effects in animal models of pain.",
      "GPR151 has been implicated in the development and progression of neurological disorders, including epilepsy and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GPR151 is not known as the free fatty acid receptor 2 (FFA2). FFA2 is another G protein-coupled receptor also known as GPR43.\n2. TRUE\n3. FALSE [correction]: GPR151 is not activated by free fatty acids. It is an orphan receptor, which means its endogenous ligand is not clearly established.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n* Influenza A subtype viruses:\n\t+ H1N1\n\t+ H3N2\n* Type B viruses:\n\t+ B/Victoria\n\t+ B/Yamagata\nTherefore, the Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of both influenza A and B types.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.\n2. Influenza A H1N1 is one of the attenuated live viruses in the Fluzone intradermal quadrivalent vaccine.\n3. Influenza A H3N2 is included as an attenuated live virus in the Fluzone intradermal quadrivalent vaccine.\n4. The vaccine contains the B/Victoria type B attenuated live virus.\n5. The B/Yamagata type B virus is also contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.",
      "Influenza A H1N1 is one of the attenuated live viruses in the Fluzone intradermal quadrivalent vaccine.",
      "Influenza A H3N2 is included as an attenuated live virus in the Fluzone intradermal quadrivalent vaccine.",
      "The vaccine contains the B/Victoria type B attenuated live virus.",
      "The B/Yamagata type B virus is also contained in the Fluzone intradermal quadrivalent vaccine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not attenuated live viruses.\n2. FALSE [correction]: Since the Fluzone intradermal quadrivalent vaccine contains inactivated viruses, Influenza A H1N1 is included but not as an attenuated live virus.\n3. FALSE [correction]: Influenza A H3N2 is included in the Fluzone intradermal quadrivalent vaccine, but it is inactivated, not attenuated live.\n4. TRUE: The vaccine does contain an inactivated B/Victoria lineage virus, but it is important to note that it is not an attenuated live virus.\n5. UNKNOWN: The inclusion of the B/Yamagata type B virus in the Fluzone intradermal quadrivalent vaccine can vary by season and formulation. Without specific information on the vaccine formulation for a given year, it is not possible to confirm its presence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE). The TNFR2 gene encodes for the tumor necrosis factor receptor 2 (TNFR2), which is a key player in the immune system and inflammation. Studies have shown that genetic variations in the TNFR2 gene are associated with an increased risk of developing SLE, a chronic autoimmune disease that affects multiple organ systems. Specifically, certain variants in the TNFR2 gene have been found to be more common in SLE patients compared to healthy controls, and these variants have been linked to an increased risk of disease flares and severity. Therefore, the TNFR2 gene is a potential genetic target for the development of new therapies for SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).\n2. The TNFR2 gene encodes for the tumor necrosis factor receptor 2 (TNFR2).\n3. Genetic variations in the TNFR2 gene are associated with an increased risk of developing SLE.\n4. Certain variants in the TNFR2 gene are more common in SLE patients compared to healthy controls.\n5. These variants in the TNFR2 gene have been linked to an increased risk of disease flares and severity in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).",
      "The TNFR2 gene encodes for the tumor necrosis factor receptor 2 (TNFR2).",
      "Genetic variations in the TNFR2 gene are associated with an increased risk of developing SLE.",
      "Certain variants in the TNFR2 gene are more common in SLE patients compared to healthy controls.",
      "These variants in the TNFR2 gene have been linked to an increased risk of disease flares and severity in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFR2 gene has been reported in scientific literature to be genetically associated with Systemic Lupus Erythematosus (SLE).\n2. TRUE: The TNFR2 gene does indeed encode for the tumor necrosis factor receptor 2 (TNFR2).\n3. TRUE: Genetic variations in the TNFR2 gene have been associated with an increased risk of developing SLE.\n4. TRUE: Certain variants in the TNFR2 gene have been found to be more common in SLE patients compared to healthy controls.\n5. UNKNOWN: While it is plausible that variants in the TNFR2 gene could be linked to disease flares and severity in SLE patients, without specific evidence or studies provided in the context, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Yes, there is currently no licensed vaccine available for peanut allergy, but there is ongoing research and development of potential treatments, including antibody therapies, such as the one mentioned in the article you provided. The study you mentioned showed promising results in a small pilot trial, with participants being able to tolerate a small amount of peanut protein after receiving a single injection of the antibody treatment. While this is a positive development, it is important to note that more research is needed to confirm the safety and effectiveness of this treatment and to determine its potential as a long-term solution for peanut allergy.\nIt is also important to note that peanut allergy is a complex and severe allergy that can have life-threatening consequences, so any potential treatment must be thoroughly tested and evaluated before it can be considered safe and effective for widespread use. If you or someone you know has a peanut allergy, it is important to consult with a healthcare professional for proper diagnosis and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no licensed vaccine available for peanut allergy.\n2. Ongoing research and development are focused on potential treatments for peanut allergy, including antibody therapies.\n3. A small pilot trial showed promising results where participants could tolerate a small amount of peanut protein after receiving an antibody treatment.\n4. More research is needed to confirm the safety and effectiveness of the antibody treatment for peanut allergy.\n5. Peanut allergy can have life-threatening consequences.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no licensed vaccine available for peanut allergy.",
      "Ongoing research and development are focused on potential treatments for peanut allergy, including antibody therapies.",
      "A small pilot trial showed promising results where participants could tolerate a small amount of peanut protein after receiving an antibody treatment.",
      "More research is needed to confirm the safety and effectiveness of the antibody treatment for peanut allergy.",
      "Peanut allergy can have life-threatening consequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff in 2023, a vaccine called Palforzia has been approved by the FDA for the treatment of peanut allergies in children.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Fxy gene in mice is located on the PAB (Pericentromeric region of the autosome) and spans both the X and Y chromosomes, with the 5' end being X-unique and the 3' end being present on both the X and Y chromosomes. In contrast, the Fxy gene in humans and another species, M. spretus, is entirely X-unique.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fxy gene in mice is located on the Pericentromeric region of the autosome (PAB).\n2. The Fxy gene in mice spans both the X and Y chromosomes.\n3. The 5' end of the Fxy gene in mice is unique to the X chromosome.\n4. The 3' end of the Fxy gene in mice is present on both the X and Y chromosomes.\n5. In humans and M. spretus, the Fxy gene is entirely unique to the X chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "The Fxy gene in mice is located on the Pericentromeric region of the autosome (PAB).",
      "The Fxy gene in mice spans both the X and Y chromosomes.",
      "The 5' end of the Fxy gene in mice is unique to the X chromosome.",
      "The 3' end of the Fxy gene in mice is present on both the X and Y chromosomes.",
      "In humans and M. spretus, the Fxy gene is entirely unique to the X chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: In humans, the FXYD1 gene (previously known as FXY) is located on chromosome 19, not the X chromosome. In M. spretus (a species of wild mouse), the information provided is not sufficient to determine the location of the Fxy gene without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! The basis of the MPE-seq method is the treatment of nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron. This treatment allows for the genome-wide characterization of chromatin structure and dynamics.\nMPE is a reagent that selectively binds to the minor groove of DNA, while EDTA is a chelator that sequesters divalent cations, such as calcium and iron. When nuclei are treated with MPE and EDTA, the interaction between MPE and DNA causes the chromatin to become more accessible to enzymes that digest the DNA, leading to a more open chromatin structure. This open chromatin structure allows for the better accessibility of the DNA to the enzymes, which can then digest the DNA and create a more fragmented genome.\nThe fragmented genome can then be sequenced using next-generation sequencing technologies, allowing for the genome-wide characterization of chromatin structure and dynamics. The resulting data can provide valuable insights into the regulation of gene expression, the organization of chromosomes, and the dynamics of chromatin remodeling.\nIn summary, the basis of the MPE-seq method is the treatment of nuclei with a complex of MPE and EDTA, which allows for the genome-wide characterization of chromatin structure and dynamics through the creation of a more open chromatin structure and the subsequent sequencing of the fragmented genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MPE-seq method involves treating nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron.\n2. Methidiumpropyl-EDTA (MPE) selectively binds to the minor groove of DNA.\n3. EDTA is a chelator that sequesters divalent cations such as calcium and iron.\n4. The treatment with MPE and EDTA leads to a more open chromatin structure by making the chromatin more accessible to enzymes that digest DNA.\n5. The fragmented genome resulting from the MPE-seq method can be sequenced using next-generation sequencing technologies.",
    "llama-2-7b-chat-hf_fact": [
      "The MPE-seq method involves treating nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron.",
      "Methidiumpropyl-EDTA (MPE) selectively binds to the minor groove of DNA.",
      "EDTA is a chelator that sequesters divalent cations such as calcium and iron.",
      "The treatment with MPE and EDTA leads to a more open chromatin structure by making the chromatin more accessible to enzymes that digest DNA.",
      "The fragmented genome resulting from the MPE-seq method can be sequenced using next-generation sequencing technologies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The treatment with MPE and ferrous iron (not EDTA alone) leads to a more open chromatin structure by making the chromatin more accessible to enzymes that digest DNA. The MPE-Fe(II) complex cleaves DNA, and EDTA is present to chelate divalent cations that could otherwise inhibit the cleavage reaction by MPE-Fe(II).\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the programming language used for implementing GWAR is Perl. The mention of implementing the tool in a standalone version of Perl suggests that it is the language of choice for this project.",
    "llama-2-7b-chat-hf_fact_raw": "1. Perl is the programming language used for implementing GWAR.",
    "llama-2-7b-chat-hf_fact": [
      "Perl is the programming language used for implementing GWAR."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Explanation]: Without additional context or information about what GWAR refers to, it is not possible to determine the truthfulness of the statement. GWAR could refer to a specific software, project, or acronym that is not widely recognized or could be domain-specific. Perl is a programming language that could be used for a variety of applications, but without knowing what GWAR is, it's impossible to confirm or deny the statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS). The document mentions that improved prognosis, such as that achieved with the survival model from the European Network for the Cure of ALS, can inform the patient and their family about the disease course and improve end-of-life planning. However, it does not specifically mention xaliproden as a treatment that improves prognosis.\nIn fact, a recent clinical trial found that xaliproden did not meet its primary endpoint of improving the progression of ALS. The trial, known as the XALIPRO-1 study, randomized 160 patients with ALS to receive either xaliproden or a placebo, and found that the two groups had similar rates of disease progression.\nWhile there is ongoing research into new treatments for ALS, including xaliproden, the current evidence suggests that there are limited treatment options available to improve the prognosis of this devastating disease. It is important for patients and their families to discuss their prognosis and end-of-life planning with their healthcare provider, and to consider participating in clinical trials of new treatments that may offer hope for improved outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).\n2. The European Network for the Cure of ALS has a survival model that can inform patients and their families about the disease course.\n3. A clinical trial named XALIPRO-1 studied the effects of xaliproden on ALS.\n4. In the XALIPRO-1 study, 160 patients with ALS were randomized to receive either xaliproden or a placebo.\n5. The XALIPRO-1 study found that xaliproden did not meet its primary endpoint of improving the progression of ALS.",
    "llama-2-7b-chat-hf_fact": [
      "There is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).",
      "The European Network for the Cure of ALS has a survival model that can inform patients and their families about the disease course.",
      "A clinical trial named XALIPRO-1 studied the effects of xaliproden on ALS.",
      "In the XALIPRO-1 study, 160 patients with ALS were randomized to receive either xaliproden or a placebo.",
      "The XALIPRO-1 study found that xaliproden did not meet its primary endpoint of improving the progression of ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the transgenes are inserted into chromosome 3. The LiPS-A3S line is within the 3' UTR region of the gene, which suggests that the transgenes are inserted into the gene on chromosome 3.",
    "llama-2-7b-chat-hf_fact_raw": "1. Transgenes are inserted into chromosome 3 in the case of the LiPS-A3S line.\n2. The LiPS-A3S line is within the 3' UTR region of a gene on chromosome 3.",
    "llama-2-7b-chat-hf_fact": [
      "Transgenes are inserted into chromosome 3 in the case of the LiPS-A3S line.",
      "The LiPS-A3S line is within the 3' UTR region of a gene on chromosome 3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout specific context or additional information about the LiPS-A3S line and the procedures used to create it, it is not possible to determine the accuracy of these statements. The details about transgene insertion and genomic locations are highly specific and would require reference to the original scientific literature or data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several deep learning tools available for predicting drug synergy. One of the most notable tools is DeepSynergy, which is a deep learning-based tool for predicting drug synergy. According to the document, DeepSynergy is available via the website <www.bioinf.jku.at/software/DeepSynergy> and can be contacted at klambauer@bioinf.jku.at.\nDeepSynergy is a tool that uses deep learning algorithms to predict drug synergy by analyzing large amounts of molecular interaction data. It can be used to identify potential drug combinations that are likely to have a synergistic effect, which can be useful in drug discovery and development.\nOther deep learning tools for predicting drug synergy include:\n1. DrugSynergy: This tool uses a deep learning model to predict drug synergy by analyzing molecular interaction data. It can be used to identify potential drug combinations that are likely to have a synergistic effect.\n2. SynergyNet: This tool uses a deep learning model to predict drug synergy by analyzing molecular interaction data. It can be used to identify potential drug combinations that are likely to have a synergistic effect.\n3. DrugCombinator: This tool uses a deep learning model to predict drug synergy by analyzing molecular interaction data. It can be used to identify potential drug combinations that are likely to have a synergistic effect.\n4. DeepDrug: This tool uses a deep learning model to predict drug synergy by analyzing molecular interaction data. It can be used to identify potential drug combinations that are likely to have a synergistic effect.\nIt is important to note that these tools are constantly being updated and improved, so it is recommended to check the latest information on each tool's website for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynergy is a deep learning-based tool for predicting drug synergy.\n2. DeepSynergy is available via the website <www.bioinf.jku.at/software/DeepSynergy>.\n3. The contact email for DeepSynergy is klambauer@bioinf.jku.at.\n4. DrugSynergy, SynergyNet, DrugCombinator, and DeepDrug are other tools that use deep learning models to predict drug synergy.\n5. These tools analyze molecular interaction data to identify potential drug combinations with a synergistic effect.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynergy is a deep learning-based tool for predicting drug synergy.",
      "DeepSynergy is available via the website <www.bioinf.jku.at/software/DeepSynergy>.",
      "The contact email for DeepSynergy is klambauer@bioinf.jku.at.",
      "DrugSynergy, SynergyNet, DrugCombinator, and DeepDrug are other tools that use deep learning models to predict drug synergy.",
      "These tools analyze molecular interaction data to identify potential drug combinations with a synergistic effect."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: While DeepSynergy is a tool that uses deep learning models to predict drug synergy, the other tools mentioned (DrugSynergy, SynergyNet, DrugCombinator, and DeepDrug) may not all use deep learning models for predicting drug synergy. Without specific information about each tool, it cannot be confirmed that all of them use deep learning models.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cloud-based platform that has been developed for comparing GWAS is easyGWAS.",
    "llama-2-7b-chat-hf_fact_raw": "1. easyGWAS is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies).",
    "llama-2-7b-chat-hf_fact": [
      "easyGWAS is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that CMB305 is a vaccine regimen that is being studied for the treatment of sarcomas. The abstract mentions that CMB305 is a heterologous prime-boost vaccination regimen that is designed to prime NY-ESO-1–specific CD8 T-cell populations and then activate the immune response with a potent TLR-4 agonist.\nThere is some evidence to suggest that CMB305 may be effective in treating sarcomas. For example, a study published in the Journal of Clinical Oncology in 2018 found that CMB305 was well-tolerated and induced anti-tumor immune responses in patients with advanced sarcomas. The study also found that CMB305 was associated with a significant improvement in overall survival in these patients.\nHowever, it is important to note that the study was small and had limited scope, so more research is needed to confirm these findings and establish the safety and efficacy of CMB305 for the treatment of sarcomas.\nIn summary, while there is some evidence to suggest that CMB305 may be effective in treating sarcomas, more research is needed to confirm these findings and establish the safety and efficacy of this vaccine regimen for this indication.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a vaccine regimen being studied for the treatment of sarcomas.\n2. CMB305 is designed to prime NY-ESO-1–specific CD8 T-cell populations and activate the immune response with a TLR-4 agonist.\n3. A study published in the Journal of Clinical Oncology in 2018 found that CMB305 was well-tolerated by patients with advanced sarcomas.\n4. The same study indicated that CMB305 induced anti-tumor immune responses in patients with advanced sarcomas.\n5. The study also reported a significant improvement in overall survival in patients with advanced sarcomas treated with CMB305.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a vaccine regimen being studied for the treatment of sarcomas.",
      "CMB305 is designed to prime NY-ESO-1–specific CD8 T-cell populations and activate the immune response with a TLR-4 agonist.",
      "A study published in the Journal of Clinical Oncology in 2018 found that CMB305 was well-tolerated by patients with advanced sarcomas.",
      "The same study indicated that CMB305 induced anti-tumor immune responses in patients with advanced sarcomas.",
      "The study also reported a significant improvement in overall survival in patients with advanced sarcomas treated with CMB305."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The study may have reported immune responses and tolerability, but without the specific article or results, we cannot confirm a significant improvement in overall survival. Clinical studies often measure various endpoints, and overall survival is a critical one that would need explicit evidence to support such a claim.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the manifestations of the Saint's Triad are:\n1. Hiatal hernia: This is a condition where the stomach bulges up into the chest through a weakened area in the diaphragm. It can cause symptoms such as heartburn, regurgitation, and difficulty swallowing.\n2. Gallbladder disease: This can include conditions such as gallstones, inflammation of the gallbladder (cholecystitis), or gallbladder cancer. Symptoms can include abdominal pain, nausea, and vomiting.\n3. Diverticulosis: This is a condition where small pouches form in the wall of the colon, typically in the lower part of the colon. Symptoms can include abdominal pain, bloating, and changes in bowel movements.\nIt is important to note that the Saint's Triad is a concept used to help diagnose and manage atypical abdominal symptoms in patients. It is not a formal medical diagnosis, but rather a tool for doctors to consider when evaluating a patient's symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hiatal hernia is a condition where the stomach bulges up into the chest through a weakened area in the diaphragm.\n2. Gallbladder disease can include conditions such as gallstones, cholecystitis, or gallbladder cancer.\n3. Diverticulosis is a condition where small pouches form in the wall of the colon, typically in the lower part of the colon.\n4. Symptoms of hiatal hernia can include heartburn, regurgitation, and difficulty swallowing.\n5. Symptoms of gallbladder disease can include abdominal pain, nausea, and vomiting.",
    "llama-2-7b-chat-hf_fact": [
      "Hiatal hernia is a condition where the stomach bulges up into the chest through a weakened area in the diaphragm.",
      "Gallbladder disease can include conditions such as gallstones, cholecystitis, or gallbladder cancer.",
      "Diverticulosis is a condition where small pouches form in the wall of the colon, typically in the lower part of the colon.",
      "Symptoms of hiatal hernia can include heartburn, regurgitation, and difficulty swallowing.",
      "Symptoms of gallbladder disease can include abdominal pain, nausea, and vomiting."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that overexpression of LY6K is associated with a worse prognosis for non-small cell lung cancer (NSCLC) patients.\nDocument 0 suggests that high levels of LY6K gene expression are observed in various tumors, including NSCLC, and are linked to tumorigenesis and progression. Additionally, the document states that LY6K is negatively correlated with poor prognosis in patients, indicating that higher levels of LY6K expression are associated with a lower survival rate.\nFurthermore, the document mentions that LY6K can stimulate the immune response of the body's immune cells, which could potentially have a positive impact on the prognosis of NSCLC patients. However, the overall effect of LY6K expression on the prognosis of NSCLC patients appears to be negative.\nTherefore, based on the information provided, it can be concluded that overexpression of LY6K is associated with a worse prognosis for NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with a worse prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K gene expression are observed in various tumors, including NSCLC.\n3. LY6K expression is linked to tumorigenesis and progression in NSCLC.\n4. Higher levels of LY6K expression are associated with a lower survival rate in NSCLC patients.\n5. LY6K can stimulate the immune response of the body's immune cells.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with a worse prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K gene expression are observed in various tumors, including NSCLC.",
      "LY6K expression is linked to tumorigenesis and progression in NSCLC.",
      "Higher levels of LY6K expression are associated with a lower survival rate in NSCLC patients.",
      "LY6K can stimulate the immune response of the body's immune cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Overexpression of LY6K is indeed associated with a worse prognosis for non-small cell lung cancer (NSCLC) patients.\n2. TRUE: High levels of LY6K gene expression have been observed in various tumors, including NSCLC.\n3. TRUE: LY6K expression is linked to tumorigenesis and progression in NSCLC.\n4. TRUE: Higher levels of LY6K expression are generally associated with a lower survival rate in NSCLC patients.\n5. FALSE [correction]: LY6K is typically associated with tumor progression and does not stimulate the immune response; rather, it may help tumor cells evade the immune system.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following Cdk targets are dephosphorylated during cytokinesis:\n1. Cdk1: The document states that downregulation of Cdk1 activity is necessary for proper cytokinesis in budding yeast.\n2. Cdk2: The document does not mention the dephosphorylation of Cdk2 during cytokinesis, but it does suggest that Cdk2 is involved in the process.\n3. Cdc14: The document states that upregulation of Cdc14, a phosphatase that counteracts Cdk activity, is necessary for proper cytokinesis.\nTherefore, based on the information provided in Document 0, the following Cdk targets are dephosphorylated during cytokinesis: Cdk1 and Cdc14.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdk1 activity is downregulated during cytokinesis in budding yeast.\n2. Cdc14, a phosphatase that counteracts Cdk activity, is upregulated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cdk1 activity is downregulated during cytokinesis in budding yeast.",
      "Cdc14, a phosphatase that counteracts Cdk activity, is upregulated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cdk1 activity is not downregulated during cytokinesis in budding yeast; it remains active until the end of mitosis to ensure successful completion of cytokinesis.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Xanamem is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response. 11β-HSD1 is responsible for converting the stress hormone cortisol to its active form, which binds to glucocorticoid receptors. By inhibiting 11β-HSD1, Xanamem can reduce the production of cortisol and alleviate stress-related disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).\n2. 11β-HSD1 is involved in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response.\n3. The enzyme 11β-HSD1 is responsible for converting cortisol to its active form.\n4. Cortisol is a stress hormone that binds to glucocorticoid receptors.\n5. Inhibiting 11β-HSD1 with Xanamem can reduce the production of cortisol.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).",
      "11β-HSD1 is involved in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response.",
      "The enzyme 11β-HSD1 is responsible for converting cortisol to its active form.",
      "Cortisol is a stress hormone that binds to glucocorticoid receptors.",
      "Inhibiting 11β-HSD1 with Xanamem can reduce the production of cortisol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The enzyme 11β-HSD1 is responsible for converting cortisone to its active form, cortisol.\n4. TRUE\n5. FALSE [correction]: Inhibiting 11β-HSD1 with Xanamem can reduce the conversion of inactive cortisone into active cortisol, not the production of cortisol itself.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the role of the Hof1-Cyk3 interaction in yeast is as follows:\nThe interaction between Hof1 and Cyk3 is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3. This interaction occurs specifically at the time of cytokinesis, but is independent of the (hyper)phosphorylation of both proteins that occurs at about the same time. Additionally, the interaction is dispensable for the normal localization of both proteins.\nIn other words, the Hof1-Cyk3 interaction plays a role in the process of cytokinesis in yeast, but it is not dependent on the phosphorylation of the proteins, and it does not affect their normal localization.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast is mediated by the Hof1 SH3 domain binding to a proline-rich motif in Cyk3.\n2. This interaction occurs specifically at the time of cytokinesis.\n3. The interaction between Hof1 and Cyk3 is independent of the phosphorylation of both proteins.\n4. The Hof1-Cyk3 interaction is dispensable for the normal localization of both Hof1 and Cyk3 proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast is mediated by the Hof1 SH3 domain binding to a proline-rich motif in Cyk3.",
      "This interaction occurs specifically at the time of cytokinesis.",
      "The interaction between Hof1 and Cyk3 is independent of the phosphorylation of both proteins.",
      "The Hof1-Cyk3 interaction is dispensable for the normal localization of both Hof1 and Cyk3 proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The interaction between Hof1 and Cyk3 is often regulated by the phosphorylation state of one or both proteins, which can affect binding affinity and interaction dynamics.\n4. FALSE [correction]: The Hof1-Cyk3 interaction is typically important for the correct localization of both Hof1 and Cyk3 proteins during cytokinesis, as protein interactions can dictate their cellular positions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following T-UCRs have been implicated in gastric cancer:\n1. CpG island methylation: T-UCRs have been found to be involved in the methylation of CpG islands in gastric cancer cells, leading to the silencing of tumor suppressor genes and the promotion of tumorigenesis.\n2. Interaction with miRNAs: T-UCRs have been shown to interact with miRNAs in gastric cancer, leading to the regulation of miRNA-mediated gene silencing and the modulation of cancer cell behavior.\n3. Direct binding to target mRNAs: T-UCRs have been found to directly bind to the 3'UTR of specific mRNAs in gastric cancer cells, leading to the regulation of gene expression and the progression of cancer.\nTherefore, based on the information provided in Document 0, the following T-UCRs have been implicated in gastric cancer:\n1. T-UCR1: involved in CpG island methylation and the silencing of tumor suppressor genes in gastric cancer cells.\n2. T-UCR2: involved in the interaction with miRNAs and the regulation of miRNA-mediated gene silencing in gastric cancer cells.\n3. T-UCR3: involved in direct binding to the 3'UTR of specific mRNAs and the regulation of gene expression in gastric cancer cells.\nIt is important to note that this answer is based on the information provided in Document 0, and further research may provide additional insights into the role of T-UCRs in gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs are involved in the methylation of CpG islands in gastric cancer cells.\n2. The methylation of CpG islands by T-UCRs leads to the silencing of tumor suppressor genes in gastric cancer.\n3. T-UCRs interact with miRNAs in gastric cancer, affecting miRNA-mediated gene silencing.\n4. T-UCRs directly bind to the 3'UTR of specific mRNAs in gastric cancer cells, influencing gene expression.\n5. The involvement of T-UCRs in these processes is implicated in the progression of gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs are involved in the methylation of CpG islands in gastric cancer cells.",
      "The methylation of CpG islands by T-UCRs leads to the silencing of tumor suppressor genes in gastric cancer.",
      "T-UCRs interact with miRNAs in gastric cancer, affecting miRNA-mediated gene silencing.",
      "T-UCRs directly bind to the 3'UTR of specific mRNAs in gastric cancer cells, influencing gene expression.",
      "The involvement of T-UCRs in these processes is implicated in the progression of gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements regarding T-UCRs (Transcribed Ultraconserved Regions) involve specific molecular biology details that are not common knowledge and would require access to current scientific research to verify. Without the specific context or research references, it is not possible to determine the truthfulness of statements 1-4. However, statement 5 is generally true as the involvement of T-UCRs in various cellular processes, including those related to cancer progression, has been a subject of research and is implicated in the progression of various cancers, including gastric cancer.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "Great, thank you for providing the necessary information! Based on the information provided, the Lupus Severity Index (LSI) appears to be a tool used to assess the severity of lupus in patients. The LSI was found to have high predictive accuracy for immunosuppressive use and early mortality in a validation dataset, and it was also found to be strongly correlated with a previously existing severity score for lupus.\nThe LSI likely takes into account various factors that contribute to the severity of lupus, such as organ involvement, disease activity, and patient symptoms. By using this index, healthcare providers can get a comprehensive view of a patient's lupus severity and make more informed decisions about their treatment and management.\nIf you have any further questions or would like to know more about the LSI, please feel free to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of lupus in patients.\n2. The LSI has high predictive accuracy for immunosuppressive use and early mortality in a validation dataset.\n3. The LSI is strongly correlated with a previously existing severity score for lupus.\n4. The LSI takes into account factors such as organ involvement, disease activity, and patient symptoms.\n5. The LSI helps healthcare providers make informed decisions about lupus treatment and management.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of lupus in patients.",
      "The LSI has high predictive accuracy for immunosuppressive use and early mortality in a validation dataset.",
      "The LSI is strongly correlated with a previously existing severity score for lupus.",
      "The LSI takes into account factors such as organ involvement, disease activity, and patient symptoms.",
      "The LSI helps healthcare providers make informed decisions about lupus treatment and management."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific medical literature or a defined context to confirm the existence or use of the Lupus Severity Index (LSI), it is not possible to determine the truth of this statement.\n2. UNKNOWN: The predictive accuracy of the LSI for immunosuppressive use and early mortality in a validation dataset cannot be confirmed without specific data or studies to reference.\n3. UNKNOWN: The correlation of the LSI with a previously existing severity score for lupus cannot be assessed without information on the LSI and the other severity score in question.\n4. UNKNOWN: Without specific details on the LSI, it is not possible to confirm whether it takes into account factors such as organ involvement, disease activity, and patient symptoms.\n5. UNKNOWN: The statement that the LSI helps healthcare providers make informed decisions about lupus treatment and management cannot be verified without additional context or evidence of its use and effectiveness.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, de novo mutations in ZSWIM6 have been associated with acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome. The mutation in question is a recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6, which is thought to cause a gain-of-function effect leading to the development of AFND.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 are associated with acromelic frontonasal dysostosis (AFND).\n2. Acromelic frontonasal dysostosis (AFND) is an autosomal-dominant severe frontonasal and limb malformation syndrome.\n3. The mutation in ZSWIM6 related to AFND is a recurrent de novo missense variant.\n4. The missense variant associated with AFND is located within the C-terminal Sin3-like domain of ZSWIM6.\n5. The mutation in ZSWIM6 is thought to cause a gain-of-function effect that leads to the development of AFND.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 are associated with acromelic frontonasal dysostosis (AFND).",
      "Acromelic frontonasal dysostosis (AFND) is an autosomal-dominant severe frontonasal and limb malformation syndrome.",
      "The mutation in ZSWIM6 related to AFND is a recurrent de novo missense variant.",
      "The missense variant associated with AFND is located within the C-terminal Sin3-like domain of ZSWIM6.",
      "The mutation in ZSWIM6 is thought to cause a gain-of-function effect that leads to the development of AFND."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acromelic frontonasal dysostosis (AFND) is typically caused by autosomal recessive inheritance, not autosomal dominant.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify vestibular schwannoma (VS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, AZD8601 appears to have in vivo effects that improve vascularization and tissue oxygenation. The document mentions that sequential dosing of AZD8601 leads to accelerated wound healing and improved tissue oxygenation, as demonstrated by the use of a boron nanoparticle-based tissue oxygen sensor. This suggests that AZD8601 may increase blood flow and oxygen delivery to the wound area, promoting faster healing and reducing the risk of complications such as infection or delayed healing.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 improves vascularization and tissue oxygenation in vivo.\n2. Sequential dosing of AZD8601 leads to accelerated wound healing.\n3. AZD8601 improves tissue oxygenation as demonstrated by a boron nanoparticle-based tissue oxygen sensor.\n4. AZD8601 may increase blood flow and oxygen delivery to the wound area.\n5. AZD8601 promotes faster healing and reduces the risk of complications such as infection or delayed healing.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 improves vascularization and tissue oxygenation in vivo.",
      "Sequential dosing of AZD8601 leads to accelerated wound healing.",
      "AZD8601 improves tissue oxygenation as demonstrated by a boron nanoparticle-based tissue oxygen sensor.",
      "AZD8601 may increase blood flow and oxygen delivery to the wound area.",
      "AZD8601 promotes faster healing and reduces the risk of complications such as infection or delayed healing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or reference to a study, clinical trial data, or scientific publication that provides evidence for these statements, it is not possible to determine the veracity of the claims about AZD8601. AZD8601 is a specific drug, and its effects would need to be substantiated by empirical research.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence, which is a stress response that can be triggered by various factors such as DNA damage, telomere erosion, and activation of oncogenic signaling.\nDuring cellular senescence, the cell cycle is permanently arrested to prevent the cell from dividing and potentially becoming cancerous. This process is accompanied by the formation of heterochromatic foci, which are regions of the chromatin that are condensed and stained differently than the rest of the chromatin. These foci are known as SAHFs.\nSAHFs are thought to play a role in the regulation of gene expression and the maintenance of cellular homeostasis, and they are often associated with the activation of certain cellular pathways that are involved in the response to stress and the regulation of cellular aging.\nIn summary, SAHFS are created as a result of cellular senescence, which is a stress response that can be triggered by various factors, and they play a role in the regulation of gene expression and the maintenance of cellular homeostasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence.\n2. Cellular senescence can be triggered by various factors such as DNA damage, telomere erosion, and activation of oncogenic signaling.\n3. During cellular senescence, the cell cycle is permanently arrested to prevent the cell from dividing.\n4. SAHFs are regions of the chromatin that are condensed and stained differently than the rest of the chromatin.\n5. SAHFs are thought to play a role in the regulation of gene expression and the maintenance of cellular homeostasis.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence.",
      "Cellular senescence can be triggered by various factors such as DNA damage, telomere erosion, and activation of oncogenic signaling.",
      "During cellular senescence, the cell cycle is permanently arrested to prevent the cell from dividing.",
      "SAHFs are regions of the chromatin that are condensed and stained differently than the rest of the chromatin.",
      "SAHFs are thought to play a role in the regulation of gene expression and the maintenance of cellular homeostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Thank you for providing the question and information. Based on the information provided, the function of the PDZ domain in SATB1 is to bind to phosphorylated serine/threonine residues on target proteins.\nThe PDZ domain is a protein domain that is involved in protein-protein interactions and is known to bind to phosphorylated serine/threonine residues on target proteins. In the case of SATB1, the N-terminal PDZ-like domain is functionally characterized as a PDZ domain that is involved in protein-protein interactions and plays a role in the regulation of SATB1's function.\nTherefore, the function of the PDZ domain in SATB1 is to bind to phosphorylated serine/threonine residues on target proteins, which is likely to play a role in the regulation of SATB1's function in gene expression and cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 binds to phosphorylated serine/threonine residues on target proteins.\n2. The PDZ domain is involved in protein-protein interactions.\n3. The N-terminal PDZ-like domain in SATB1 is functionally characterized as a PDZ domain.\n4. The PDZ domain in SATB1 plays a role in the regulation of SATB1's function.\n5. SATB1 is involved in gene expression and cellular processes.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 binds to phosphorylated serine/threonine residues on target proteins.",
      "The PDZ domain is involved in protein-protein interactions.",
      "The N-terminal PDZ-like domain in SATB1 is functionally characterized as a PDZ domain.",
      "The PDZ domain in SATB1 plays a role in the regulation of SATB1's function.",
      "SATB1 is involved in gene expression and cellular processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain typically binds to specific sequences at the C-termini of target proteins, not phosphorylated serine/threonine residues.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS technique is based on the principles of quantum healing, as described in Deepak Chopra's book \"Quantum Healing.\" According to Chopra, quantum healing is a holistic approach to healing that involves the use of consciousness and intention to transform the body's cells and molecules at the quantum level. This technique aims to relieve and dissolve pain, improve healing, and create the basis for stronger immunity by addressing the underlying imbalances that can lead to sickness and disease.\nChopra explains that the body is made up of trillions of cells, each of which is governed by the laws of quantum mechanics. By using the power of consciousness and intention, it is possible to influence these cells and molecules at the quantum level, leading to profound healing and transformation.\nThe BLISS technique involves a series of steps and practices that are designed to help individuals tap into their own inner healing power and access the quantum field of consciousness. By using this technique, individuals can learn to heal themselves and others, and create a more harmonious and balanced state of being.\nIn summary, the basis of the BLISS technique is the idea that the body and mind are interconnected and that by using the power of consciousness and intention, it is possible to heal and transform the body at the quantum level. This technique is based on the principles of quantum healing, as described in Deepak Chopra's book \"Quantum Healing.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is based on the principles of quantum healing.\n2. Deepak Chopra's book \"Quantum Healing\" describes the principles upon which the BLISS technique is based.\n3. Quantum healing involves using consciousness and intention to transform the body's cells and molecules at the quantum level.\n4. The BLISS technique aims to relieve pain, improve healing, and strengthen immunity by addressing underlying imbalances.\n5. The BLISS technique includes a series of steps and practices to help individuals tap into their inner healing power and access the quantum field of consciousness.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is based on the principles of quantum healing.",
      "Deepak Chopra's book \"Quantum Healing\" describes the principles upon which the BLISS technique is based.",
      "Quantum healing involves using consciousness and intention to transform the body's cells and molecules at the quantum level.",
      "The BLISS technique aims to relieve pain, improve healing, and strengthen immunity by addressing underlying imbalances.",
      "The BLISS technique includes a series of steps and practices to help individuals tap into their inner healing power and access the quantum field of consciousness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is vague as \"BLISS technique\" could refer to various methods or practices, and without specific context, it's unclear whether it is indeed based on the principles of quantum healing.\n2. UNKNOWN: Without additional context about the BLISS technique and whether it is directly related to Deepak Chopra's book \"Quantum Healing,\" it is not possible to confirm the accuracy of this statement.\n3. TRUE: Deepak Chopra's concept of quantum healing indeed involves using consciousness and intention to bring about healing at the quantum level within the body.\n4. UNKNOWN: The statement about the aims of the BLISS technique cannot be verified as true or false without specific information about what the BLISS technique entails.\n5. UNKNOWN: Similar to the previous statements, without concrete information about the BLISS technique and its practices, the truthfulness of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following are 3 NK3R antagonists:\n1. RWJ-70037: This is a potent and selective NK3R antagonist that has been shown to reduce hot flashes in postmenopausal women.\n2. MK-0752: This is a novel NK3R antagonist that has been shown to have efficacy in reducing hot flashes and improving sleep quality in postmenopausal women.\n3. LY-317679: This is a potent and selective NK3R antagonist that has been shown to reduce hot flashes and improve sleep quality in postmenopausal women.\nIt is important to note that these are just a few examples of NK3R antagonists that have been studied for the treatment of menopausal vasomotor symptoms, and there may be other compounds that have similar effects. Additionally, the efficacy and safety of these compounds have not been fully established in clinical trials, and further research is needed to determine their potential as therapeutic agents.",
    "llama-2-7b-chat-hf_fact_raw": "1. RWJ-70037 is a potent and selective NK3R antagonist.\n2. MK-0752 is a novel NK3R antagonist.\n3. LY-317679 is a potent and selective NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "RWJ-70037 is a potent and selective NK3R antagonist.",
      "MK-0752 is a novel NK3R antagonist.",
      "LY-317679 is a potent and selective NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific context or additional information about the compounds RWJ-70037, MK-0752, and LY-317679, it is not possible to determine the accuracy of these statements. These appear to be names or identifiers for chemical compounds, and their properties as NK3R antagonists would need to be verified with scientific literature or databases.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is PF-05190457.",
    "llama-2-7b-chat-hf_fact_raw": "1. PF-05190457 is an oral ghrelin receptor inverse agonist.\n2. PF-05190457 was profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "PF-05190457 is an oral ghrelin receptor inverse agonist.",
      "PF-05190457 was profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protective efficacy of Vaxchora against moderate to severe cholera is not explicitly stated. However, we can infer some information from the context.\nVaxchora is a vaccine approved for use in adults 18 years and older for the prevention of cholera caused by Vibrio cholerae serogroup O1 or O139. The vaccine is given orally, and it is recommended to be taken 2-10 days before traveling to an area where cholera is common.\nAccording to Document 0, cholera is a potentially life-threatening bacterial infection that occurs in the intestines and causes severe diarrhea and dehydration, with a high incidence in Africa, Southeast Asia, and other locations around the world. Moderate to severe cholera can lead to severe dehydration, shock, and even death if left untreated.\nWhile the vaccine's protective efficacy against moderate to severe cholera is not explicitly stated, it is reasonable to assume that the vaccine provides some protection against the disease, given its ability to prevent cholera infection in the first place. However, the exact level of protection against moderate to severe cholera is not provided in the information provided.\nTherefore, based on the information provided, it is unclear what the protective efficacy of Vaxchora is against moderate to severe cholera. Further research or consultation with a medical professional would be necessary to determine the vaccine's effectiveness against severe cholera infections.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a vaccine approved for use in adults 18 years and older.\n2. Vaxchora is used for the prevention of cholera caused by Vibrio cholerae serogroup O1 or O139.\n3. The vaccine is administered orally.\n4. It is recommended to take Vaxchora 2-10 days before traveling to an area where cholera is common.\n5. Cholera is a bacterial infection that can lead to severe dehydration, shock, and death if left untreated.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a vaccine approved for use in adults 18 years and older.",
      "Vaxchora is used for the prevention of cholera caused by Vibrio cholerae serogroup O1 or O139.",
      "The vaccine is administered orally.",
      "It is recommended to take Vaxchora 2-10 days before traveling to an area where cholera is common.",
      "Cholera is a bacterial infection that can lead to severe dehydration, shock, and death if left untreated."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora is used for the prevention of cholera caused by Vibrio cholerae serogroup O1. It is not indicated for protection against serogroup O139.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the first cholera vaccine approved in the US is Vaxchora. According to Document 0, Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is the first cholera vaccine approved in the US.\n2. The Food and Drug Administration approved Vaxchora for the prophylaxis of cholera infection.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is the first cholera vaccine approved in the US.",
      "The Food and Drug Administration approved Vaxchora for the prophylaxis of cholera infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is likely to be an autosomal recessive genetic mutation. The passage states that CVIDs are a genetically heterogeneous group of disorders with both familial and sporadic genetic background, and that they have an autosomal recessive and autosomal dominant inheritance pattern. However, the passage specifically highlights the autosomal recessive pattern as the most common genetic mechanism underlying CVID in Europeans.\nTherefore, based on the information provided, the answer to the user's question is:\nThe most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is an autosomal recessive genetic mutation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variable immunodeficiency (CVID) in Europeans is most commonly caused by an autosomal recessive genetic mutation.\n2. CVIDs are a genetically heterogeneous group of disorders.\n3. CVIDs can have both familial and sporadic genetic backgrounds.\n4. CVIDs can be inherited in an autosomal recessive or autosomal dominant pattern.",
    "llama-2-7b-chat-hf_fact": [
      "Common variable immunodeficiency (CVID) in Europeans is most commonly caused by an autosomal recessive genetic mutation.",
      "CVIDs are a genetically heterogeneous group of disorders.",
      "CVIDs can have both familial and sporadic genetic backgrounds.",
      "CVIDs can be inherited in an autosomal recessive or autosomal dominant pattern."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Common variable immunodeficiency (CVID) in Europeans is not most commonly caused by an autosomal recessive genetic mutation; the genetic causes of CVID are complex and not fully understood, but most cases are sporadic and not linked to a clear autosomal recessive pattern.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the IFIT1 gene plays a role in Systemic Lupus Erythematosus (SLE) by being involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs) in SLE. ISGs are genes that are expressed in response to interferons (IFNs), which are proteins that play a crucial role in the immune system's defense against viral infections. In SLE, the overproduction and upregulation of ISGs can contribute to the development and progression of the disease. The IFIT1 gene, in particular, has been shown to be upregulated in SLE patients and may play a role in the pathogenesis of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs) in Systemic Lupus Erythematosus (SLE).\n2. Interferon-stimulated genes (ISGs) are expressed in response to interferons, which are proteins important for the immune system's defense against viral infections.\n3. The overproduction and upregulation of ISGs can contribute to the development and progression of Systemic Lupus Erythematosus (SLE).\n4. The IFIT1 gene has been shown to be upregulated in patients with Systemic Lupus Erythematosus (SLE).\n5. The IFIT1 gene may play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE).",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is involved in the overproduction and upregulation of Interferon-stimulated genes (ISGs) in Systemic Lupus Erythematosus (SLE).",
      "Interferon-stimulated genes (ISGs) are expressed in response to interferons, which are proteins important for the immune system's defense against viral infections.",
      "The overproduction and upregulation of ISGs can contribute to the development and progression of Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene has been shown to be upregulated in patients with Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene may play a role in the pathogenesis of Systemic Lupus Erythematosus (SLE)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with current scientific understanding. The IFIT1 gene is indeed involved in the immune response and has been implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) through the overproduction and upregulation of Interferon-stimulated genes (ISGs). ISGs are expressed in response to interferons, which play a crucial role in the immune system's defense against viral infections, and their dysregulation is associated with SLE. The IFIT1 gene has been shown to be upregulated in patients with SLE, suggesting a role in the disease's development and progression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! The Liverpool Elbow Score is a validated scoring system used to assess the functional status of the elbow in patients with elbow disorders. It was developed to evaluate multiple aspects of elbow function, including pain, stiffness, and range of motion. The score is based on a combination of patient-reported outcomes and clinician assessment, and it has been shown to be reliable and valid in various studies. The Liverpool Elbow Score can help clinicians and researchers evaluate the effectiveness of treatments for elbow disorders and monitor changes in elbow function over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is used to assess the functional status of the elbow in patients with elbow disorders.\n2. It evaluates multiple aspects of elbow function, including pain, stiffness, and range of motion.\n3. The score is based on a combination of patient-reported outcomes and clinician assessment.\n4. The Liverpool Elbow Score has been shown to be reliable and valid in various studies.\n5. It is used to evaluate the effectiveness of treatments for elbow disorders and monitor changes in elbow function over time.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score is used to assess the functional status of the elbow in patients with elbow disorders.",
      "It evaluates multiple aspects of elbow function, including pain, stiffness, and range of motion.",
      "The score is based on a combination of patient-reported outcomes and clinician assessment.",
      "The Liverpool Elbow Score has been shown to be reliable and valid in various studies.",
      "It is used to evaluate the effectiveness of treatments for elbow disorders and monitor changes in elbow function over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Thank you for asking! The 100,000 Genomes Project was a groundbreaking initiative launched in the UK in 2015 to sequence the genomes of 100,000 patients with rare diseases and cancer. Sarcoma, a rare and complex cancer, was one of the diseases included in the project.\nAccording to Document 0, sarcoma ranked third overall among the number of patients' samples sent for sequencing in the project. This means that a significant number of sarcoma patients participated in the project, providing valuable insights into the genetic mutations that drive this disease.\nThe 100,000 Genomes Project has contributed significantly to our understanding of sarcoma and has identified new potential therapeutic targets for this disease. For example, the project has identified specific genetic mutations that are commonly found in sarcomas, such as mutations in the TP53 gene, which is a tumor suppressor gene that is frequently mutated in many types of cancer, including sarcoma.\nThe project has also identified novel genetic mutations that are specific to sarcoma subtypes, such as chondrosarcoma and leiomyosarcoma. These findings have the potential to lead to the development of new, targeted therapies for sarcoma patients.\nOverall, the 100,000 Genomes Project has provided a wealth of information about sarcoma and has paved the way for further research into this complex and rare disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in the UK in 2015.\n2. The project aimed to sequence the genomes of 100,000 patients with rare diseases and cancer, including sarcoma.\n3. Sarcoma ranked third overall among the number of patients' samples sent for sequencing in the project.\n4. The project identified specific genetic mutations in sarcomas, such as mutations in the TP53 gene.\n5. Novel genetic mutations specific to sarcoma subtypes, such as chondrosarcoma and leiomyosarcoma, were identified through the project.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in the UK in 2015.",
      "The project aimed to sequence the genomes of 100,000 patients with rare diseases and cancer, including sarcoma.",
      "Sarcoma ranked third overall among the number of patients' samples sent for sequencing in the project.",
      "The project identified specific genetic mutations in sarcomas, such as mutations in the TP53 gene.",
      "Novel genetic mutations specific to sarcoma subtypes, such as chondrosarcoma and leiomyosarcoma, were identified through the project."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, protein ALEX1 does contain armadillo repeats. The document mentions that armadillo (arm) repeat-containing proteins, such as ARMCX1, are involved in development, maintenance of tissue integrity, and tumorigenesis, and their common feature is a 42-amino acid motif, the arm repeat. Since ALEX1 is not specifically mentioned as an exception, it can be inferred that it also contains armadillo repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. Armadillo (arm) repeat-containing proteins are involved in development, maintenance of tissue integrity, and tumorigenesis.\n3. A common feature of armadillo repeat-containing proteins is a 42-amino acid motif known as the arm repeat.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "Armadillo (arm) repeat-containing proteins are involved in development, maintenance of tissue integrity, and tumorigenesis.",
      "A common feature of armadillo repeat-containing proteins is a 42-amino acid motif known as the arm repeat."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: A common feature of armadillo repeat-containing proteins is a motif that is approximately 40 amino acids in length, not specifically 42.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some enzymes that remove histone modifications:\n1. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, thereby reversing the acetylation process carried out by histone acetyltransferases (HATs). HDACs are known to target promoter regions and play a crucial role in regulating gene expression.\n2. Lysine-specific demethylase 1 (LSD1): LSD1 is an enzyme that removes methyl groups from histone H3 lysine 4 (H3K4), which is a mark associated with active gene expression. LSD1 is also involved in the deacetylation of histone H3 lysine 9 (H3K9), which is a mark associated with gene silencing.\n3. JMJD2A: JMJD2A is a histone demethylase that removes methyl groups from histone H3 lysine 9 (H3K9), leading to the activation of gene expression.\n4. KDM5A: KDM5A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27), leading to the activation of gene expression.\n5. KDM6A: KDM6A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27), leading to the activation of gene expression.\nThese are some of the enzymes that play a role in removing histone modifications and regulating gene expression. However, it's important to note that there are many other enzymes involved in this process, and the specific enzymes involved may depend on the context and the type of gene being regulated.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n2. Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4 (H3K4).\n3. JMJD2A is a histone demethylase that removes methyl groups from histone H3 lysine 9 (H3K9).\n4. KDM5A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).\n5. KDM6A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4 (H3K4).",
      "JMJD2A is a histone demethylase that removes methyl groups from histone H3 lysine 9 (H3K9).",
      "KDM5A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).",
      "KDM6A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: KDM5A is a histone demethylase that removes methyl groups from histone H3 lysine 4 (H3K4), but not from histone H3 lysine 27 (H3K27).\n5. FALSE [correction]: KDM6A is a histone demethylase that removes methyl groups from histone H3 lysine 27 (H3K27), but not from histone H3 lysine 4 (H3K4).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there is a potential risk of brain tumor induction from head CT exams performed on children and adolescents. The low dose radiation exposure from head CT scans may increase the risk of tumor induction, although the risk is considered low. However, it is important to note that the incidence of brain tumor induction from head CT exams is not well established and more research is needed to fully understand the risk. Therefore, healthcare providers should weigh the benefits of head CT scans in pediatric patients against the potential risks, and consider alternative imaging modalities when possible.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT exams performed on children and adolescents may increase the risk of brain tumor induction.\n2. The radiation exposure from head CT scans is low dose.\n3. The risk of tumor induction from head CT scans is considered low.\n4. The incidence of brain tumor induction from head CT exams is not well established.\n5. More research is needed to fully understand the risk of brain tumor induction from head CT exams.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT exams performed on children and adolescents may increase the risk of brain tumor induction.",
      "The radiation exposure from head CT scans is low dose.",
      "The risk of tumor induction from head CT scans is considered low.",
      "The incidence of brain tumor induction from head CT exams is not well established.",
      "More research is needed to fully understand the risk of brain tumor induction from head CT exams."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, Otx2 is associated with naive pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with naive pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with naive pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there are 17 DNaseI hypersensitive sites (DHSs) marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are 17 DNaseI hypersensitive sites marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact": [
      "There are 17 DNaseI hypersensitive sites marking the murine beta globin locus region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some European influenza vaccines:\n1. Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - GlaxoSmithKline Biologicals)\n2. Pandemic Influenza Vaccine H5N1 - Baxter AG\n3. Pandemic influenza vaccine H5N1 - AstraZeneca (previously Pandemic influenza vaccine H5N1 - Medimmune)\nIt's important to note that the availability and composition of influenza vaccines may vary by country and region, and this list may not be exhaustive. Additionally, the information provided in Document 0 is specific to the pandemic influenza vaccine H5N1, and may not be applicable to other types of influenza vaccines.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adjupanrix is a European influenza vaccine previously known as Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) and is produced by GlaxoSmithKline Biologicals.\n2. Pandemic Influenza Vaccine H5N1 is produced by Baxter AG.\n3. Pandemic influenza vaccine H5N1 is produced by AstraZeneca, previously known as Pandemic influenza vaccine H5N1 by Medimmune.",
    "llama-2-7b-chat-hf_fact": [
      "Adjupanrix is a European influenza vaccine previously known as Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) and is produced by GlaxoSmithKline Biologicals.",
      "Pandemic Influenza Vaccine H5N1 is produced by Baxter AG.",
      "Pandemic influenza vaccine H5N1 is produced by AstraZeneca, previously known as Pandemic influenza vaccine H5N1 by Medimmune."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Pandemic Influenza Vaccine H5N1 known as Celvapan is produced by Baxter AG.\n3. FALSE [correction]: Pandemic influenza vaccine H5N1 known as Fluenz Tetra is produced by AstraZeneca, previously known as Pandemic influenza vaccine H5N1 by Medimmune.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. According to the information provided in Document 0, the paramyxovirus family has a single strand of negative-sense RNA that serves as a template for transcription and replication. This means that the genome is replicated and transcribed in a negative sense, meaning that the RNA molecule is complementary to the template strand. Additionally, the genome only encodes one polymerase, which suggests that the genome is segmented and not continuous.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. The Paramyxovirus genome serves as a template for transcription and replication.\n3. The RNA molecule of the Paramyxovirus genome is complementary to the template strand.\n4. The Paramyxovirus genome encodes one polymerase.\n\nNote: The statement that the Paramyxovirus genome is segmented is incorrect according to current scientific understanding. Paramyxoviruses have a non-segmented, single-stranded RNA genome. Therefore, the last part of the answer provided is factually inaccurate and should not be included as a verified factual statement.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "The Paramyxovirus genome serves as a template for transcription and replication.",
      "The RNA molecule of the Paramyxovirus genome is complementary to the template strand.",
      "The Paramyxovirus genome encodes one polymerase.",
      "te: The statement that the Paramyxovirus genome is segmented is incorrect according to current scientific understanding. Paramyxoviruses have a non-segmented, single-stranded RNA genome. Therefore, the last part of the answer provided is factually inaccurate and should not be included as a verified factual statement."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - The RNA molecule of the Paramyxovirus genome is indeed complementary to the mRNA, which is the template strand for protein synthesis.\n4. FALSE [correction]: The Paramyxovirus genome encodes for multiple proteins, including more than one involved in polymerase activity (e.g., the large (L) protein and the phosphoprotein (P) which together form the RNA-dependent RNA polymerase complex).\n5. UNKNOWN - The statement to be evaluated is missing. However, based on the note provided, it seems there was a statement about the Paramyxovirus genome being segmented, which would be false. The correction would be: Paramyxoviruses have a non-segmented, single-stranded RNA genome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Roflumilast Cream is effective for the treatment of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast Cream is used for the treatment of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast Cream is used for the treatment of plaque psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document 0, there are several tools that have been developed for identifying and visualizing ncRNA promoters:\n1. ncPro-ML: As mentioned in the document, this is a new method proposed for identifying the promoter of ncRNA in Homo sapiens and Mus musculus. It uses different kinds of sequence encoding schemes to identify the promoter regions of ncRNA.\n2. RNAProM: This tool uses a combination of sequence and structural features to predict the promoter regions of ncRNA. It can also predict the orientation of the transcript and the location of the ribosome binding site.\n3. PrognoseR: This tool uses a machine learning approach to predict the promoter regions of ncRNA. It takes into account a variety of features, including sequence composition, secondary structure, and conservation across different species.\n4. PromoterFinder: This tool uses a combination of sequence and structural features to predict the promoter regions of ncRNA. It can also predict the orientation of the transcript and the location of the ribosome binding site.\n5. RNApromoter: This tool uses a machine learning approach to predict the promoter regions of ncRNA. It takes into account a variety of features, including sequence composition, secondary structure, and conservation across different species.\nThese are just a few examples of the tools that have been developed for identifying and visualizing ncRNA promoters. There may be other tools available as well, and the choice of tool will depend on the specific needs and goals of the researcher.",
    "llama-2-7b-chat-hf_fact_raw": "1. ncPro-ML is a method developed for identifying the promoter of ncRNA in Homo sapiens and Mus musculus.\n2. RNAProM predicts the promoter regions of ncRNA using a combination of sequence and structural features.\n3. PrognoseR is a tool that predicts the promoter regions of ncRNA through a machine learning approach considering various features.\n4. PromoterFinder predicts ncRNA promoter regions and can also predict the orientation of the transcript and the location of the ribosome binding site.\n5. RNApromoter uses a machine learning approach to predict ncRNA promoter regions, taking into account features like sequence composition and secondary structure.",
    "llama-2-7b-chat-hf_fact": [
      "ncPro-ML is a method developed for identifying the promoter of ncRNA in Homo sapiens and Mus musculus.",
      "RNAProM predicts the promoter regions of ncRNA using a combination of sequence and structural features.",
      "PrognoseR is a tool that predicts the promoter regions of ncRNA through a machine learning approach considering various features.",
      "PromoterFinder predicts ncRNA promoter regions and can also predict the orientation of the transcript and the location of the ribosome binding site.",
      "RNApromoter uses a machine learning approach to predict ncRNA promoter regions, taking into account features like sequence composition and secondary structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided, SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells compared to conventional glioma cell lines. Some of the example genes identified by SWIM tool are:\n1. CAV1 (caveolin 1)\n2. COL5A1 (collagen type V alpha 1 chain)\n3. COL6A3 (collagen type VI alpha 3 chain)\n4. FLNB (filamin B)\n5. PDGFRA (platelet-derived growth factor receptor alpha)\n6. TIMP1 (tissue inhibitor of metalloproteinases 1)\n7. TWIST1 (twist family bHLH transcription factor 1)\n8. VIM (vimentin)\nThese genes are down-regulated in glioblastoma stem-like cells, indicating that they may play a role in the maintenance of stem-like properties in these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells.\n2. CAV1 (caveolin 1) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.\n3. COL5A1 (collagen type V alpha 1 chain) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.\n4. COL6A3 (collagen type VI alpha 3 chain) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.\n5. PDGFRA (platelet-derived growth factor receptor alpha) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells.",
      "CAV1 (caveolin 1) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.",
      "COL5A1 (collagen type V alpha 1 chain) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.",
      "COL6A3 (collagen type VI alpha 3 chain) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool.",
      "PDGFRA (platelet-derived growth factor receptor alpha) is identified as a down-regulated gene in glioblastoma stem-like cells by the SWIM tool."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific results or data from the SWIM tool (Subnetwork of Wide Influence in the Molecular interactome), it is not possible to verify the accuracy of these statements regarding the down-regulation of specific genes in glioblastoma stem-like cells.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several R packages that have been developed for studying Topologically Associating Domains (TADs):\n1. TADsplimer: This is the first computational tool to systematically detect TAD splits and mergers across the genome between Hi-C samples, as mentioned in the document.\n2. TADtrack: This package provides a comprehensive framework for the analysis of TADs, including the detection of TAD boundaries, the identification of TAD-related genes, and the analysis of TAD dynamics.\n3. TADseq: This package is designed to analyze Hi-C data and identify TADs based on the spatial proximity of chromatin regions.\n4. ChromHMM: This package uses a hidden Markov model to predict the 3D organization of chromatin and identify TADs based on the spatial proximity of chromatin regions.\n5. TopoTools: This package provides a set of tools for the analysis of TADs, including the detection of TAD boundaries, the identification of TAD-related genes, and the analysis of TAD dynamics.\nThese packages can be used to analyze TADs in various organisms, including humans, and can provide valuable insights into the structure and function of TADs in different cell types and tissues.",
    "llama-2-7b-chat-hf_fact_raw": "1. TADsplimer is a computational tool designed to detect TAD splits and mergers across the genome between Hi-C samples.\n2. TADtrack is an R package that offers a framework for TAD analysis, including detection of boundaries and identification of related genes.\n3. TADseq is an R package created to analyze Hi-C data for the identification of Topologically Associating Domains.\n4. ChromHMM is an R package that uses a hidden Markov model to predict the 3D organization of chromatin, including the identification of TADs.\n5. TopoTools is an R package that provides tools for TAD analysis, including detection of boundaries and identification of related genes.",
    "llama-2-7b-chat-hf_fact": [
      "TADsplimer is a computational tool designed to detect TAD splits and mergers across the genome between Hi-C samples.",
      "TADtrack is an R package that offers a framework for TAD analysis, including detection of boundaries and identification of related genes.",
      "TADseq is an R package created to analyze Hi-C data for the identification of Topologically Associating Domains.",
      "ChromHMM is an R package that uses a hidden Markov model to predict the 3D organization of chromatin, including the identification of TADs.",
      "TopoTools is an R package that provides tools for TAD analysis, including detection of boundaries and identification of related genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TADseq is not an R package; it is a sequencing technique used to identify Topologically Associating Domains (TADs).\n4. FALSE [correction]: ChromHMM is not an R package; it is a computational tool that uses a hidden Markov model to characterize the chromatin states across the genome but is not specifically focused on the identification of TADs.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is RegulonDB. According to Document 0, RegulonDB has collected, harmonized, and centralized data from hundreds of experiments for nearly two decades and is considered a point of reference for transcriptional regulation in Escherichia coli (E. coli). RegulonDB provides a comprehensive database of transcriptional regulation in E. coli, including information on regulatory elements, transcription factors, and their target genes. It also includes tools for analyzing and predicting the regulation of gene expression in E. coli, making it a valuable resource for researchers studying bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.\n3. RegulonDB is considered a point of reference for transcriptional regulation in Escherichia coli (E. coli).\n4. The database includes information on regulatory elements, transcription factors, and their target genes in E. coli.\n5. RegulonDB provides tools for analyzing and predicting the regulation of gene expression in E. coli.",
    "llama-2-7b-chat-hf_fact": [
      "RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "RegulonDB has been collecting, harmonizing, and centralizing data from experiments for nearly two decades.",
      "RegulonDB is considered a point of reference for transcriptional regulation in Escherichia coli (E. coli).",
      "The database includes information on regulatory elements, transcription factors, and their target genes in E. coli.",
      "RegulonDB provides tools for analyzing and predicting the regulation of gene expression in E. coli."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RegulonDB is a database, not a bioconductor tool, developed for accessing bacterial regulatory networks.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the end products of the shikimate pathway are chorismate and aromatic amino acids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chorismate is an end product of the shikimate pathway.\n2. Aromatic amino acids are end products of the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Chorismate is an end product of the shikimate pathway.",
      "Aromatic amino acids are end products of the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chorismate is not an end product of the shikimate pathway; it is an intermediate compound that leads to the synthesis of other compounds.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome. Nelson's syndrome is a rare but potentially severe condition that can develop in patients who have undergone bilateral adrenalectomy for Cushing's disease. Cabergoline, a dopamine receptor agonist, has been shown to be effective in reducing the symptoms of Nelson's syndrome, including hyperpigmentation, virilization, and adrenal insufficiency. However, it is important to note that cabergoline is not a cure for Nelson's syndrome, and other treatments may also be necessary to manage the condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome can develop in patients who have undergone bilateral adrenalectomy for Cushing's disease.\n3. Cabergoline is a dopamine receptor agonist.\n4. Cabergoline has been shown to be effective in reducing symptoms of Nelson's syndrome such as hyperpigmentation, virilization, and adrenal insufficiency.\n5. Cabergoline is not a cure for Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome can develop in patients who have undergone bilateral adrenalectomy for Cushing's disease.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline has been shown to be effective in reducing symptoms of Nelson's syndrome such as hyperpigmentation, virilization, and adrenal insufficiency.",
      "Cabergoline is not a cure for Nelson's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome; it is used to treat conditions associated with hyperprolactinemia, such as prolactinomas.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cabergoline is not indicated for the treatment of Nelson's syndrome symptoms. Nelson's syndrome involves the growth of an ACTH-secreting pituitary adenoma after bilateral adrenalectomy for Cushing's disease, and treatment options may include surgery, radiation therapy, and medications to control hormone levels, but not specifically cabergoline for the symptoms mentioned.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the main manifestation of Liebenberg syndrome is abnormal development of the arms, resulting in characteristic arm malformations that can vary in severity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is characterized by abnormal development of the arms.\n2. Liebenberg syndrome results in arm malformations.\n3. The severity of arm malformations in Liebenberg syndrome can vary.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is characterized by abnormal development of the arms.",
      "Liebenberg syndrome results in arm malformations.",
      "The severity of arm malformations in Liebenberg syndrome can vary."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is characterized by abnormal development of the elbows, forearms, and hands, which can resemble the hind limbs of an animal.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following are orally bioavailable MPS1 kinase inhibitors:\n1. MPI-0479605 (IC50 = 0.004 μM for MPS1 enzyme and IC50 = 0.1 μM for HCT-116 cells)\nNote: The IC50 values represent the concentration of the inhibitor required to inhibit the activity of the MPS1 enzyme or cell growth by 50%. A lower IC50 value indicates greater potency as an inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.\n2. The IC50 value of MPI-0479605 for the MPS1 enzyme is 0.004 μM.\n3. The IC50 value of MPI-0479605 for HCT-116 cells is 0.1 μM.",
    "llama-2-7b-chat-hf_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.",
      "The IC50 value of MPI-0479605 for the MPS1 enzyme is 0.004 μM.",
      "The IC50 value of MPI-0479605 for HCT-116 cells is 0.1 μM."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nThe first statement is true as MPI-0479605 is indeed an orally bioavailable inhibitor of the MPS1 kinase. However, without specific scientific literature or data provided regarding the IC50 values of MPI-0479605 for the MPS1 enzyme and HCT-116 cells, the accuracy of the second and third statements cannot be determined. IC50 values can vary based on experimental conditions and methodologies, so these values would need to be referenced from a specific study or source to verify their truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, golimumab has not been specifically tested for diabetes. The document mentions that golimumab is a human monoclonal antibody specific for tumor necrosis factor alpha (TNF-alpha), which is a protein that plays a role in the immune system and inflammation. However, the document does not mention any studies or trials that have evaluated the use of golimumab for diabetes.\nType 1 diabetes is an autoimmune disease that is characterized by the loss of insulin-producing beta cells in the pancreas, leading to high blood sugar levels. While golimumab is not approved for the treatment of diabetes, other medications such as insulin and glucagon-like peptide-1 (GLP-1) receptor agonists are used to manage blood sugar levels in people with diabetes.\nIf you have any further questions or concerns, please feel free to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a human monoclonal antibody specific for tumor necrosis factor alpha (TNF-alpha).\n2. TNF-alpha is a protein that plays a role in the immune system and inflammation.\n3. Type 1 diabetes is characterized by the loss of insulin-producing beta cells in the pancreas.\n4. Insulin and glucagon-like peptide-1 (GLP-1) receptor agonists are used to manage blood sugar levels in people with diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a human monoclonal antibody specific for tumor necrosis factor alpha (TNF-alpha).",
      "TNF-alpha is a protein that plays a role in the immune system and inflammation.",
      "Type 1 diabetes is characterized by the loss of insulin-producing beta cells in the pancreas.",
      "Insulin and glucagon-like peptide-1 (GLP-1) receptor agonists are used to manage blood sugar levels in people with diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that progeria is caused by an autosomal recessive gene. The disorder is described as an \"extremely rare\" and \"progressive genetic disorder\" that causes children to age rapidly, starting in their first two years of life. This suggests that the disorder is caused by a mutation in a gene that is inherited from both parents, as autosomal recessive genetic disorders are caused by mutations in genes that are located on the autosomal chromosomes (as opposed to X-linked genetic disorders, which are caused by mutations in genes located on the X chromosome).\nAdditionally, the fact that children with progeria generally appear healthy at birth suggests that the mutation that causes the disorder is not present at birth, but rather occurs later in development. This is consistent with an autosomal recessive pattern of inheritance, in which a child must inherit two copies of the mutated gene (one from each parent) in order to develop the disorder.\nIt is important to note that while the information provided suggests that progeria is likely caused by an autosomal recessive gene, the exact genetic cause of the disorder has not been definitively identified. Further research is needed to determine the specific genetic mutation or mutations that are responsible for progeria.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the question and the document, common variants at 12q14 and 12q24 are associated with hippocampal volume. Specifically, the ENIGMA Consortium & the Cohorts for Heart and Aging (CHA) found that these variants are associated with reduced hippocampal volume in the brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with hippocampal volume.\n2. The ENIGMA Consortium & the Cohorts for Heart and Aging (CHA) found an association between these variants and reduced hippocampal volume in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "Common variants at 12q14 and 12q24 are associated with hippocampal volume.",
      "The ENIGMA Consortium & the Cohorts for Heart and Aging (CHA) found an association between these variants and reduced hippocampal volume in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the ligands of the Roundabout (Robo) receptors are the Slit protein family.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are the Slit protein family.",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are the Slit protein family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that TFII-I does play a role in megakaryopoiesis. The document states that TFII-I acts as a repressor of β-globin gene transcription and is implicated in the differentiation of erythro-megakaryocytic cells. This suggests that TFII-I may be involved in the regulation of genes involved in megakaryocyte development and differentiation, which is a process known as megakaryopoiesis.\nMegakaryopoiesis is the process by which megakaryocytes, the precursors of platelets, are formed in the bone marrow. This process involves the coordinated regulation of multiple genes involved in cell growth, differentiation, and maturation. TFII-I, as a transcription factor, plays a critical role in regulating the expression of these genes and is essential for proper megakaryocyte development.\nTherefore, based on the information provided, it can be concluded that TFII-I does have a role in megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I acts as a repressor of β-globin gene transcription.\n2. TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.\n3. Megakaryopoiesis is the process by which megakaryocytes, the precursors of platelets, are formed in the bone marrow.\n4. The process of megakaryopoiesis involves the coordinated regulation of multiple genes involved in cell growth, differentiation, and maturation.\n5. TFII-I is a transcription factor that plays a role in regulating the expression of genes essential for proper megakaryocyte development.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I acts as a repressor of β-globin gene transcription.",
      "TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.",
      "Megakaryopoiesis is the process by which megakaryocytes, the precursors of platelets, are formed in the bone marrow.",
      "The process of megakaryopoiesis involves the coordinated regulation of multiple genes involved in cell growth, differentiation, and maturation.",
      "TFII-I is a transcription factor that plays a role in regulating the expression of genes essential for proper megakaryocyte development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I is generally known as a transcriptional activator, not a repressor, of the β-globin gene.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, atenolol is not metabolized by CYP2D6 to a clinically significant extent. The document states that atenolol is metabolized primarily by CYP3A4 to inactive metabolites, and that CYP2D6 metabolism is not clinically significant. Therefore, it is unlikely that atenolol will be metabolized by CYP2D6 to a significant extent.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is not metabolized by CYP2D6 to a clinically significant extent.\n2. Atenolol is metabolized primarily by CYP3A4 to inactive metabolites.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is not metabolized by CYP2D6 to a clinically significant extent.",
      "Atenolol is metabolized primarily by CYP3A4 to inactive metabolites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Atenolol is not significantly metabolized by the liver and is excreted primarily unchanged in the urine. It is not primarily metabolized by CYP3A4 to inactive metabolites.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the versions of ExpansionHunter are:\n1. ExpansionHunter-v5.0.0\n2. Latest ExpansionHunter v5.0.0\nThe latest version of ExpansionHunter, v5.0.0, introduces significant changes to accelerate the analysis of large genome-wide STR catalogs, including improvements to the build system, bug fixes, and catalog updates. Additionally, the latest version allows for the acceleration of genotyping across multiple threads using the new `--threads` option.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter-v5.0.0 is a version of ExpansionHunter.\n2. The latest version of ExpansionHunter is v5.0.0.\n3. ExpansionHunter v5.0.0 includes improvements to the build system.\n4. ExpansionHunter v5.0.0 includes bug fixes and catalog updates.\n5. The `--threads` option in ExpansionHunter v5.0.0 allows for the acceleration of genotyping across multiple threads.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter-v5.0.0 is a version of ExpansionHunter.",
      "The latest version of ExpansionHunter is v5.0.0.",
      "ExpansionHunter v5.0.0 includes improvements to the build system.",
      "ExpansionHunter v5.0.0 includes bug fixes and catalog updates.",
      "The `--threads` option in ExpansionHunter v5.0.0 allows for the acceleration of genotyping across multiple threads."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (Without current information, it's not possible to confirm whether v5.0.0 is the latest version of ExpansionHunter.)\n3. UNKNOWN (Without specific release notes or documentation, it's not possible to confirm the improvements to the build system in version 5.0.0.)\n4. UNKNOWN (Without specific release notes or documentation, it's not possible to confirm the inclusion of bug fixes and catalog updates in version 5.0.0.)\n5. TRUE (The `--threads` option is commonly used in computational tools to specify the number of threads for parallel processing, which would accelerate genotyping across multiple threads.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided, Adamts18 appears to play a role in hormone receptor signaling.\nAdamts18 is a protease that is involved in the regulation of extracellular matrix (ECM) remodeling and has been shown to be required for stem cell activation. The document you provided mentions that Adamts18 interacts with multiple binding partners in the basement membrane and genetically interacts with Col18a1, a basal membrane-specific proteoglycan.\nStudies have shown that Adamts18 is involved in the regulation of hormone receptor signaling, particularly in the context of breast cancer. For example, one study found that Adamts18 is overexpressed in breast cancer cells and promotes the activation of estrogen receptors (ER) and progesterone receptors (PR) (1). Another study found that Adamts18 regulates the expression of the ER alpha subunit and promotes the proliferation of ER-positive breast cancer cells (2).\nTherefore, based on the information provided, it can be inferred that Adamts18 plays a role in hormone receptor signaling by regulating the expression and activity of hormone receptors in various cell types, including breast cancer cells.\nReferences:\n1. Liu et al. (2015). Adamts18 regulates estrogen receptor alpha expression and promotes proliferation of ER-positive breast cancer cells. Oncogene, 34(3), 347-357.\n2. Zhang et al. (2013). Adamts18 is overexpressed in breast cancer and promotes the activation of estrogen receptors. BioMed Research International, 2013, 1-8.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a protease involved in the regulation of extracellular matrix remodeling.\n2. Adamts18 is required for stem cell activation.\n3. Adamts18 interacts with multiple binding partners in the basement membrane and genetically interacts with Col18a1.\n4. Adamts18 is overexpressed in breast cancer cells and promotes the activation of estrogen receptors and progesterone receptors.\n5. Adamts18 regulates the expression of the estrogen receptor alpha subunit and promotes the proliferation of ER-positive breast cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a protease involved in the regulation of extracellular matrix remodeling.",
      "Adamts18 is required for stem cell activation.",
      "Adamts18 interacts with multiple binding partners in the basement membrane and genetically interacts with Col18a1.",
      "Adamts18 is overexpressed in breast cancer cells and promotes the activation of estrogen receptors and progesterone receptors.",
      "Adamts18 regulates the expression of the estrogen receptor alpha subunit and promotes the proliferation of ER-positive breast cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: ADAMTS18 is indeed a protease that is involved in the regulation of extracellular matrix remodeling.\n2. UNKNOWN: The role of ADAMTS18 in stem cell activation is not well-established and would require specific scientific evidence to confirm.\n3. TRUE: ADAMTS18 is known to interact with multiple binding partners in the extracellular matrix, and genetic interactions with collagen, such as Col18a1, are plausible given the role of ADAMTS proteases in matrix organization.\n4. UNKNOWN: The specific role of ADAMTS18 in breast cancer and its effect on estrogen and progesterone receptors would require citation of specific scientific studies to confirm its overexpression and functional impact.\n5. UNKNOWN: Similar to statement 4, the regulation of estrogen receptor alpha subunit by ADAMTS18 and its role in the proliferation of ER-positive breast cancer cells would need to be supported by specific scientific research to be confirmed as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Thiazovivin is a ROCK (Rho-associated protein kinase) inhibitor, which means it works by blocking the activity of ROCK proteins in cells. ROCK proteins are involved in regulating various cellular processes, including cell migration, differentiation, and survival. By inhibiting ROCK activity, Thiazovivin can modulate these processes and potentially have therapeutic effects in various diseases.\nIn the context of the protocol provided, Thiazovivin was selected for use due to its effectiveness at lower concentrations (2 μM) compared to other ROCK inhibitors such as Y27632 and HA-1077. This suggests that Thiazovivin may be more efficient or cost-effective for use in the protocol compared to other ROCK inhibitors. However, it is important to note that the choice of ROCK inhibitor will depend on various factors, including the specific research question or therapeutic application, as well as any potential off-target effects or toxicities associated with each inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a ROCK (Rho-associated protein kinase) inhibitor.\n2. ROCK proteins are involved in regulating cell migration, differentiation, and survival.\n3. Thiazovivin inhibits the activity of ROCK proteins in cells.\n4. Thiazovivin is effective at lower concentrations (2 μM) compared to other ROCK inhibitors like Y27632 and HA-1077.\n5. The choice of ROCK inhibitor depends on factors such as the specific research question or therapeutic application, and potential off-target effects or toxicities.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a ROCK (Rho-associated protein kinase) inhibitor.",
      "ROCK proteins are involved in regulating cell migration, differentiation, and survival.",
      "Thiazovivin inhibits the activity of ROCK proteins in cells.",
      "Thiazovivin is effective at lower concentrations (2 μM) compared to other ROCK inhibitors like Y27632 and HA-1077.",
      "The choice of ROCK inhibitor depends on factors such as the specific research question or therapeutic application, and potential off-target effects or toxicities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (Without specific data or a reference to compare the effectiveness of Thiazovivin at lower concentrations to other ROCK inhibitors, it is not possible to confirm the accuracy of this statement.)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  }
]